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Abstract
Frontotemporal Dementia (FTD) is a neurodegenerative disorder that results in atrophy
within the frontal and/or temporal lobes. Clinically, patients with FTD present with progressive
deterioration in behaviour and/or language abilities. FTD has a strong genetic component with
approximately 40% of patients reporting a family history. Specifically, mutations in microtubuleassociated protein tau (MAPT), progranulin (GRN) and expanded repeats in the chromosome 9
open reading frame 72 (C9orf72) are the main genetic causes of FTD. Currently, no diseasemodifying treatments exist, and off-label medications have been used for symptomatic
management of behaviours. Substantial progress has been made to understand the underlying
pathology of the disease and clinical trials targeting FTD are in progress. As clinical trials begin,
the identification of disease markers will be critical to measure treatment effects, indicate when
treatments should be initiated and serve as potential targets for treatments. Therefore, there is a
critical need to identify disease markers in FTD.
The present work aimed to elucidate behavioural, structural, and functional changes in
FTD from the preclinical to the symptomatic disease stage. Study I delineated the initial
symptoms in patients with genetic FTD and in at-risk gene mutation carriers (preclinical
mutation carriers and non-mutation carriers). This study revealed gene-specific patterns of initial
symptoms during the preclinical and symptomatic disease period. Study II examined the brain’s
ventricular volumes in genetically at-risk mutation carriers. Preclinical mutation carriers
exhibited larger ventricular volume (i.e. greater neuronal atrophy), relative to biologically related
mutation non-carriers. Study III delineated the functional neural correlates underlying
disinhibition and behavioural flexibility in patients with FTD. Relative to healthy controls,
patents with FTD exhibited decreased activity within the ventral and dorsal lateral regions of the
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prefrontal cortex. This study reveals that patients with FTD exhibit aberrant neural functioning
relative to healthy controls in a task indexing behavioural flexibility.
Overall, this work suggests that behavioural and neuroanatomical disease-alteration occur
during the preclinical disease stage and functional neural deficits underlying behavioural
difficulties can be detected in symptomatic patients. These results may be applied to future
clinical trial designs to assess the efficacy of treatments and determine potential treatment
targets.
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Summary for Lay Audience
Frontotemporal Dementia (FTD) is a specific type of dementia that leads to brain tissue
loss. Patients with FTD demonstrate behaviour and/or language problems including disinhibition,
loss of empathy, difficulty attributing the correct meaning to words and word production.
Although no disease-modifying treatments exist, substantial progress has been made to
understand the pathology of the disease. As clinical trials begin, the identification of biomarkers
will be essential to: (1) indicate disease presence and progression, (2) measure treatment
effectiveness, (3) indicate when treatments should be administered, and (4) lead to the selection
of treatment targets. Thus, there is a critical need to identify disease markers of FTD.
The present thesis examined the behavioural, structural, and functional changes in FTD
from the preclinical (prior to disease occurrence) to the disease stage. Study I examined the
initial symptoms in patients with FTD and in preclinical mutation carriers (individuals with the
disease-causing mutation but who do not yet meet the criteria for the disease), and non-mutation
carriers (individuals who are not carrying the disease-causing mutation). This study found that
patients’ initial symptoms differ based on the underlying genetic mutation, and preclinical
mutation carriers show unique symptoms relative to mutation non-carriers. Study II examined
the volumes of the brain’s ventricles (cavities filled with cerebrospinal fluid) in genetically atrisk mutation carriers. Preclinical mutation carriers exhibited greater brain tissue loss relative to
biologically related mutation non-carriers. Study III assessed the functional neural correlates
underlying poor behavioural flexibility in patients with FTD. Relative to healthy controls,
patients with FTD showed decreased activity within the regions of the frontal lobe known to be
important for appropriate decision-making.
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Overall, this work suggests that disease-alterations in behaviour and brain structure occur
and can be detected during the preclinical disease stage prior to the onset of the disease.
Furthermore, this work also demonstrates that problems in brain function related to behaviour
flexibility can be detected in patients with FTD. These results may inform the selection of
disease markers for clinical trial designs.
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Chapter 1: Introduction
1.1 Frontotemporal Dementia
Frontotemporal Dementia (FTD) is a heterogenous neurodegenerative disorder resulting
in progressive deterioration in behaviour and/or language abilities. FTD includes three core
subtypes: behavioural variant (bvFTD) and two primary progressive aphasias (PPA), semantic
variant PPA (sv-PPA) and nonfluent/agrammatic variant PPA (nfvPPA). Related disorders
include FTD with motor neuron disease (FTD-MND), progressive supranuclear palsy syndrome
(PSP-S), and corticobasal syndrome (CBS). Although distinct clinical subtypes exist, the
presenting phenotype often converges with other sub-types as the disease progresses [1,2], which
may complicate diagnosis if not recognized early.

1.2 Epidemiology
FTD is the second most prevalent early onset dementia occurring before the age 65 [3],
with a prevalence of 18 to 36 per 100,000 in individuals 45-64 years of age [4]. FTD is primarily
diagnosed between the ages of 45-65, with approximately 10% of cases occurring in individuals
younger than 45 years of age [4], and the prevalence more than doubling amongst those older
than 65 years of age [4,5]. Importantly, though the prevalence is likely underestimated due to
lack of expertise by primary care physicians with limited expertise in behavioural neurology [4],
and the absence of validated biomarkers to distinguish FTD from other neurologic and
psychiatric disorders [6].

1.3 Burden
FTD causes a substantial economic and social burden to the caregiver, patient and
society. The mean age of disease onset occurs during a time when an individual’s contribution to
1

society is at its greatest, as many patients are in their prime earning years and have dependent
children [7]. Overall household income decreases significantly after diagnosis, and the total
annual per-patient cost is nearly two times higher than the reported cost for Alzheimer’s Disease
(AD) [7]. In addition to the contribution to society, the burden to the caregiver is substantial:
67% of caregivers of patients with FTD reported a notable decline in their own health and 53%
reported increased personal health care costs [7]. Relative to carers of patients with AD,
caregivers of people with FTD report greater burden [8,9], and experience twice the levels of
depression, even after controlling for age and duration of symptoms [10].

1.4 Prognosis
Across the syndromes, the mean survival time of patients with FTD is approximately 7-8
years from diagnosis [11]. In a sample of 124 patients, the most common cause of death was
respiratory system disorder (27%), circulatory system disorder (19%) and cachexia (14%).
Additionally, 11.5% of patients died from cancer, and in 11.5% of patients, the cause of death
was unknown [12]. Having genetic FTD has been found to be associated with a shorter survival
time [13]; other demographic characteristics including age at illness onset or severity of
dementia at the time of diagnosis have not been found to be associated with survival [12,14].

1.5 What causes FTD?
1.5.1 Genetic FTD
FTD has a strong genetic component with approximately 40% of patients reporting a family
history and approximately 10% demonstrate an autosomal dominant pattern of inheritance [15].
Importantly, the exact percentage of cases with a family history may vary as inaccurate reporting
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of family history of FTD may be attributed to psychiatric disease, another dementia or other
diagnoses. Heritability varies across the clinical subtypes with the bvFTD phenotype showing
the strongest heritability and the language variants showing the least [15-17]. Mutations in three
genes have been shown to be the most frequent genetic causes of FTD including microtubuleassociated protein tau (MAPT) [18,19], progranulin (GRN) [20,21], and expanded repeats in the
chromosome 9 open reading frame 72 (C9orf72) [22,23] (Table 1.1). Together, these genes
account for 5-10% of all FTD with some variability depending on the case series [24].

Table 1.1: Summary of FTD-related genetic mutations
FTD gene
MAPT
GRN

C9orf72

Frequency[25,26]

Age at symptom
onset (years)[27]

Disease duration
(years)[27]

Pathology[26]

Familial: 5-20%
Sporadic: 0-3%
Familial: 5-10%
Sporadic: 1-5%

49.5
Range: 17-82
61.3
Range: 25-90

9.3
Range: 0-45
7.1
Range: 0-27

Tau protein deposits

Familial: 21%
Sporadic: 6%

58.2
Range: 20-91

6.4
Range: 0-36

Accumulation of TAR
DNA-binding protein 43
(TDP-43)
Accumulation of TAR
DNA-binding protein 43
(TDP-43)

1.5.1.1 Microtubule-associated Protein Tau (MAPT)
The MAPT gene located on chromosome 17 was the first pathological mutation found to
cause FTD [18,19]. To date, 63 different MAPT mutations have been identified in patients with
FTLD [24]. Patients often present with bvFTD [28], though some may develop semantic
impairments and parkinsonism as the disease progresses [29]. Importantly, significant variability
remains in the presenting phenotype, even between families carrying the same mutation [30].
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1.5.1.2 Progranulin (GRN)
Mutations in the GRN gene lead to haploinsufficiency, resulting in reduced levels of
progranulin protein, a growth factor involved in regulating developmental events, inflammation
and wound repair [31]. To date, 114 different GRN mutations causing FTD have been identified
[24]. There is considerable variability in the age of disease onset, even for patients carrying
identical GRN mutations [32]. As well, the presenting phenotype in the setting of a GRN
mutation is quite heterogeneous with patients exhibiting Alzheimer’s Disease, Corticobasal
Syndrome, or nfvPPA, with the majority of patients exhibiting bvFTD phenotype [27,33].

1.5.1.3 Chromosome 9 open reading frame 72 (C9orf72)
Pathogenic hexanucleotide (GGGGCC) repeat expansion of the C9orf72 gene is a major
genetic cause of FTD [22]. The normal hexanucleotide repeat size is quite variable across
individuals and the smallest repeat size to confer risk is currently unknown [34]; however, most
consider > 30 repeats as pathogenic [33]. The most common phenotype is bvFTD, followed by
mild cognitive impairment (MCI), then FTD with ALS [28].

1.5.2 Sporadic FTD
Approximately, 60% of patients report no family history of FTD and are considered
“sporadic” [15]. A pathogenic variant is found in 5% of sporadic cases with mutations in the
C9orf72 being the most frequent [26,28]. Furthermore, previous head trauma has been found to
be a significant risk factor for the development of sporadic FTD when compared with age and
gender-matched controls [35]. Although the majority of familial and sporadic cases arise from

4

different underlying pathologies and genetic factors, both forms show similar behavioural,
cognitive and motor measures [36].

1.6 FTD Syndromes
Although there are three distinct clinical variants of FTD, each presenting with a unique
phenotype, the clinical profile within each variant is quite heterogenous. Nevertheless, the
subtypes are categorized under the broader name of FTD due to the shared clinical features, high
degree of anatomical overlap in structural and functional brain imaging and overlap in
pathologies [37]. Furthermore, as FTD progresses, the symptoms of the three variants converge
as the focal neural degeneration progresses through the networks of the frontal and temporal
lobes [38].

1.6.1 Behavioural Variant FTD (bvFTD)
bvFTD is the most common variant and accounts for approximately 60% of cases [39].
The clinical symptomatology of bvFTD is quite heterogeneous and is characterized by a
deterioration of behaviour and/or cognition that begins insidiously and progresses gradually over
time. The core diagnostic features include behavioural disinhibition, apathy, loss of sympathy,
hyperorality, and/or perseverative or compulsive behaviours [40]. Additionally, patients may
also demonstrate frontal and/or anterior temporal atrophy, hypoperfusion or hypometabolism
[40].
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1.6.2 Semantic-variant Primary Progressive Aphasia (sv-PPA)
Sv-PPA accounts for 20% of FTD cases [39] and is clinically characterized by a loss of
semantic knowledge resulting in word comprehension difficulties and anomia [41]. Early during
the disease, comprehension for high frequency words is intact but patients may experience
difficulty understanding low frequency words. Patients may also present with surface dyslexia
and dysgraphia where atypical spelling or pronunciation of words are regularized, for example
island is pronounced “is” – “land” [41]. Imaging features include hypoperfusion,
hypometabolism, and/or atrophy of the dominant anterior temporal lobe, with common
involvement of the non-dominant side as well [41]. Adding to the complexity, as the atrophy
progresses, behavioural symptoms emerge including emotional withdrawal, disinhibition, apathy
[42].

1.6.3 Nonfluent/agrammatic-variant Primary Progressive Aphasia (nfvPPA)
nfvPPA accounts for 25% of all FTD cases [39]. The hallmark features of nfvPPA are the
presence of agrammatic and effortful speech, and apraxia of speech [41]. Patients may make
inconsistent phonemic errors including deletions, distortions, insertions, substitutions or
transpositions of speech sounds [41]. As the disease progresses, patients will make grammatical
and spelling errors and comprehension of complex sentences is reduced [43]. Imaging-supported
diagnosis involves predominant left posterior fronto-insular atrophy or hypoperfusion or
hypometabolism [41].

6

1.7 Current Challenges
1.7.1 Diagnostic Delay and Misdiagnosis
Although the current diagnostic criteria demonstrates good sensitivity to detect FTD [40],
the vast heterogeneity in clinical presentation across and within syndromes, and the significant
overlap in symptom dimensions with other diseases, poses a challenge in accurately detecting
patients early. There is a delay of nearly 6-7 years before patients receive an accurate diagnosis
[42,44]. As well, patients with FTD, especially those with bvFTD subtype, are commonly
misdiagnosed with a psychiatric illness [45,46], leading to incorrect disease prognosis and
unnecessary treatments. Ultimately, the identification of FTD-related biomarkers sensitive to
early disease onset would help mitigate this diagnostic challenge.

1.7.2 Current Treatment Interventions
At present, there are no U.S. Food and Drug Administration (FDA) or Health Canada
approved therapies for FTD, and no treatments exist that can stop or slow the progression of this
disease. Off-label medications have been used for symptomatic management of behaviours;
however, there is little evidence from randomized, placebo-controlled trials supporting their use
[47]. Nonpharmacological interventions targeting environment adaptation, behaviour strategies
and caregiver training and education have also been employed [48]. Although these interventions
alleviate some of the caregiver burden, they do not modify the course of the disease as they do
not target the underlying pathology of FTD [6]. Currently, some of the first clinical trials
targeting FTD are in progress or anticipated (Table 1.2). Importantly though, one key remaining
challenge in clinical trial design for FTD is the vast heterogeneity of clinical symptoms, even in
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individuals with the same mutation or underlying pathology, making it difficult to measure
treatment effects and identify appropriate outcome measures [6].

Table 1.2: Current drugs in clinical trials for FTD
Drug
AL001
AL001
AL001
Metformin
Novolin-R
insulin
Syntocinon
AADvac1

Population
Healthy participants and
carriers of GRN
Carriers of GRN or pathogenic
forms of C9orf72
Carriers or at-risk carriers of
GRN
ALS/FTD with C9orf72
FTD

Status
Recruiting

Phase
Phase 1

Identifier
NCT03636204

Recruiting

Phase 2

NCT03987295

Not yet
recruiting
Recruiting
Recruiting

Phase 3

NCT04374136

Phase 2
Phase 2

NCT04220021
NCT04115384

Probable FTD
Non-fluent PPA

Recruiting
Active, not
recruiting
Recruiting

Phase 2
Phase 1

NCT03260920
NCT03174886

Phase 2

NCT02862210

Lithium
Participants with a diagnosis of
carbonate
bvFTD, sv-PPA or nfv-PPA
Based on clinicalTrials.gov, accessed May 25 2020

1.8 Knowledge Gaps for Optimization of Clinical Trials in FTD
1.8.1 The Need for Biomarkers
With the development of symptomatic and disease-modifying treatments, the
identification of biomarkers will be critical for clinical trial efficiency. Biomarkers may facilitate
earlier detection of symptoms and diagnosis prior to irreversible neuronal loss. Furthermore, by
improving diagnostic accuracy, recruited study populations will be more homogenous and thus,
the necessary sample size needed to detect treatment effects will be reduced [49]. As well, the
identification of biomarkers that can predict disease progression and symptom severity may act
as outcome measures to indicate when treatments should be initiated and to assess treatment
efficacy. To date, promising fluid biomarkers including cerebrospinal fluid and serum/plasma
levels of neurofilament chains and progranulin are being explored [6,50]. As well, the
8

quantification of individualized patterns of atrophy has been shown to be another potential
candidate [6,51]. Importantly, though, no validated markers for FTD have been established for
clinical trials [52,53]. Consequently, it is critical to identify potential biomarkers that can be
applied to develop efficient clinical trials, monitor disease progression, and evaluate treatment
effects.

1.9 Early Clinical Features in FTD
Prediction of the initial symptoms of FTD in an individual patient remains a critical
challenge both for clinical trial design and diagnosis of FTD. The initial symptoms are a critical
milestone that will require correlation with other potential biomarkers. However, in line with the
differing diagnostic criteria for the sub-types, the predominant initial symptoms in FTD differ
according to the clinical syndrome [54,55]. Importantly though, there remains substantial
heterogeneity in the initial symptom endorsement even within an FTD subtype. For example,
patients with bvFTD may also endorse memory, language, or other cognitive symptoms as the
initial symptom(s). Likewise, patients with SD may also report behavioural, memory and other
cognitive problems as the initial symptom(s) [54,55]. Furthermore, the initial symptoms of FTD
reported by caregivers are not always congruent with the most common symptoms observed
during the first clinic assessment [56,57]. Moreover, patients often develop overlapping
symptoms of different FTD subtypes as the disease progresses [58].

1.9.2 Initial Symptoms in Symptomatic Genetic FTD
Assessing the initial symptoms based on genetic mutation offers a unique opportunity to
examine the behavioural, cognitive and neuropsychological disease-related changes that are
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associated with a known underlying pathology. Studies assessing symptomatic carriers of
C9orf72 or GRN have found that behavioural/personality changes are a common initial
complaint (C9orf72: [58,59]; GRN: [57,60]). As well, problems with memory and language may
also occur (C9orf72: [61,62]; GRN: [57,63]). In carriers of MAPT, behavioural symptoms are
reported to be the most common symptom [64-67], with memory and language impairments
occurring at a lower frequency [64,67]. Currently, no study has evaluated and systematically
compared the initial symptoms across the three main FTD-causing genetic mutations in a large
cohort of patients. This knowledge will be instrumental in determining which biomarkers are
most sensitive to each genotype, and for the design of clinical trials targeting preclinical
mutation carriers and conversion to the symptomatic state.

1.9.3 Initial Symptoms in Asymptomatic Genetic FTD
It is currently unclear whether other neuropsychiatric, behavioural or cognitive changes
may occur in FTD mutation carriers in the preclinical period, before the first classic symptoms of
FTD are clearly present. Although studies have evaluated cognitive and neuropsychiatric
alterations during the preclinical period [68-72], the occurrence of these symptoms across the
three main mutation groups during the preclinical period has not been established. Moreover,
other symptoms prevalent in FTD including disinhibition, apathy, social inappropriateness and
altered food preferences have not been thoroughly explored in preclinical mutation carriers.
Assessing the occurrence of FTD-related symptoms during the preclinical disease stage will
indicate whether related measurements may be utilized to inform the initiation of treatments.
Overall, identifying gene-specific patterns of symptom endorsement during the
preclinical period can inform outcome measures to assess the effectiveness of symptomatic
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or disease-modifying treatments targeting different pathologies. Additionally, this
knowledge can inform the selection of outcome measures in basket-design trials where the
targeted therapy is assessed across different mutations with the same underlying pathology.
Furthermore, evaluating the endorsement of FTD-related symptoms during the preclinical
period across multiple domains of functioning can help determine whether specific
symptom occurrence is related to the underlying pathology of FTD, a consequence of
normal aging or due to the stress/burden of having a family member with FTD.

1.10 Brain Volumetric Changes in FTD
1.10.1 Grey Matter Atrophy Patterns in FTD
Frontal and/or temporal atrophy are the classic neuroimaging features in FTD. Early
changes are evident within the orbitofrontal cortex, anterior cingulate cortex, superior temporal
gyrus, medial frontal gyrus, insula, hippocampus, ventral striatum and thalamus [73,74]. Over
time, atrophy progresses within the frontal, temporal and parietal lobes, specifically within the
temporal lobes (bilaterally), left inferior frontal gyri, posterior cingulate (bilaterally), and right
parietal lobe [75,76]. Despite the level of heterogeneity in imaging findings, there is a general
consensus in the regional pattern of atrophy in each of the clinical syndromes. The bvFTD
syndrome is characterized by volume loss in the frontal and temporal lobes, particularly in the
prefrontal cortex, anterior temporal lobes, insula, anterior cingulate, striatum and thalamus.
Atrophy in sv-PPA is predominant within the left temporal lobe, including the inferior temporal
and fusiform gyri, temporal pole and the parahippocampal and entorhinal cortex. As well, left
temporal lobe involvement is also found in nfvPPA, though mainly involves the inferior frontal
gyrus, dorsolateral PFC, superior temporal gyrus and insula [77].
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1.10.1.1 Grey Matter Atrophy Patterns by Gene
Distinct associations have been found between regional brain atrophy and the underlying
pathogenic mutation. Relative to MAPT and C9orf72 carriers, GRN mutation carriers
demonstrate a faster rate of whole brain atrophy and asymmetry, with greater left versus right
side involvement [78-80]. As well, in GRN carriers, grey matter loss is predominantly in the
inferior and posterior temporal lobes, parietal lobes, posterior cingulate and precuneus [80-82].
Carriers of the C9orf72 expansion show more wide-spread atrophy with involvement in the
frontal lobes (orbitofrontal, medial prefrontal and dorsolateral PFC), temporal parietal, occipital
lobes and cerebellum [81,83]. In MAPT carriers, grey matter loss is predominant in the anterior
and medial temporal lobes [81-83]. Overall, there appears to be some overlapping yet distinctive
patterns of atrophy across the main genetic forms of FTD.

1.10.1.2 Preclinical Grey Matter Changes.
Studies investigating asymptomatic genetic mutation carriers have found subtle brain
volume alterations occurring prior to clinical onset. Specifically, as a group, preclinical mutation
carriers exhibit significant grey matter loss relative to mutation non-carriers [84-86].
Furthermore, grey matter volume changes have been found to emerge 2 years prior to expected
disease onset [68]. Within each genetic mutation cohort, the cortical atrophy in preclinical
participants is similar to the expected pattern found in symptomatic patients [80,84,86-88].
Overall, the pathological process of FTD that results in atrophy begins during the preclinical
period in genetic mutation carriers, prior to the onset of clinical symptoms.
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1.10.2 Ventricular Volume in FTD
In addition to grey matter volume, one emerging marker of atrophy in neurodegenerative
disease is the measure of ventricular volume. As ventricular volume expansion is consistently
seen across the heterogenous clinical and genetic syndromes, ventricular volume may serve as a
single measure to detect changes in FTD. Specifically, the contrast in intensity between the
cerebrospinal fluid and surrounding tissue makes the ventricles an ideal region for automatic
segmentation procedures [89], highlighting the efficiency as a potential neuroimaging tool.
Furthermore, the position of the ventricles makes them less susceptible to distortions due to
gradient non-linearity [89], and inhomogeneity artifacts compared to whole brain volume [90],
supporting reliability of this method across clinical centres and scanners.
Across the FTD subtypes and genetic mutations, ventricular expansion is evident across
the heterogenous clinical and genetic subtypes of FTD [56,79,91-95]. Only one study to date has
examined ventricular expansion in preclinical mutation carriers and reported stable volumes over
a 6-month follow-up period [96]; however, this study only assessed a single mutation group
(C9orf72) and included a small sample (n=7).
Importantly, aside from Floeter, Bageac, Danielian, Braun, Traynor and Kwan [96],
no study has assessed the sensitivity of ventricular volume measurements in preclinical
mutation carriers in FTD. Identifying ventricular volume changes in genetically at-risk
individuals could predict when the pathophysiology can be detected prior to disease onset.
This knowledge may inform the timing of future therapeutic interventions and be used as
outcome markers to assess treatment efficacy.
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1.11 Functional Neural Changes in Symptomatic Frontotemporal Dementia
1.11.1 Behaviour Flexibility in FTD
Despite facing negative social, legal and physical consequences, patients with FTD
exhibit difficulty modifying their behaviour. For example, patients with disinhibited symptoms
continue to engage in inappropriate social behaviour (e.g. aggression, over-familiarity with
strangers), exhibit a loss of manners (e.g. making insensitive comments, lack of social etiquette),
or continue to overspend or gamble despite severe debt accumulation [40,97]. Pathophysiologic
changes and atrophy in the frontal and temporal lobes have been found to be associated with
these prevalent disinhibited behaviours. In patients, reduced cerebral blood flow within the OFC,
bilateral inferior frontal gyrus (BA 47), left anterior cingulate gyrus (BA 32) and right caudate
nucleus and left insula (BA 13), have been associated with greater engagement of antisocial
behaviours [98]. Additionally, atrophy in the orbital and inferior frontal cortex, insula and right
middle temporal regions has been associated with caregiver-reported disinhibited behaviours
[99]. As disinhibition is one of the earliest symptoms to emerge in patients with FTD [40], and
poses a great stress to caregivers [99], identifying effective treatments for these behaviours is
essential. Furthermore, given the existing challenges in clinical trial design due to the relatively
low base-rates of FTD and the diagnostic challenges, leading to recruitment challenges, the
heterogeneity of clinical symptoms , and the time-intensive and costly nature of conducting
trials, it is critical to identify markers that can guide treatment selection and be used as efficient
outcome measures for clinical trials (i.e. proof of concept or challenge study) [6].
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1.11.2 Reversal Learning
Reversal learning is a measure of adaptive behavioural flexibility that assesses the ability
to alter behaviour when reinforcement contingencies change [100]. Performance on reversal
learning task is associated with the degree of disinhibited and socially inappropriate behaviours
exhibited by patients with frontal lobe lesions [100]. Through trial and error, participants learn
stimulus-reward contingencies (acquisition phase), selecting stimuli associated with reward and
avoiding stimuli associated with punishment. During the reversal phase, the reinforcement
contingencies change, such that the stimuli that were previously associated with punishment are
now associated with a reward, and those initially associated with punishment are now rewarded.
The underlying neural regions and neurotransmitters mediating successful reversal learning are
well-characterized in healthy populations. In conjunction with the extent literature, delineating
the underlying neural deficits associated with reversal learning in FTD can determine the
mechanisms mediating the associated behavioural deficits, and can inform potential targets for
treatment interventions.

1.11.2.1 Neural Correlates of Reversal Learning
Based on fMRI and lesion studies in non-human primates and humans, specific neural
regions have been found to be involved and/or make critical contributions to successful reversal
learning including the orbital frontal cortex/ventromedial prefrontal cortex (OFC/vmPFC),
ventrolateral PFC (vlPFC), dorsolateral PFC (dlPFC), and regions of the striatum.
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1.11.2.2 OFC/vmPFC
Patients with OFC damage report awareness of the reversed feedback contingencies but
are unable to adjust their behaviours accordingly [100,101]. It has been suggested that the
OFC/vmPFC is critical when adjustments of behaviour are prompted following changes in
reward contingency [100-104].
fMRI studies demonstrate that during the omission of an expected reward, the
OFC/vmPFC demonstrates a decrease in signal from baseline (negative prediction error),
whereas the presentation of an unexpected reward results in an increase in activity (positive
prediction error) [103]. Following this, it has been suggested that the OFC/vmPFC encodes the
reward values of objects/responses, as well as violations in this encoding through a prediction
error which signals the discrepancy between the expected and actual reward [103]. In line with a
prediction error formulation, the OFC/vmPFC has been found to be less active during reversal
errors relative to rewarded correct responses [105,106].

1.11.2.3 Lateral PFC
The dlPFC has been found to be integral for aspects of cognition that are important
during successful reversal learning including attention shifting [107,108], and learning reward
and punishment information for decision making [102,108]. Lesion studies have reported mixed
findings regarding the necessity of the lateral frontal cortex in reversal learning. Studies have
reported that lesions to the dlPFC does not impact reversal learning [102,107]. However, during
more complex reversal learning tasks that include probabilistic feedback, the dlPFC seems to be
critical for successful performance [101,109].
Functional neuroimaging studies have implicated the role of the lateral PFC during
reversal learning. Specifically, the dlPFC has been found to respond to decision conflict during
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reversal of a reward [105,110,111], and when differentiating between two reward options that are
similar in value [110]. As the dlPFC responds to decision conflict, it has been argued that this
region augments the representation of relevant stimuli and reinforcement information to guide
subsequent behaviours [105,112]. The vlPFC has been shown to be engaged when suboptimal
responses have been made (a reversal error), and thus, an alternative behaviour is warranted
[105,110,111]. Specifically, Cools, et al. [113] demonstrated that the vlPFC responded to the last
reversal error preceding a successful reversal in behaviour. Thus, it has been proposed that this
region is involved in selecting appropriate behaviours/motor responses. In fact, Budhani, Marsh,
Pine and Blair [105] suggested that following a conflict (e.g. reversal error), the dlFC
representing the stimulus features of the object within the vlPFC which then control motor
responding to alter subsequent behaviour.

1.11.2.4 Striatum
Lesion studies also propose a fronto-striatal circuit that is critical for processing reward
and punishment and mediating behaviours during reversal learning [114,115]. For example,
Divac, et al. [116] demonstrated that monkeys with lesions to the ventrolateral region of the head
of the caudate, a region which receives connections from the OFC, experience deficits in the
reversal learning component of the Wisconsin General Test. Furthermore, excitotoxic lesions to
the striatum or the OFC impaired the ability to reverse stimulus-reward contingencies [115].
Overall, functional and lesion studies suggest that the striatum interacts with regions within the
frontal cortex to mediate subsequent responding when a behavioural adjustment is warranted.
Functional neuroimaging studies have also implicated the involvement of the striatum in
response to reversal errors [117-119]. In particular, the ventral striatum has been shown to be
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engaged during the final reversal error prior to a behavioural change [113]. Other studies have
reported the engagement of the caudate during punished reversal errors [105] and when new
searches are initiated (e.g. during reversal or stimulus-set change) [120]. Dissociable regions of
the striatum have been shown to be engaged in separate elements of stimulus-response learning.
Specifically, the dorsal striatum has been shown to be engaged during response selection and is
proposed to mediate decision making. In contrast, the ventral striatum has been found to be
engaged during feedback and is proposed to underlie learning associations between stimuli and
responses [121]. Likewise, O'Doherty [103] suggested the role of the ventral striatum in
representing predicted future reward values, and the dorsal striatum in learning the specific
actions that need to be performed to obtain the reward (stimulus-response associations). As well,
it has been proposed that the caudate is involved in maintaining adaptive goal-directed behaviour
by evaluating action-outcome contingencies [122]. During reversal learning tasks, it has been
proposed that the caudate interacts with the vlPFC during instances of response conflict (i.e.
receiving negative feedback), to augment motor responses [105,118]. In line with this model,
Mitchell, Rhodes, Pine and Blair [118] demonstrated increased activity within the vlPFC and
caudate during instances of conflict (e.g. reversal errors, non-reversal errors and correct reversal
responses).

1.11.3 Neurotransmitters involved in Reversal Learning
Pharmacological studies have revealed a differential contribution of monoamine
neurotransmitters during reversal learning. Serotonin depletion in the marmoset PFC results in
perseverative responding to previously rewarded stimuli, suggesting a role for serotonin in
behavioural flexibility [123]. This role of serotonin has been suggested to be specific to the OFC
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as serotonergic depletion in the medial caudate does not impact reversal learning performance
[124], or attentional set-shifting, which is mediated by the dlPFC [107,125].
Dopamine neurons encode prediction error signalling [126] which has been found to be
mediated by the OFC, amygdala and ventral striatum [103]. Dopaminergic depletions of the
marmoset OFC do not impact reversal learning performance [127]; however, depletion in the
medial caudate leads to reversal deficits [124]. Studies in Parkinson’s Disease (PD) have
suggested that dopaminergic medication may overdose brain regions with relatively intact levels
of dopamine including the ventromedial caudate, and replete dopamine-depleted regions
including the dorsal striatum [128,129]. Consequently, patients with PD exhibit impaired
reversal learning performance on dopaminergic medication relative to off medication [129,130].
As well, in healthy controls with presumably optimal baseline dopamine levels, administration of
levodopa resulted in greater reversal errors relative to when participants were on placebo [131].

1.11.4 Reversal Learning in FTD
Consistent with the suggestion that patients with FTD exhibit deficits in flexibly
modifying behaviour, the available evidence suggests that FTD is associated with reversal
learning impairments [132-134]. Although patients adequately associate each stimulus with its
reinforcement value, when the reward contingencies change, patients continued to select the
previously rewarded stimulus, and thus make more reversal errors relative to controls [132,134].
One study has found an association between the number of reversal errors made and atrophy
within the anterior cingulate cortex (BA 24) and the medial/lateral OFC (BA 11, 47) [133]. This
suggests that the inability to suppress a previously rewarded behaviour in favour of an alternative
behaviour may be associated with degeneration of the frontal cortex.
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To date, no study has evaluated the functional neural correlates of reversal learning
in FTD. Delineating the pathophysiology of impaired behavioural flexibility in FTD can
inform whether reversal learning deficits are the result of impaired prediction error
signalling during an unexpected reinforcement (vmPFC), impaired conflict processing
(dmPFC), and/or implementing alternative motor responses (caudate/vlPFC). These
findings may provide targets for future pharmacological or behavioural interventions
mediating these underlying cognitive functions.

1.12 Thesis Objectives and Hypothesis
The overall objective of this thesis is to elucidate behavioural, structural and functional
changes in FTD from the preclinical to the symptomatic disease stage. This goal was addressed
using a multifaceted approach whereby three independent studies were conducted in patients
with FTD and/or individuals who are genetically at-risk for developing FTD. The central
hypothesis is that potential markers and outcome measures for clinical trial designs will be
identified in preclinical and symptomatic individuals. Ultimately, the results of these studies will
extend previous work on the potential candidate biomarkers sensitive to FTD to help diagnose
patients earlier and more accurately, and characterize the functional processes that underlie
symptoms of FTD to identify potential targets for treatments, and inform clinical trial designs.
Additionally, these results may help delineate the natural progression of this disease from the
preclinical, prodromal and affected stages and supplement our knowledge on the vulnerable
brain networks that can be targets for future therapies.
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Study 1: Early Symptoms in Symptomatic and Preclinical Genetic Frontotemporal Lobar
Degeneration
Identification of the initial symptoms that represent the earliest functional manifestations
of the pathophysiology of FTD are a critical outcome measure for future interventions aiming to
prevent conversion to clinical FTD. The first objective of this study was to evaluate whether
preclinical carriers of a pathogenic mutation demonstrate greater or unique symptoms relative to
biologically related mutation non-carriers. The second objective was to evaluate whether the
initial symptoms differed as a function of the specific genetic mutation during the preclinical and
symptomatic period. Although some symptoms may be present in both familial mutation carriers
and non-carriers due to shared environmental factors and stress/burden of having a family
member with FTD, we hypothesize that as preclinical carriers approach the time of expected
disease onset, they will endorse greater FTD-related symptoms relative to non-carriers.
Additionally, consistent with the previous literature [83], we predict that specific symptom
endorsement will differ across the genetic mutations within the preclinical and symptomatic
mutation carriers.

Study 2: Ventricular Volume Expansion in Preclinical Genetic Frontotemporal Dementia
Some work has evaluated ventricular volume in patients with FTD and has found greater
ventricular expansion in FTD relative to healthy controls [56,95]; however, no study has
assessed ventricular volume expansion in preclinical mutation carriers in FTD. Ventricular
volume measures are robust to scanner inhomogeneities and are amenable to robust automatic
segmentation due to the intense contrast in intensity between the ventricles and surrounding
tissue (Nestor et al, 2008). Investigating ventricular volume measurements during the preclinical
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disease period will inform whether these measurements can be used to identify pathogenic
changes prior to disease onset. The objective of the present study was to examine ventricular
volume change over a one-year period in carriers of an FTD-causing mutation and non-carriers,
to determine its potential utility as a biomarker of early preclinical disease. In line with previous
research showing smaller cortical volumes during the preclinical period in mutation carriers
[135], we hypothesize that mutation carriers (symptomatic and preclinical mutation carriers) will
show greater ventricular expansion relative to non-carriers. Additionally, we predict that
preclinical mutation carriers alone will show greater ventricular expansion relative to noncarriers.

Study 3: Neural Correlates of Reversal Learning in Frontotemporal Dementia
Disinhibition and poor behaviour flexibility is an early and debilitating symptom in FTD;
thus, investigating the neural mechanisms mediating these symptoms is warranted. Specifically,
assessing the underlying neural correlates can inform whether these behavioural deficits are the
result of impaired prediction error signalling during an unexpected reinforcement (vmPFC),
impaired conflict processing (dmPFC), and/or deficits in implementing alternative motor
responses (caudate/vlPFC). Delineating the aberrant pathophysiology may inform potential
pharmacologic or behavioural interventions. With this, the objective of this study to identify
whether patients with FTD reveal abnormal neural deficits in an fMRI-reversal learning task. We
hypothesize that patients with FTD will reveal abnormal activity in areas important in reversal
learning including the mPFC (dorsal and ventral regions), and ventrolateral PFC, during the
reversal learning task, especially during the reversal trials.

22

References

[1]

Mackenzie IR, Neumann M. Molecular neuropathology of frontotemporal dementia:
insights into disease mechanisms from postmortem studies. J Neurochem 2016;138 Suppl
1: 54-70.

[2]

Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG. The evolution and
pathology of frontotemporal dementia. Brain 2005;128: 1996-2005.

[3]

Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal
dementia. Neurology 2002;58: 1615-21.

[4]

Knopman DS, Roberts RO. Estimating the number of persons with frontotemporal lobar
degeneration in the US population. J Mol Neurosci 2011;45: 330-5.

[5]

Coyle-Gilchrist IT, Dick KM, Patterson K, Vázquez Rodríquez P, Wehmann E, Wilcox
A, Lansdall CJ, Dawson KE, Wiggins J, Mead S, Brayne C, Rowe JB. Prevalence,
characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology
2016;86: 1736-43.

[6]

Boxer AL, Gold M, Feldman H, Boeve BF, Dickinson SL, Fillit H, Ho C, Paul R,
Pearlman R, Sutherland M, Verma A, Arneric SP, Alexander BM, Dickerson BC, Dorsey
ER, Grossman M, Huey ED, Irizarry MC, Marks WJ, Masellis M, McFarland F, Niehoff
D, Onyike CU, Paganoni S, Panzara MA, Rockwood K, Rohrer JD, Rosen H, Schuck
RN, Soares HD, Tatton N. New directions in clinical trials for frontotemporal lobar
degeneration: Methods and outcome measures. Alzheimers Dement 2020;16: 131-143.

[7]

Galvin JE, Howard DH, Denny SS, Dickinson S, Tatton N. The social and economic
burden of frontotemporal degeneration. Neurology 2017;89: 2049-2056.

[8]

Riedijk SR, De Vugt ME, Duivenvoorden HJ, Niermeijer MF, Van Swieten JC, Verhey
FR, Tibben A. Caregiver burden, health-related quality of life and coping in dementia
caregivers: a comparison of frontotemporal dementia and Alzheimer's disease. Dement
Geriatr Cogn Disord 2006;22: 405-12.

[9]

Boutoleau-Bretonnière C, Vercelletto M, Volteau C, Renou P, Lamy E. Zarit burden
inventory and activities of daily living in the behavioral variant of frontotemporal
dementia. Dement Geriatr Cogn Disord 2008;25: 272-7.

23

[10]

Mioshi E, Bristow M, Cook R, Hodges JR. Factors underlying caregiver stress in
frontotemporal dementia and Alzheimer's disease. Dement Geriatr Cogn Disord 2009;27:
76-81.

[11]

Kansal K, Mareddy M, Sloane KL, Minc AA, Rabins PV, McGready JB, Onyike CU.
Survival in Frontotemporal Dementia Phenotypes: A Meta-Analysis. Dement Geriatr
Cogn Disord 2016;41: 109-22.

[12]

Nunnemann S, Last D, Schuster T, Förstl H, Kurz A, Diehl-Schmid J. Survival in a
German population with frontotemporal lobar degeneration. Neuroepidemiology
2011;37: 160-5.

[13]

Cosseddu M, Benussi A, Gazzina S, Turrone R, Archetti S, Bonomi E, Biasiotto G,
Zanella I, Ferrari R, Cotelli MS, Alberici A, Padovani A, Borroni B. Mendelian forms of
disease and age at onset affect survival in frontotemporal dementia. Amyotroph Lateral
Scler Frontotemporal Degener 2018;19: 87-92.

[14]

Onyike CU. What is the life expectancy in frontotemporal lobar degeneration?
Neuroepidemiology 2011;37: 166-7.

[15]

Rohrer JD, Guerreiro R, Vandrovcova J, Uphill J, Reiman D, Beck J, Isaacs AM, Authier
A, Ferrari R, Fox NC, Mackenzie IR, Warren JD, de Silva R, Holton J, Revesz T, Hardy
J, Mead S, Rossor MN. The heritability and genetics of frontotemporal lobar
degeneration. Neurology 2009;73: 1451-6.

[16]

Seelaar H, Kamphorst W, Rosso SM, Azmani A, Masdjedi R, de Koning I, Maat-Kievit
JA, Anar B, Donker Kaat L, Breedveld GJ, Dooijes D, Rozemuller JM, Bronner IF,
Rizzu P, van Swieten JC. Distinct genetic forms of frontotemporal dementia. Neurology
2008;71: 1220-6.

[17]

Po K, Leslie FV, Gracia N, Bartley L, Kwok JB, Halliday GM, Hodges JR, Burrell JR.
Heritability in frontotemporal dementia: more missing pieces? J Neurol 2014;261: 21707.

[18]

Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S,
Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies
P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse
M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun
H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok
JB, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA,
Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink P. Association of missense
and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature
1998;393: 702-5.

24

[19]

Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the
tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad
Sci U S A 1998;95: 7737-41.

[20]

Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R,
Vandenberghe R, Dermaut B, Martin JJ, van Duijn C, Peeters K, Sciot R, Santens P, De
Pooter T, Mattheijssens M, Van den Broeck M, Cuijt I, Vennekens K, De Deyn PP,
Kumar-Singh S, Van Broeckhoven C. Null mutations in progranulin cause ubiquitinpositive frontotemporal dementia linked to chromosome 17q21. Nature 2006;442: 920-4.

[21]

Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C,
Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary D,
Melquist S, Richardson A, Dickson D, Berger Z, Eriksen J, Robinson T, Zehr C, Dickey
CA, Crook R, McGowan E, Mann D, Boeve B, Feldman H, Hutton M. Mutations in
progranulin cause tau-negative frontotemporal dementia linked to chromosome 17.
Nature 2006;442: 916-9.

[22]

DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ,
Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung
GY, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK,
Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, GraffRadford NR, Rademakers R. Expanded GGGGCC hexanucleotide repeat in noncoding
region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72: 24556.

[23]

Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, Schymick
JC, Laaksovirta H, van Swieten JC, Myllykangas L, Kalimo H, Paetau A, Abramzon Y,
Remes AM, Kaganovich A, Scholz SW, Duckworth J, Ding J, Harmer DW, Hernandez
DG, Johnson JO, Mok K, Ryten M, Trabzuni D, Guerreiro RJ, Orrell RW, Neal J,
Murray A, Pearson J, Jansen IE, Sondervan D, Seelaar H, Blake D, Young K, Halliwell
N, Callister JB, Toulson G, Richardson A, Gerhard A, Snowden J, Mann D, Neary D,
Nalls MA, Peuralinna T, Jansson L, Isoviita VM, Kaivorinne AL, Hölttä-Vuori M,
Ikonen E, Sulkava R, Benatar M, Wuu J, Chiò A, Restagno G, Borghero G, Sabatelli M,
Heckerman D, Rogaeva E, Zinman L, Rothstein JD, Sendtner M, Drepper C, Eichler EE,
Alkan C, Abdullaev Z, Pack SD, Dutra A, Pak E, Hardy J, Singleton A, Williams NM,
Heutink P, Pickering-Brown S, Morris HR, Tienari PJ, Traynor BJ. A hexanucleotide
repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.
Neuron 2011;72: 257-68.

[24]

Greaves CV, Rohrer JD. An update on genetic frontotemporal dementia. J Neurol
2019;266: 2075-2086.

[25]

Benussi A, Padovani A, Borroni B. Phenotypic Heterogeneity of Monogenic
Frontotemporal Dementia. Front Aging Neurosci 2015;7: 171.
25

[26]

Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular
basis of frontotemporal dementia. Nat Rev Neurol 2012;8: 423-34.

[27]

Moore KM, Nicholas J, Grossman M, McMillan CT, Irwin DJ, Massimo L, Van Deerlin
VM, Warren JD, Fox NC, Rossor MN, Mead S, Bocchetta M, Boeve BF, Knopman DS,
Graff-Radford NR, Forsberg LK, Rademakers R, Wszolek ZK, van Swieten JC, Jiskoot
LC, Meeter LH, Dopper EG, Papma JM, Snowden JS, Saxon J, Jones M, PickeringBrown S, Le Ber I, Camuzat A, Brice A, Caroppo P, Ghidoni R, Pievani M, Benussi L,
Binetti G, Dickerson BC, Lucente D, Krivensky S, Graff C, Öijerstedt L, Fallström M,
Thonberg H, Ghoshal N, Morris JC, Borroni B, Benussi A, Padovani A, Galimberti D,
Scarpini E, Fumagalli GG, Mackenzie IR, Hsiung GR, Sengdy P, Boxer AL, Rosen H,
Taylor JB, Synofzik M, Wilke C, Sulzer P, Hodges JR, Halliday G, Kwok J, SanchezValle R, Lladó A, Borrego-Ecija S, Santana I, Almeida MR, Tábuas-Pereira M, Moreno
F, Barandiaran M, Indakoetxea B, Levin J, Danek A, Rowe JB, Cope TE, Otto M,
Anderl-Straub S, de Mendonça A, Maruta C, Masellis M, Black SE, Couratier P,
Lautrette G, Huey ED, Sorbi S, Nacmias B, Laforce R, Jr., Tremblay ML, Vandenberghe
R, Damme PV, Rogalski EJ, Weintraub S, Gerhard A, Onyike CU, Ducharme S,
Papageorgiou SG, Ng ASL, Brodtmann A, Finger E, Guerreiro R, Bras J, Rohrer JD. Age
at symptom onset and death and disease duration in genetic frontotemporal dementia: an
international retrospective cohort study. Lancet Neurol 2020;19: 145-156.

[28]

Ramos EM, Dokuru DR, Van Berlo V, Wojta K, Wang Q, Huang AY, Deverasetty S,
Qin Y, van Blitterswijk M, Jackson J, Appleby B, Bordelon Y, Brannelly P, Brushaber
DE, Dickerson B, Dickinson S, Domoto-Reilly K, Faber K, Fields J, Fong J, Foroud T,
Forsberg LK, Gavrilova R, Ghoshal N, Goldman J, Graff-Radford J, Graff-Radford N,
Grant I, Grossman M, Heuer HW, Hsiung GR, Huey E, Irwin D, Kantarci K, Karydas A,
Kaufer D, Kerwin D, Knopman D, Kornak J, Kramer JH, Kremers W, Kukull W, Litvan
I, Ljubenkov P, Lungu C, Mackenzie I, Mendez MF, Miller BL, Onyike C, Pantelyat A,
Pearlman R, Petrucelli L, Potter M, Rankin KP, Rascovsky K, Roberson ED, Rogalski E,
Shaw L, Syrjanen J, Tartaglia MC, Tatton N, Taylor J, Toga A, Trojanowski JQ,
Weintraub S, Wong B, Wszolek Z, Rademakers R, Boeve BF, Rosen HJ, Boxer AL,
Coppola G. Genetic screening of a large series of North American sporadic and familial
frontotemporal dementia cases. Alzheimers Dement 2020;16: 118-130.

[29]

Rohrer JD, Warren JD. Phenotypic signatures of genetic frontotemporal dementia. Curr
Opin Neurol 2011;24: 542-9.

[30]

Pottier C, Ravenscroft TA, Sanchez-Contreras M, Rademakers R. Genetics of FTLD:
overview and what else we can expect from genetic studies. J Neurochem 2016;138
Suppl 1: 32-53.

[31]

He Z, Bateman A. Progranulin (granulin-epithelin precursor, PC-cell-derived growth
factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med (Berl) 2003;81:
600-12.

26

[32]

Gass J, Cannon A, Mackenzie IR, Boeve B, Baker M, Adamson J, Crook R, Melquist S,
Kuntz K, Petersen R, Josephs K, Pickering-Brown SM, Graff-Radford N, Uitti R,
Dickson D, Wszolek Z, Gonzalez J, Beach TG, Bigio E, Johnson N, Weintraub S,
Mesulam M, White CL, 3rd, Woodruff B, Caselli R, Hsiung GY, Feldman H, Knopman
D, Hutton M, Rademakers R. Mutations in progranulin are a major cause of ubiquitinpositive frontotemporal lobar degeneration. Hum Mol Genet 2006;15: 2988-3001.

[33]

Woollacott IO, Rohrer JD. The clinical spectrum of sporadic and familial forms of
frontotemporal dementia. J Neurochem 2016;138 Suppl 1: 6-31.

[34]

Rohrer JD, Isaacs AM, Mizielinska S, Mead S, Lashley T, Wray S, Sidle K, Fratta P,
Orrell RW, Hardy J, Holton J, Revesz T, Rossor MN, Warren JD. C9orf72 expansions in
frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurol 2015;14: 291301.

[35]

Rosso SM, Landweer EJ, Houterman M, Donker Kaat L, van Duijn CM, van Swieten JC.
Medical and environmental risk factors for sporadic frontotemporal dementia: a
retrospective case-control study. J Neurol Neurosurg Psychiatry 2003;74: 1574-6.

[36]

Heuer HW, Wang P, Rascovsky K, Wolf A, Appleby B, Bove J, Bordelon Y, Brannelly
P, Brushaber DE, Caso C, Coppola G, Dickerson B, Dickinson S, Domoto-Reilly K,
Faber K, Ferrall J, Fields J, Fishman A, Fong J, Foroud T, Forsberg LK, Gearhart D,
Ghazanfari B, Ghoshal N, Goldman J, Graff-Radford J, Graff-Radford N, Grant I,
Grossman M, Haley D, Hsiung GY, Huey E, Irwin D, Jones D, Kantarci K, Karydas A,
Kaufer D, Kerwin D, Knopman D, Kornak J, Kramer JH, Kraft R, Kremers WK, Kukull
W, Litvan I, Ljubenkov P, Mackenzie IR, Maldonado M, Manoochehri M, McGinnis S,
McKinley E, Mendez MF, Miller BL, Onyike C, Pantelyat A, Pearlman R, Petrucelli L,
Potter M, Rademakers R, Ramos EM, Rankin KP, Roberson ED, Rogalski E, Sengdy P,
Shaw L, Syrjanen J, Tartaglia MC, Tatton N, Taylor J, Toga A, Trojanowski J,
Weintraub S, Wong B, Wszolek Z, Boeve BF, Rosen HJ, Boxer AL. Comparison of
sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North
American cohort. Alzheimers Dement 2020;16: 60-70.

[37]

Hodges JR, Patterson K. Semantic dementia: a unique clinicopathological syndrome.
Lancet Neurol 2007;6: 1004-14.

[38]

Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet 2015;386: 1672-82.

[39]

Johnson JK, Diehl J, Mendez MF, Neuhaus J, Shapira JS, Forman M, Chute DJ,
Roberson ED, Pace-Savitsky C, Neumann M, Chow TW, Rosen HJ, Forstl H, Kurz A,
Miller BL. Frontotemporal lobar degeneration: demographic characteristics of 353
patients. Arch Neurol 2005;62: 925-30.

27

[40]

Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten
JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A,
Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham
CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC,
Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, DiehlSchmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F,
Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL. Sensitivity of revised
diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain
2011;134: 2456-77.

[41]

Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM,
Rohrer JD, Black S, Boeve BF, Manes F, Dronkers NF, Vandenberghe R, Rascovsky K,
Patterson K, Miller BL, Knopman DS, Hodges JR, Mesulam MM, Grossman M.
Classification of primary progressive aphasia and its variants. Neurology 2011;76: 100614.

[42]

Seeley WW, Bauer AM, Miller BL, Gorno-Tempini ML, Kramer JH, Weiner M, Rosen
HJ. The natural history of temporal variant frontotemporal dementia. Neurology 2005;64:
1384-90.

[43]

Sivasathiaseelan H, Marshall CR, Agustus JL, Benhamou E, Bond RL, van Leeuwen
JEP, Hardy CJD, Rohrer JD, Warren JD. Frontotemporal Dementia: A Clinical Review.
Semin Neurol 2019;39: 251-263.

[44]

Guimarães HC, Vale TC, Pimentel V, de Sá NC, Beato RG, Caramelli P. Analysis of a
case series of behavioral variant frontotemporal dementia: emphasis on diagnostic delay.
Dement Neuropsychol 2013;7: 55-59.

[45]

Pose M, Cetkovich M, Gleichgerrcht E, Ibáñez A, Torralva T, Manes F. The overlap of
symptomatic dimensions between frontotemporal dementia and several psychiatric
disorders that appear in late adulthood. Int Rev Psychiatry 2013;25: 159-67.

[46]

Woolley JD, Khan BK, Murthy NK, Miller BL, Rankin KP. The diagnostic challenge of
psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior
psychiatric diagnosis in patients with early neurodegenerative disease. J Clin Psychiatry
2011;72: 126-33.

[47]

Tsai RM, Boxer AL. Treatment of frontotemporal dementia. Curr Treat Options Neurol
2014;16: 319.

[48]

Barton C, Ketelle R, Merrilees J, Miller B. Non-pharmacological Management of
Behavioral Symptoms in Frontotemporal and Other Dementias. Curr Neurol Neurosci
Rep 2016;16: 14.

28

[49]

Tsai RM, Boxer AL. Therapy and clinical trials in frontotemporal dementia: past, present,
and future. J Neurochem 2016;138 Suppl 1: 211-21.

[50]

Zetterberg H, van Swieten JC, Boxer AL, Rohrer JD. Review: Fluid biomarkers for
frontotemporal dementias. 2019;45: 81-87.

[51]

Staffaroni AM, Ljubenkov PA, Kornak J, Cobigo Y, Datta S, Marx G, Walters SM,
Chiang K, Olney N, Elahi FM, Knopman DS, Dickerson BC, Boeve BF, Gorno-Tempini
ML, Spina S, Grinberg LT, Seeley WW, Miller BL, Kramer JH, Boxer AL, Rosen HJ.
Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia
clinical trials. Brain 2019;142: 443-459.

[52]

Logroscino G, Imbimbo BP, Lozupone M, Sardone R, Capozzo R, Battista P, Zecca C,
Dibello V, Giannelli G, Bellomo A, Greco A, Daniele A, Seripa D, Panza F. Promising
therapies for the treatment of frontotemporal dementia clinical phenotypes: from
symptomatic to disease-modifying drugs. 2019;20: 1091-1107.

[53]

Rohrer JD, Warren JD, Fox NC, Rossor MN. Presymptomatic studies in genetic
frontotemporal dementia. Rev Neurol (Paris) 2013;169: 820-4.

[54]

Shinagawa S, Ikeda M, Fukuhara R, Tanabe H. Initial symptoms in frontotemporal
dementia and semantic dementia compared with Alzheimer's disease. Dement Geriatr
Cogn Disord 2006;21: 74-80.

[55]

Pijnenburg YA, Gillissen F, Jonker C, Scheltens P. Initial complaints in frontotemporal
lobar degeneration. Dement Geriatr Cogn Disord 2004;17: 302-6.

[56]

Mahoney CJ, Downey LE, Ridgway GR, Beck J, Clegg S, Blair M, Finnegan S, Leung
KK, Yeatman T, Golden H, Mead S, Rohrer JD, Fox NC, Warren JD. Longitudinal
neuroimaging and neuropsychological profiles of frontotemporal dementia with
C9ORF72 expansions. Alzheimers Res Ther 2012;4: 41.

[57]

Rademakers R, Baker M, Gass J, Adamson J, Huey ED, Momeni P, Spina S, Coppola G,
Karydas AM, Stewart H, Johnson N, Hsiung GY, Kelley B, Kuntz K, Steinbart E, Wood
EM, Yu CE, Josephs K, Sorenson E, Womack KB, Weintraub S, Pickering-Brown SM,
Schofield PR, Brooks WS, Van Deerlin VM, Snowden J, Clark CM, Kertesz A, Boylan
K, Ghetti B, Neary D, Schellenberg GD, Beach TG, Mesulam M, Mann D, Grafman J,
Mackenzie IR, Feldman H, Bird T, Petersen R, Knopman D, Boeve B, Geschwind DH,
Miller B, Wszolek Z, Lippa C, Bigio EH, Dickson D, Graff-Radford N, Hutton M.
Phenotypic variability associated with progranulin haploinsufficiency in patients with the
common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol
2007;6: 857-68.

29

[58]

Van Langenhove T, van der Zee J, Gijselinck I, Engelborghs S, Vandenberghe R,
Vandenbulcke M, De Bleecker J, Sieben A, Versijpt J, Ivanoiu A, Deryck O, Willems C,
Dillen L, Philtjens S, Maes G, Bäumer V, Van Den Broeck M, Mattheijssens M, Peeters
K, Martin JJ, Michotte A, Santens P, De Jonghe P, Cras P, De Deyn PP, Cruts M, Van
Broeckhoven C. Distinct clinical characteristics of C9orf72 expansion carriers compared
with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTLD cohort. JAMA
Neurol 2013;70: 365-73.

[59]

Sha SJ, Takada LT, Rankin KP, Yokoyama JS, Rutherford NJ, Fong JC, Khan B,
Karydas A, Baker MC, DeJesus-Hernandez M, Pribadi M, Coppola G, Geschwind DH,
Rademakers R, Lee SE, Seeley W, Miller BL, Boxer AL. Frontotemporal dementia due
to C9ORF72 mutations: clinical and imaging features. Neurology 2012;79: 1002-11.

[60]

Le Ber I, Camuzat A, Hannequin D, Pasquier F, Guedj E, Rovelet-Lecrux A, HahnBarma V, van der Zee J, Clot F, Bakchine S, Puel M, Ghanim M, Lacomblez L, Mikol J,
Deramecourt V, Lejeune P, de la Sayette V, Belliard S, Vercelletto M, Meyrignac C, Van
Broeckhoven C, Lambert JC, Verpillat P, Campion D, Habert MO, Dubois B, Brice A.
Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological,
imaging and genetic study. Brain 2008;131: 732-46.

[61]

Kaivorinne AL, Bode MK, Paavola L, Tuominen H, Kallio M, Renton AE, Traynor BJ,
Moilanen V, Remes AM. Clinical Characteristics of C9ORF72-Linked Frontotemporal
Lobar Degeneration. Dement Geriatr Cogn Dis Extra 2013;3: 251-62.

[62]

Snowden JS, Rollinson S, Thompson JC, Harris JM, Stopford CL, Richardson AM, Jones
M, Gerhard A, Davidson YS, Robinson A, Gibbons L, Hu Q, DuPlessis D, Neary D,
Mann DM, Pickering-Brown SM. Distinct clinical and pathological characteristics of
frontotemporal dementia associated with C9ORF72 mutations. Brain 2012;135: 693-708.

[63]

Mann DMA, Snowden JS. Frontotemporal lobar degeneration: Pathogenesis, pathology
and pathways to phenotype. Brain Pathol 2017;27: 723-736.

[64]

Piguet O, Brooks WS, Halliday GM, Schofield PR, Stanford PM, Kwok JB, Spillantini
MG, Yancopoulou D, Nestor PJ, Broe GA, Hodges JR. Similar early clinical
presentations in familial and non-familial frontotemporal dementia. J Neurol Neurosurg
Psychiatry 2004;75: 1743-5.

[65]

Pickering-Brown SM, Richardson AM, Snowden JS, McDonagh AM, Burns A, Braude
W, Baker M, Liu WK, Yen SH, Hardy J, Hutton M, Davies Y, Allsop D, Craufurd D,
Neary D, Mann DM. Inherited frontotemporal dementia in nine British families
associated with intronic mutations in the tau gene. Brain 2002;125: 732-51.

30

[66]

Garrard P, Carroll E. Presymptomatic semantic impairment in a case of fronto-temporal
lobar degeneration associated with the +16 mutation in MAPT. Neurocase 2005;11: 37183.

[67]

Borrego-Écija S, Morgado J, Palencia-Madrid L, Grau-Rivera O, Reñé R, Hernández I,
Almenar C, Balasa M, Antonell A, Molinuevo JL, Lladó A, Martínez de Pancorbo M,
Gelpi E, Sánchez-Valle R. Frontotemporal Dementia Caused by the P301L Mutation in
the MAPT Gene: Clinicopathological Features of 13 Cases from the Same Geographical
Origin in Barcelona, Spain. Dement Geriatr Cogn Disord 2017;44: 213-221.

[68]

Jiskoot LC, Panman JL, Meeter LH, Dopper EGP, Donker Kaat L, Franzen S, van der
Ende EL, van Minkelen R, Rombouts S, Papma JM, van Swieten JC. Longitudinal
multimodal MRI as prognostic and diagnostic biomarker in presymptomatic familial
frontotemporal dementia. Brain 2019;142: 193-208.

[69]

Cheran G, Silverman H. Psychiatric symptoms in preclinical behavioural-variant
frontotemporal dementia in MAPT mutation carriers. 2018;89: 449-455.

[70]

Jiskoot LC, Panman JL, van Asseldonk L, Franzen S, Meeter LHH, Donker Kaat L, van
der Ende EL, Dopper EGP, Timman R, van Minkelen R, van Swieten JC, van den Berg
E, Papma JM. Longitudinal cognitive biomarkers predicting symptom onset in
presymptomatic frontotemporal dementia. J Neurol 2018;265: 1381-1392.

[71]

Barandiaran M, Estanga A, Moreno F, Indakoetxea B, Alzualde A, Balluerka N, Martí
Massó JF, López de Munain A. Neuropsychological features of asymptomatic c.7091G>A progranulin mutation carriers. J Int Neuropsychol Soc 2012;18: 1086-90.

[72]

Dopper EG, Rombouts SA, Jiskoot LC, Heijer T, de Graaf JR, Koning I, Hammerschlag
AR, Seelaar H, Seeley WW, Veer IM, van Buchem MA, Rizzu P, van Swieten JC.
Structural and functional brain connectivity in presymptomatic familial frontotemporal
dementia. Neurology 2013;80: 814-23.

[73]

Seeley WW, Crawford R, Rascovsky K, Kramer JH, Weiner M, Miller BL, GornoTempini ML. Frontal paralimbic network atrophy in very mild behavioral variant
frontotemporal dementia. Arch Neurol 2008;65: 249-55.

[74]

Borroni B, Cosseddu M, Pilotto A, Premi E, Archetti S, Gasparotti R, Cappa S, Padovani
A. Early stage of behavioral variant frontotemporal dementia: clinical and neuroimaging
correlates. Neurobiol Aging 2015;36: 3108-3115.

[75]

Krueger CE, Dean DL, Rosen HJ, Halabi C, Weiner M, Miller BL, Kramer JH.
Longitudinal rates of lobar atrophy in frontotemporal dementia, semantic dementia, and
Alzheimer's disease. Alzheimer Dis Assoc Disord 2010;24: 43-8.
31

[76]

Whitwell JL, Anderson VM, Scahill RI, Rossor MN, Fox NC. Longitudinal patterns of
regional change on volumetric MRI in frontotemporal lobar degeneration. Dement
Geriatr Cogn Disord 2004;17: 307-10.

[77]

Gordon E, Rohrer JD, Fox NC. Advances in neuroimaging in frontotemporal dementia. J
Neurochem 2016;138 Suppl 1: 193-210.

[78]

Rohrer JD, Ridgway GR, Modat M, Ourselin S, Mead S, Fox NC, Rossor MN, Warren
JD. Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by
progranulin and tau mutations. Neuroimage 2010;53: 1070-6.

[79]

Whitwell JL, Boeve BF, Weigand SD, Senjem ML, Gunter JL, Baker MC, DeJesusHernandez M, Knopman DS, Wszolek ZK, Petersen RC, Rademakers R, Jack CR, Jr.,
Josephs KA. Brain atrophy over time in genetic and sporadic frontotemporal dementia: a
study of 198 serial magnetic resonance images. Eur J Neurol 2015;22: 745-52.

[80]

Fumagalli GG, Basilico P, Arighi A, Bocchetta M, Dick KM, Cash DM, Harding S,
Mercurio M, Fenoglio C, Pietroboni AM, Ghezzi L, van Swieten J, Borroni B, de
Mendonça A, Masellis M, Tartaglia MC, Rowe JB, Graff C, Tagliavini F, Frisoni GB,
Laforce R, Jr., Finger E, Sorbi S, Scarpini E, Rohrer JD, Galimberti D. Distinct patterns
of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed
by visual rating scales. Alzheimers Res Ther 2018;10: 46.

[81]

Whitwell JL, Weigand SD, Boeve BF, Senjem ML, Gunter JL, DeJesus-Hernandez M,
Rutherford NJ, Baker M, Knopman DS, Wszolek ZK, Parisi JE, Dickson DW, Petersen
RC, Rademakers R, Jack CR, Jr., Josephs KA. Neuroimaging signatures of
frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain
2012;135: 794-806.

[82]

Whitwell JL, Jack CR, Jr., Boeve BF, Senjem ML, Baker M, Rademakers R, Ivnik RJ,
Knopman DS, Wszolek ZK, Petersen RC, Josephs KA. Voxel-based morphometry
patterns of atrophy in FTLD with mutations in MAPT or PGRN. Neurology 2009;72:
813-20.

[83]

Snowden JS, Adams J, Harris J, Thompson JC, Rollinson S, Richardson A, Jones M,
Neary D, Mann DM, Pickering-Brown S. Distinct clinical and pathological phenotypes in
frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations.
Amyotroph Lateral Scler Frontotemporal Degener 2015;16: 497-505.

[84]

Cash DM, Bocchetta M, Thomas DL, Dick KM, van Swieten JC, Borroni B, Galimberti
D, Masellis M, Tartaglia MC, Rowe JB, Graff C, Tagliavini F, Frisoni GB, Laforce R,
Jr., Finger E, de Mendonça A, Sorbi S, Rossor MN, Ourselin S, Rohrer JD. Patterns of
gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study.
Neurobiol Aging 2018;62: 191-196.
32

[85]

Premi E, Grassi M, van Swieten J, Galimberti D, Graff C, Masellis M, Tartaglia C,
Tagliavini F, Rowe JB, Laforce R, Jr., Finger E, Frisoni GB, de Mendonça A, Sorbi S,
Gazzina S, Cosseddu M, Archetti S, Gasparotti R, Manes M, Alberici A, Cardoso MJ,
Bocchetta M, Cash DM, Ourselin S, Padovani A, Rohrer JD, Borroni B. Cognitive
reserve and TMEM106B genotype modulate brain damage in presymptomatic
frontotemporal dementia: a GENFI study. Brain 2017;140: 1784-1791.

[86]

Chen Q, Boeve BF, Schwarz CG, Reid R, Tosakulwong N, Lesnick TG, Bove J,
Brannelly P, Brushaber D, Coppola G, Dheel C, Dickerson BC, Dickinson S, Faber K,
Fields J, Fong J, Foroud T, Forsberg L, Gavrilova RH, Gearhart D, Ghoshal N, Goldman
J, Graff-Radford J, Graff-Radford NR, Grossman M, Haley D, Heuer HW, Hsiung GR,
Huey E, Irwin DJ, Jack CR, Jones DT, Jones L, Karydas AM, Knopman DS, Kornak J,
Kramer J, Kremers W, Kukull WA, Lapid M, Lucente D, Lungu C, Mackenzie IRA,
Manoochehri M, McGinnis S, Miller BL, Pearlman R, Petrucelli L, Potter M,
Rademakers R, Ramos EM, Rankin KP, Rascovsky K, Sengdy P, Shaw L, Syrjanen J,
Tatton N, Taylor J, Toga AW, Trojanowski J, Weintraub S, Wong B, Boxer AL, Rosen
H, Wszolek Z, Kantarci K. Tracking white matter degeneration in asymptomatic and
symptomatic MAPT mutation carriers. Neurobiol Aging 2019;83: 54-62.

[87]

Popuri K, Dowds E, Beg MF, Balachandar R, Bhalla M, Jacova C, Buller A, Slack P,
Sengdy P, Rademakers R, Wittenberg D, Feldman HH, Mackenzie IR, Hsiung GR. Gray
matter changes in asymptomatic C9orf72 and GRN mutation carriers. Neuroimage Clin
2018;18: 591-598.

[88]

Panman JL, Jiskoot LC, Bouts M, Meeter LHH, van der Ende EL, Poos JM, Feis RA,
Kievit AJA, van Minkelen R, Dopper EGP, Rombouts S, van Swieten JC, Papma JM.
Gray and white matter changes in presymptomatic genetic frontotemporal dementia: a
longitudinal MRI study. Neurobiol Aging 2019;76: 115-124.

[89]

Nestor SM, Rupsingh R, Borrie M, Smith M, Accomazzi V, Wells JL, Fogarty J, Bartha
R. Ventricular enlargement as a possible measure of Alzheimer's disease progression
validated using the Alzheimer's disease neuroimaging initiative database. Brain
2008;131: 2443-54.

[90]

Whitwell JL, Jack CR, Jr., Pankratz VS, Parisi JE, Knopman DS, Boeve BF, Petersen
RC, Dickson DW, Josephs KA. Rates of brain atrophy over time in autopsy-proven
frontotemporal dementia and Alzheimer disease. Neuroimage 2008;39: 1034-40.

[91]

Rohrer JD, McNaught E, Foster J, Clegg SL, Barnes J, Omar R, Warrington EK, Rossor
MN, Warren JD, Fox NC. Tracking progression in frontotemporal lobar degeneration:
serial MRI in semantic dementia. Neurology 2008;71: 1445-51.

33

[92]

Knopman DS, Jack CR, Jr., Kramer JH, Boeve BF, Caselli RJ, Graff-Radford NR,
Mendez MF, Miller BL, Mercaldo ND. Brain and ventricular volumetric changes in
frontotemporal lobar degeneration over 1 year. Neurology 2009;72: 1843-9.

[93]

Gordon E, Rohrer JD, Kim LG, Omar R, Rossor MN, Fox NC, Warren JD. Measuring
disease progression in frontotemporal lobar degeneration: a clinical and MRI study.
Neurology 2010;74: 666-73.

[94]

Rohrer JD, Clarkson MJ, Kittus R, Rossor MN, Ourselin S, Warren JD, Fox NC. Rates of
hemispheric and lobar atrophy in the language variants of frontotemporal lobar
degeneration. J Alzheimers Dis 2012;30: 407-11.

[95]

Whitwell JL, Jack CR, Jr., Parisi JE, Knopman DS, Boeve BF, Petersen RC, Ferman TJ,
Dickson DW, Josephs KA. Rates of cerebral atrophy differ in different degenerative
pathologies. Brain 2007;130: 1148-58.

[96]

Floeter MK, Bageac D, Danielian LE, Braun LE, Traynor BJ, Kwan JY. Longitudinal
imaging in C9orf72 mutation carriers: Relationship to phenotype. Neuroimage Clin
2016;12: 1035-1043.

[97]

Convery R, Mead S, Rohrer JD. Review: Clinical, genetic and neuroimaging features of
frontotemporal dementia. 2019;45: 6-18.

[98]

Nakano S, Asada T, Yamashita F, Kitamura N, Matsuda H, Hirai S, Yamada T.
Relationship between antisocial behavior and regional cerebral blood flow in
frontotemporal dementia. Neuroimage 2006;32: 301-6.

[99]

Massimo L, Powers C, Moore P, Vesely L, Avants B, Gee J, Libon DJ, Grossman M.
Neuroanatomy of apathy and disinhibition in frontotemporal lobar degeneration. Dement
Geriatr Cogn Disord 2009;27: 96-104.

[100] Rolls ET, Hornak J, Wade D, McGrath J. Emotion-related learning in patients with social
and emotional changes associated with frontal lobe damage. J Neurol Neurosurg
Psychiatry 1994;57: 1518-24.
[101] Hornak J, O'Doherty J, Bramham J, Rolls ET, Morris RG, Bullock PR, Polkey CE.
Reward-related reversal learning after surgical excisions in orbito-frontal or dorsolateral
prefrontal cortex in humans. J Cogn Neurosci 2004;16: 463-78.
[102] Fellows LK, Farah MJ. Ventromedial frontal cortex mediates affective shifting in
humans: evidence from a reversal learning paradigm. Brain 2003;126: 1830-7.

34

[103] O'Doherty JP. Reward representations and reward-related learning in the human brain:
insights from neuroimaging. Curr Opin Neurobiol 2004;14: 769-76.
[104] Dias R, Robbins TW, Roberts AC. Primate analogue of the Wisconsin Card Sorting Test:
effects of excitotoxic lesions of the prefrontal cortex in the marmoset. Behav Neurosci
1996;110: 872-86.
[105] Budhani S, Marsh AA, Pine DS, Blair RJ. Neural correlates of response reversal:
considering acquisition. Neuroimage 2007;34: 1754-65.
[106] Finger EC, Marsh AA, Mitchell DG, Reid ME, Sims C, Budhani S, Kosson DS, Chen G,
Towbin KE, Leibenluft E, Pine DS, Blair JR. Abnormal ventromedial prefrontal cortex
function in children with psychopathic traits during reversal learning. Arch Gen
Psychiatry 2008;65: 586-94.
[107] Dias R, Robbins TW, Roberts AC. Dissociation in prefrontal cortex of affective and
attentional shifts. Nature 1996;380: 69-72.
[108] Manes F, Sahakian B, Clark L, Rogers R, Antoun N, Aitken M, Robbins T. Decisionmaking processes following damage to the prefrontal cortex. Brain 2002;125: 624-39.
[109] Tsuchida A, Doll BB, Fellows LK. Beyond reversal: a critical role for human
orbitofrontal cortex in flexible learning from probabilistic feedback. J Neurosci 2010;30:
16868-75.
[110] Mitchell DG, Luo Q, Avny SB, Kasprzycki T, Gupta K, Chen G, Finger EC, Blair RJ.
Adapting to dynamic stimulus-response values: differential contributions of inferior
frontal, dorsomedial, and dorsolateral regions of prefrontal cortex to decision making. J
Neurosci 2009;29: 10827-34.
[111] Remijnse PL, Nielen MM, Uylings HB, Veltman DJ. Neural correlates of a reversal
learning task with an affectively neutral baseline: an event-related fMRI study.
Neuroimage 2005;26: 609-18.
[112] Mitchell DG. The nexus between decision making and emotion regulation: a review of
convergent neurocognitive substrates. Behav Brain Res 2011;217: 215-31.
[113] Cools R, Clark L, Owen AM, Robbins TW. Defining the neural mechanisms of
probabilistic reversal learning using event-related functional magnetic resonance
imaging. J Neurosci 2002;22: 4563-7.
[114] Castañé A, Theobald DE, Robbins TW. Selective lesions of the dorsomedial striatum
impair serial spatial reversal learning in rats. Behav Brain Res 2010;210: 74-83.
35

[115] Clarke HF, Robbins TW, Roberts AC. Lesions of the medial striatum in monkeys
produce perseverative impairments during reversal learning similar to those produced by
lesions of the orbitofrontal cortex. J Neurosci 2008;28: 10972-82.
[116] Divac I, Rosvold HE, Szwarcbart MK. Behavioral effects of selective ablation of the
caudate nucleus. J Comp Physiol Psychol 1967;63: 184-90.
[117] Ghahremani DG, Monterosso J, Jentsch JD, Bilder RM, Poldrack RA. Neural
components underlying behavioral flexibility in human reversal learning. Cereb Cortex
2010;20: 1843-52.
[118] Mitchell DG, Rhodes RA, Pine DS, Blair RJ. The contribution of ventrolateral and
dorsolateral prefrontal cortex to response reversal. Behav Brain Res 2008;187: 80-7.
[119] Rogers RD, Andrews TC, Grasby PM, Brooks DJ, Robbins TW. Contrasting cortical and
subcortical activations produced by attentional-set shifting and reversal learning in
humans. J Cogn Neurosci 2000;12: 142-62.
[120] Hampshire A, Chaudhry AM, Owen AM, Roberts AC. Dissociable roles for lateral
orbitofrontal cortex and lateral prefrontal cortex during preference driven reversal
learning. Neuroimage 2012;59: 4102-12.
[121] Hiebert NM, Vo A, Hampshire A, Owen AM, Seergobin KN, MacDonald PA. Striatum
in stimulus-response learning via feedback and in decision making. Neuroimage
2014;101: 448-57.
[122] Grahn JA, Parkinson JA, Owen AM. The cognitive functions of the caudate nucleus.
Prog Neurobiol 2008;86: 141-55.
[123] Clarke HF, Dalley JW, Crofts HS, Robbins TW, Roberts AC. Cognitive inflexibility after
prefrontal serotonin depletion. Science 2004;304: 878-80.
[124] Clarke HF, Hill GJ, Robbins TW, Roberts AC. Dopamine, but not serotonin, regulates
reversal learning in the marmoset caudate nucleus. J Neurosci 2011;31: 4290-7.
[125] Clarke HF, Walker SC, Crofts HS, Dalley JW, Robbins TW, Roberts AC. Prefrontal
serotonin depletion affects reversal learning but not attentional set shifting. J Neurosci
2005;25: 532-8.
[126] Schultz W. Updating dopamine reward signals. Curr Opin Neurobiol 2013;23: 229-38.

36

[127] Clarke HF, Walker SC, Dalley JW, Robbins TW, Roberts AC. Cognitive inflexibility
after prefrontal serotonin depletion is behaviorally and neurochemically specific. Cereb
Cortex 2007;17: 18-27.
[128] Swainson R, Rogers RD, Sahakian BJ, Summers BA, Polkey CE, Robbins TW.
Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal
or temporal lobe lesions: possible adverse effects of dopaminergic medication.
Neuropsychologia 2000;38: 596-612.
[129] Cools R, Barker RA, Sahakian BJ, Robbins TW. Enhanced or impaired cognitive
function in Parkinson's disease as a function of dopaminergic medication and task
demands. Cereb Cortex 2001;11: 1136-43.
[130] Graef S, Biele G, Krugel LK, Marzinzik F, Wahl M, Wotka J, Klostermann F, Heekeren
HR. Differential influence of levodopa on reward-based learning in Parkinson's disease.
Front Hum Neurosci 2010;4: 169.
[131] Vo A, Seergobin KN, Morrow SA, MacDonald PA. Levodopa impairs probabilistic
reversal learning in healthy young adults. Psychopharmacology (Berl) 2016;233: 275363.
[132] Rahman S, Sahakian BJ, Hodges JR, Rogers RD, Robbins TW. Specific cognitive
deficits in mild frontal variant frontotemporal dementia. Brain 1999;122 ( Pt 8): 1469-93.
[133] Bertoux M, Volle E, Funkiewiez A, de Souza LC, Leclercq D, Dubois B. Social
Cognition and Emotional Assessment (SEA) is a marker of medial and orbital frontal
functions: a voxel-based morphometry study in behavioral variant of frontotemporal
degeneration. J Int Neuropsychol Soc 2012;18: 972-85.
[134] Bertoux M, Funkiewiez A, O'Callaghan C, Dubois B, Hornberger M. Sensitivity and
specificity of ventromedial prefrontal cortex tests in behavioral variant frontotemporal
dementia. Alzheimers Dement 2013;9: S84-94.
[135] Rohrer JD, Nicholas JM, Cash DM, van Swieten J, Dopper E, Jiskoot L, van Minkelen R,
Rombouts SA, Cardoso MJ, Clegg S, Espak M, Mead S, Thomas DL, De Vita E,
Masellis M, Black SE, Freedman M, Keren R, MacIntosh BJ, Rogaeva E, Tang-Wai D,
Tartaglia MC, Laforce R, Jr., Tagliavini F, Tiraboschi P, Redaelli V, Prioni S, Grisoli M,
Borroni B, Padovani A, Galimberti D, Scarpini E, Arighi A, Fumagalli G, Rowe JB,
Coyle-Gilchrist I, Graff C, Fallström M, Jelic V, Ståhlbom AK, Andersson C, Thonberg
H, Lilius L, Frisoni GB, Pievani M, Bocchetta M, Benussi L, Ghidoni R, Finger E, Sorbi
S, Nacmias B, Lombardi G, Polito C, Warren JD, Ourselin S, Fox NC, Rossor MN,
Binetti G. Presymptomatic cognitive and neuroanatomical changes in genetic
frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI)
study: a cross-sectional analysis. Lancet Neurol 2015;14: 253-62.
37

Chapter 2: Early Symptoms in Symptomatic and Preclinical Genetic Frontotemporal
Lobar Degeneration1
2.1 Introduction
Frontotemporal dementia (FTD) is a neurodegenerative disorder with approximately 40%
of patients showing a strong family history, with mutations in the chromosome 9 open reading
frame 72 (C9orf72), progranulin (GRN) or microtubule-associated protein tau (MAPT) genes
each accounting for 5-10% of patients with FTD [1]. While therapies targeting the underlying
pathology are in development [2], currently, no treatments are available to prevent or alter the
course of disease progression.
Even during the early stages of disease, symptoms of FTD are quite impairing [3]; thus,
treatments will likely need to be administered during the preclinical stage, before a patient meets
the current international consensus criteria [4,5]. Consequently, there is a growing interest in
identifying biomarkers and clinical endpoints that can best inform when to administer these
interventions and how to track treatment efficacy. A major challenge in designing clinical trials
and the designation of clinical endpoints is the heterogeneity of genetic FTD at the phenotypic
[6], and pathological levels [7,8]. For instance, clinical symptoms in genetic FTD range from
language disturbances [5] to behavioural and neuropsychiatric features [4], which occur at
various frequencies and ages even within families, and have different neuroanatomic associations
[9,10]. Furthermore, at present, it is not yet known whether or when symptoms associated with
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genetic FTD may occur during the prodromal period, and whether such symptoms may be
specific to the later development of clinical FTD.
To inform clinical endpoint selection for future clinical trials in at-risk cohorts, the first
objective of the current study was to evaluate the most frequent initial symptoms in patients with
symptomatic genetic FTD due to C9orf72, GRN or MAPT mutations. The second objective was
to evaluate whether preclinical mutation carriers demonstrate greater or different symptoms
relative to biologically related non-carriers during the preclinical period.

2.2 Method
2.2.1 Participants
The current study used data from the Genetic Frontotemporal Dementia Initiative
(GENFI) multicentre cohort study, which consists of research centres across Europe and Canada
(http://genfi.org.uk/). This dataset is comprised of (1) known symptomatic carriers of a
pathogenic mutation in the GRN or MAPT genes or with a pathogenic expansion in the C9orf72
gene (greater than 30 repeats) with clinical diagnoses based on the international consensus
diagnostic criteria [4,5], and (2) first-degree biological family members of a known GRN, MAPT
or C9orf72 mutation carrier who are at-risk for developing FTD and were not yet demonstrating
evidence of progressive cognitive or behavioral symptoms (including both preclinical carriers
and non-carriers). All eligible and interested participants were enrolled in the study. Importantly,
the majority of at-risk family members in the GENFI study, and the local GENFI research teams,
were not aware of their genetic status at the time of the assessments. After their baseline visit,
participants were followed for up to five annual visits. All participants had an identified
informant who completed clinical scales (see below). Participants with completed study
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measures were included in the analysis; information on other demographic variables was
complete for all participants in the study. The data was part of the GENFI data freeze 4 collected
at 22 GENFI sites (2012-2018). Local ethics committees at each site approved the study and all
participants provided written informed consent at enrollment.

2.2.2 Study Measures
GENFI Symptom List: The initial 37-symptom list was designed to include a variety of
FTD-related symptoms based on standardized rating scales (Appendix A: method section 1.0,
Table A.1, A.2 and result section 2.0). Informants of symptomatic patients (typically a spouse or
sibling) described the initial symptom and trained research coordinators selected the
corresponding symptom from the list. For at-risk family members, clinicians completed the
GENFI symptom list with the at-risk family member and their study informant, and evaluated the
presence of each symptom using a 5-point Likert scale (0=absent, 0.5= questionable/very mild,
1=mild, 2=moderate, 3=severe). Symptom ratings of questionable/very mild, mild, moderate,
severe were coded as symptom endorsement and absent coded as symptom absent.

2.2.2.1 Cambridge Behavioural Inventory Questionnaire-Revised (CBI-R)
Informants of at-risk family members completed the CBI-R [11]. This questionnaire was used to
evaluate the at-risk groups’ symptoms within the past 4 weeks. Each question is evaluated on a
5-point scale, where higher scores indicate greater symptom endorsement and severity. Symptom
domains included memory and orientation, everyday skills, self-care, abnormal behaviour, mood,
beliefs, eating habits, sleep, stereotypic and motor behaviours and motivation. Each domain
includes 2 to 8 sub-items.
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Years from expected onset was used to determine whether participants who were closer to the
age of anticipated clinical onset endorsed greater symptoms. Years from expected onset (YEO)
was calculated by subtracting the mean age of clinical onset within the family from the
participant’s current age [10,12]. Negative values denote that the participant is at an age prior to
expected clinical onset; positive values indicate that the participant is at an age after expected
clinical onset.

2.2.3 Statistical Analysis
GENFI Symptom List: Descriptive statistics were used to illustrate the most frequent
symptoms endorsed at participants’ initial visits. Differences amongst the three genetic groups in
the frequency of the most prevalent sub-symptoms were examined using Chi-squared test or
Fisher’s exact test for the symptomatic patients and at-risk individuals, and separately comparing
preclinical mutation carriers and non-carriers for each gene mutation. Mixed models were not
used to account for potential clustering effects of family membership and site, due to the low
symptom endorsement (creating small samples) by patients and at-risk family members.
For symptomatic and at-risk family members, a composite index was created for each
gene based on three most frequently endorsed initial symptoms for each of the symptomatic
genetic groups (C9orf72 & MAPT: disinhibition, apathy, memory; GRN: apathy, articulation,
fluency). For each composite, participants attained a score of 1 if they endorsed at least one
symptom within each composite (0=no symptoms endorsed, 1= at least one symptom endorsed).
Note only the predominant initial symptom was recorded in the GENFI intake for affected
participants. To evaluate the effectiveness of this composite to differentiate between mutation
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carriers and non-carriers, sensitivity and specificity values were computed
(https://www.medcalc.org/calc/diagnostic_test.php).
To evaluate changes in symptom endorsement over time in at-risk family members who
had at least one follow-up visit, a difference score was calculated by subtracting symptom
endorsement at the final visit from symptom endorsement at the first visit (0=not endorsed,
1=symptom endorsed). This resulted in three categories for each symptom: decrease in symptom
endorsement over time (score of -1), no change in symptom endorsement over time (score of 0),
increase in symptom endorsement over time (score of 1). Calculating change scores enabled all
participants to be included in the analysis, regardless of the number of follow-up visits. Chisquared tests/Fisher’s Exact tests were completed to assess group differences.
To evaluate whether the initial symptoms were similar amongst patients from the same
family, a congruency score was calculated as the number of pairwise comparisons in which
family members shared an initial symptom, divided by the total number of possible pairwise
comparisons. A congruency score was also calculated to evaluate the congruency of initial
predominant symptoms for specific GRN and MAPT mutations.

2.2.3.1 Cambridge Behavioural Inventory Questionnaire-Revised
A generalized linear mixed model with a Laplace likelihood approximation function was
used to examine differences in the total CBI-R scores between preclinical mutation carriers vs.
non-mutation carriers at the initial GENFI visit as a function of years from expected clinical
onset. This analysis accounted for potential clustering effects based on family membership. Plots
of the CBI-R total scores suggested a Poisson distribution; however, due to overdispersion as
indicated through the Pearson Chi-Square/DF (4.62), a negative binomial distribution with a log
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link function was used. For the total score, no participant had studentized residuals greater than
+/- 3.. Predictor variables included random effects [family membership] and fixed effects
[genetic status (preclinical vs. non-carriers), years from expected onset, and an interaction
between genetic status and years from expected onset]. Examination of the residuals suggested
the use of weights to account for the within-family correlation in the model. Given the variability
in contribution of family membership to predicting age of onset by mutation group [10], a
confirmatory analysis was conducted substituting years from expected onset with the
participant’s age. Of note, as age was highly correlated with years from expected onset (r=0.84,
p<0.001), participant’s age could not be included in the model due to multicollinearity. However,
when age was substituted for estimated years from expected onset, the pattern of results was
similar (Table A.3).
Change scores (symptom score at final visit – score at first visit)/ time interval) were
calculated to compare longitudinal data. Participants with studentized residuals greater than +/- 3
were removed (Table A.4), and a linear mixed model was used (see Appendix A, method section
3.0 on the description of the model formation). Predictor variables included random effects
[family membership] and fixed effects [genetic status (preclinical vs. non-carriers), years from
expected onset or participant’s age, CBI total score at baseline, and an interaction between
genetic status and years from expected onset]. A confirmatory analysis was run substituting
participant’s age at baseline for the years from expected onset (Table A.3). As differences
between the preclinical and non-carriers in the total CBI scores may be obscured by opposed
group differences in the sub-scale scores, we also examined group differences at baseline and
longitudinally for each of the sub-scales by using the model developed for the total score. For
these models, the same parameters were used with one exception: the sub-scale score at baseline
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was used as a fixed effect instead of the CBI total score at baseline. For both the baseline and
change score analysis, the potential influence of specific FTD-causing mutations was examined
by assessing the impact of genetic mutation type as the grouping variable (C9orF72, GRN,
MAPT, mutation non-carriers), and post-hoc comparisons were conducted between each genetic
group and non-carriers. For brevity, the results from the models with the genetic mutation group
are reported in the manuscript.

2.3 Results
2.3.1 Participants
185 patients diagnosed with FTD (C9orf72 n=87, GRN n=65, MAPT n=33) were
included in the analysis. Additionally, two groups of at-risk family members completed the
GENFI symptom list and CBI-R scales: 637 at-risk family members (317 preclinical mutation
carriers, 320 mutation non-carriers) and 588 at risk individuals (294 preclinical carriers, 294 noncarriers) completed the GENFI symptom list and CBI-R scales, respectively (Table 2.1).

2.3.2 Predominant Initial Symptoms in Symptomatic Patients
Across the entire cohort the most frequently endorsed initial symptoms were apathy
(23%), disinhibition (18%), memory impairments (12%) decreased fluency (8%) and impaired
articulation (5%; Figure 2.1, Table A.5). When the most frequent initial symptoms were
compared amongst the mutation groups, patients with MAPT mutations presented with
disinhibition more frequently relative to C9orf72 and GRN carriers, and displayed memory
impairments more frequently than GRN carriers. GRN carriers exhibited impaired articulation

44

and decreased fluency more often than C9orf72 and MAPT carriers. No group differences were
observed for apathy.
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Table 2.1: Demographics table for symptomatic and at-risk family members

N
Handedness
Right
Left
Ambidextrous
Sex
Male
Female
Genotype

Total

C9orf72

185

87

Age at onset (SD)

65

Contrasts

33

Preclinical&

Non-carrier&

317

320

*#

At-risk Family Members
Contrasts&
Preclinical^
294

Non-carrier^

p=0.14*#

p=0.16

174

80

65

29

282

298

275

262

9
2

5
2

0
0

4
0

31
4

20
2

17
2

28
4

X2=6.2,
p=0.045
108
77

57
30

30
35

21
12

X2=0.90,
p=0.34
123
194

136
184

X2=0.86,
p=0.35
112
182

123
171

X2=0.21,
p=0.90

62
4

33
28

31
0

9
6
1
0
0
3
2

0
0
0
2
1
1
0

0
0
0
1
0
1
0

62.3
(8.5)

63.7 (8.3)

63.5
(6.9)

56.2 (9.5)

58.1
(8.8)

58.8 (9.0)

60.6
(7.2)

51.1 (7.7)

F(2,184)=11.5,
p<0.001#
C9> MAPT
GRN > MAPT
F(2,184)=11.5,
p<0.001#
C9>MAPT
GRN >MAPT

X2=0.58,
p=0.75

117
144
56

115
144
61

104
138
52

103
132
59

121
80
72
30
10
4

118
98
58
27
15
4

124
80
60
22
7
1

122
95
38
23
16
0

2.6 (1.4) [n=196]

2.5 (1.5)
[n=202]
46.3 (14.0)

2.5 (1.3) [n=170]

2.4 (1.5) [n=172]

44.0 (11.9)

46.7 (14.1)

44.0 (11.8)
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t(394.7) = -0.6,
p=0.54
t(619)=2.3,
p=0.03

Contrasts^

294

*#

p=0.02

C9orf72
GRN
MAPT
Maximum
number of visits
1
2
3
4
5
6
Diagnosis
bvFTD
PPA
FTD-ALS
ALS
PSP
CBS
AD
Dementia- NOS
Other
Time interval for
change score (SD)
Age (SD)

Symptomatic Patients
GRN
MAPT

t(340)= -0.7,
p=0.49
t(570.1)=2.6,
p=0.01

Education, Yrs,
(SD)
Years from
expected disease
onset (SD)**

•
•
•
•
•
•

12.2
(4.0)

12.6 (4.0)

11.2
(4.0)

13.2 (3.6)

F(2,184)=3.5,
p=0.03#
MAPT> GRN
(p=0.065)

14.3 (3.3)

13.9 (3.6)

t(635)= -1.5,
p=0.13

14.3 (3.3)

13.9 (3.6)

t(586)= -1.58,
p=0.1

-14.4 (11.8)

-13.2 (14.1)

t(618.5) = 1.17,
p=0.24

-14.5 (12.0)

-12.9 (14.2)

t(569.3)=
1.51, p=0.13

Chi-squared (X2), Fisher’s Exact tests (if expected cell count was less than 5), independent sample t-tests or one-way analysis of variance were used to discern
group differences for relevant variables
# Bonferroni correction applied
&
At-risk participants from 248 families. Participants completed the GENFI symptom list
^At-risk participants from 228 families. Participants completed the CBI questionnaire
*#Fisher’s Exact Test was used
**Years from expected onset was calculated by subtracting the participant’s age at the time of participation from the mean age of disease onset within the family

47

Figure 2.1. Symptom endorsement in symptomatic patients and at-risk family members

Percentage of patients and at-risk individuals that endorsed symptoms identified as the most frequent symptoms in symptomatic patients.
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2.3.3 Symptom Congruency
Fourteen families had at least two related patients in the study cohort; amongst these
families, the average percentage congruency for first symptom similarity was 19% (Table A.6).
Five families with a MAPT mutation and 7 families with a GRN mutation had at least two
related symptomatic patients in the study cohort and the specific genotype was known. Of the
specific genotypes, the average congruency score was 33% for MAPT and 20% for GRN
mutations (Table A.7).

2.3.4 Symptom Endorsement in at-risk Family Members (GENFI symptom list)
There were no significant differences between at-risk individuals (preclinical C9orf72,
GRN, MAPT vs. non-carriers) or between preclinical genetic groups in the proportion of
participants who endorsed the initial symptoms most commonly reported in affected patients (i.e.
apathy, disinhibition, decreased fluency, impaired articulation and memory impairments) (Figure
2.2 & Table A.5, A.8). Overall, at-risk genetic groups (preclinical C9orf72, GRN, MAPT vs.
non-carriers) showed a similar pattern of symptom endorsement over time, with a very low
proportion of participants reporting changes in the most common initial symptoms (Table A.9).

3.3.5 Composite Scores
The sensitivity and specificity values indicate the composite indices differentiate between
symptomatic FTD and mutation non-carriers for each of the gene groups with sensitivities from
94% to 97% and specificities of 80%. For at-risk family members, the composite indices showed
low sensitivity (8-33%), with medium specificity (76-91%) to differentiate between preclinical
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mutation carriers from non-carriers beginning from -5, -2 and 0 years to expected age of onset
(Table A.10, A.11).

Figure 2.2. Baseline symptom endorsement by genotype in at-risk family members

Percentage of preclinical and non-mutation carriers that endorse each of the sub-symptoms
identified as the most frequent symptom in symptomatic patients

2.3.6 Symptom Endorsement & Severity in at-risk Family Members (CBI-R questionnaire)
CBI-R scores at baseline: As participants approached the anticipated time of onset there
was a significant increase in the reported total symptom score, memory and orientation, sleep,
motivation, eating habits, and stereotypic and motor behaviours scores. When adjusting for
expected years to onset and relative to non-carriers, post-hoc contrasts showed that MAPT
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carriers experienced greater mood, sleep, and motivation symptoms; C9orf72 carriers endorsed
greater abnormal behaviour and stereotypic & motor symptoms; and GRN carriers had lower
mood scores (Table 2.2; Figure 2.3).
Longitudinal CBI scores: Improved symptoms over time (negative change scores) were
associated with greater symptom scores at baseline when adjusted for expected years to onset
and carrier status across all participants. There were also significant associations between
expected years to onset and memory and orientation scores, stereotypic and motor behaviours,
but also for eating habits (Table 2.2). Within the sub-scales, GRN and C9orf72 preclinical
carriers demonstrated worse everyday skills over time relative to mutation non-carriers, but only
the GRN carriers’ scores met statistical significance (Figure 2.4).

2.4 Discussion
As the first study to compare initial symptoms in symptomatic and at-risk patients with
genetic FTD across the three main genetic mutations MAPT, C9orf72 and GRN, our findings
demonstrate the overlap and differences in the presence and frequencies of specific FTD-related
symptoms. We also report the first longitudinal differences between preclinical mutation carriers
in comparison to familial non-carriers in the endorsement of symptoms prior to diagnosis.
Important to the interpretation of symptom reports and design of clinical trials, we found that
preclinical MAPT and C9orf72 mutation carriers endorsed greater symptoms at the initial
assessment (approximately 14 years prior to anticipated age of onset), and over time GRN and
C9orf72 mutation carriers exhibited poorer everyday skills. The direct comparison of symptoms
among mutation groups may be important in the consideration of basket-design clinical trials
where, for example, patients with TDP-43 pathology arising from different mutations (C9orf72
& GRN) may be grouped together.
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Table 2.2: CBI-R total and sub-scale scores at baseline and over time for at-risk family members
by genetic group (no outliers included)
.

N
Total Score
C9orf72
GRN
MAPT
YEO
Baseline score
C9orf72*YEO
GRN*YEO
MAPT*YEO
Memory and Orientation
C9orf72
GRN
MAPT
YEO
Baseline score
C9orf72*YEO
GRN*YEO
MAPT*YEO
Everyday Skills
C9orf72
GRN
MAPT
YEO
Baseline score
C9orf72*YEO
GRN*YEO
MAPT*YEO
Abnormal Behaviour
C9orf72
GRN
MAPT
YEO
Baseline score
C9orf72*YEO
GRN*YEO
MAPT*YEO
Mood
C9orf72
GRN
MAPT
YEO
Baseline score
C9orf72*YEO
GRN*YEO
MAPT*YEO
Beliefs
C9orf72
GRN
MAPT
YEO
Baseline score
C9orf72*YEO
GRN*YEO
MAPT*YEO

588
104
138
52

588
104
138
52

588
104
138
52

588
104
138
52

587
104
137
52

Baseline#
Estimate (95% CI)

p-value

N

Change Score
Estimate (95% CI)

p-value

336
1.34 (0.78, 2.31)
0.95 (0.52, 1.73)
1.96 (0.88, 4.38)
1.02 (1, 1.03)
-

0.29
0.86
0.1
0.02
-

0.28 (-1.42, 1.97)
0.38 (-0.8, 1.56)
0.39 (-1.37, 2.15)
0.03 (-0.01, 0.07)
-0.15 (-0.21, -0.1)

0.75
0.53
0.66
0.11
<.0001

1 (0.98, 1.03)
1 (0.97, 1.03)
1 (0.96, 1.05)

0.8
0.87
0.85

0.01 (-0.08, 0.11)
-0.02 (-0.08, 0.05)
-0.01 (-0.12, 0.1)

0.78
0.63
0.86

0.88 (0.51, 1.52)
1.03 (0.56, 1.89)
0.89 (0.39, 2.03)
1.03 (1.01, 1.04)
0.98 (0.96, 1.01)
1.01 (0.98, 1.04)
0.99 (0.95, 1.03)

0.65
0.92
0.78
0.001
0.29
0.47
0.59

-0.02 (-0.41, 0.37)
-0.03 (-0.3, 0.25)
-0.01 (-0.42, 0.41)
0.01 (0.002, 0.02)
-0.18 (-0.23, -0.13)
-0.003 (-0.02, 0.02)
-0.002 (-0.02, 0.01)
0.0003 (-0.02, 0.03)

0.92
0.85
0.98
0.02
<.0001
0.74
0.78
0.98

0.77 (0.09, 6.56)
0.71 (0.1, 4.92)
1.08 (0.05, 22.27)
1.03 (0.97, 1.09)

0.81
0.72
0.96
0.34

0.07 (-0.01, 0.14)
0.11 (0.05, 0.16)
0.03 (-0.06, 0.11)
0.001 (0, 0)

0.09
0.0001
0.53
0.57
<.0001

1 (0.89, 1.13)
1.05 (0.93, 1.2)
0.96 (0.82, 1.11)

0.96
0.42
0.57

2.16 (1.09, 4.26)
0.83 (0.36, 1.91)
2.07 (0.8, 5.38)
1 (0.98, 1.02)
-

0.03
0.67+
0.14
0.9
-

1.02 (0.98, 1.06)
1 (0.96, 1.04)
0.99 (0.95, 1.04)

0.37
0.99
0.77

1.22 (0.7, 2.12)
0.46 (0.23, 0.93)
2.75 (1.29, 5.89)
1.01 (0.99, 1.03)
-

0.49
0.03
0.01
0.26
-

1 (0.97, 1.03)
0.97 (0.94, 1)
1.01 (0.97, 1.05)

0.80
0.05
0.58

334
49
85
33

335
50
85
32

334
48
86
33

334
49
84
33

340
49
86
33

52

-0.5 (-0.55, -0.45)
0.003 (0, 0.01)
0.003 (0, 0.01)
0.0002 (0, 0.01)

0.21
0.07
0.95

-0.02 (-0.3, 0.25)
-0.03 (-0.22, 0.15)
-0.02 (-0.3, 0.26)
0.004 (0, 0.01)
-0.23 (-0.28, -0.18)

0.86
0.73
0.89
0.19
<.0001

-0.006 (-0.02, 0.01)
-0.007 (-0.02, 0)
-0.0033 (-0.02, 0.01)

0.47
0.23
0.71

-0.07 (-0.47, 0.34)
0.18 (-0.11, 0.47)
0.38 (-0.05, 0.81)
-0.002 (-0.01, 0.01)
-0.23 (-0.28, -0.18)

0.75
0.2
0.08
0.7
<.0001

-0.018 (-0.04, 0)
-0.003 (-0.02, 0.01)
0.0031 (-0.02, 0.03)

0.11
0.73
0.81

-0.004 (-0.02, 0.01)
-0.01 (-0.02, 0.0014)
-0.01 (-0.02, 0.01)
0.00007 (-0.0002, 0.0004)
-0.38 (-0.41, -0.34)
-0.00017 (-0.0009, 0.0005)
-0.00017 (-0.0007, 0.0004)
-0.0001 (-0.0009, 0.0007)

0.56
0.097
0.46
0.62
<.0001
0.64
0.52
0.86

Eating habits
C9orf72
GRN
MAPT
YEO
Baseline score
C9orf72*YEO
GRN*YEO
MAPT*YEO
Sleep
C9orf72
GRN
MAPT
YEO
Baseline score
C9orf72*YEO
GRN*YEO
MAPT*YEO
Stereotypic and motor
behaviours
C9orf72
GRN
MAPT
YEO
Baseline score
C9orf72*YEO
GRN*YEO
MAPT*YEO
Motivation
C9orf72
GRN
MAPT
YEO
Baseline score
C9orf72*YEO
GRN*YEO
MAPT*YEO

•
•

•
•

•
•

588
104
138
52

588
104
138
52

0.61 (0.16, 2.32)
1.57 (0.46, 5.39)
0.68 (0.1, 4.82)
1.05 (1.01, 1.09)
0.96 (0.89, 1.03)
1 (0.94, 1.07)
0.95 (0.87, 1.05)

0.46
0.47
0.70
0.01
0.25
0.91
0.35

1.4 (0.75, 2.64)
1.16 (0.56, 2.39)
3.37 (1.46, 7.74)
1.03 (1.01, 1.05)

0.29
0.68
0.004
0.01

1.01 (0.97, 1.05)
1 (0.96, 1.04)
1.03 (0.98, 1.08)

0.56
0.86
0.26

588
104
138
52

587
104
138
52

335
49
86
32

334
49
86
32

-0.02 (-0.2, 0.16)
0 (-0.13, 0.1247)
0.1 (-0.09, 0.29)
0.0041 (0.0001, 0.008)
-0.35 (-0.39, -0.31)
-0.006 (-0.02, 0.005)
-0.00002 (-0.007, 0.007)
0.003 (-0.008, 0.01)

0.83
0.99
0.29
0.04
<.0001
0.28
0.996
0.6

-0.13 (-0.39, 0.13)
0.05 (-0.14, 0.23)
0.02 (-0.26, 0.3)
-0.0009 (-0.007, 0.005)
-0.28 (-0.33, -0.22)

0.33
0.62
0.89
0.76
<.0001

-0.008 (-0.02, 0.006)
0.003 (-0.008, 0.01)
-0.005 (-0.02, 0.01)

0.25
0.63
0.54

-0.12 (-0.42, 0.18)
0.08 (-0.13, 0.28)
0.002 (-0.31, 0.32)
0.0079 (0.001, 0.01)
-0.3 (-0.37, -0.24)

0.44
0.47
0.99
0.02
<.0001

-0.01 (-0.03, 0.007)
0.0001 (-0.01, 0.01)
0.002 (-0.02, 0.02)

0.23
0.99
0.86

0.093 (-0.19, 0.38)
0.02 (-0.19, 0.22)
0.0004 (-0.3, 0.3)
0.002 (-0.0047, 0.008)
-0.26 (-0.33, -0.19)
0.005 (-0.0109, 0.02)
0.006 (-0.0057, 0.02)
-0.006 (-0.0247, 0.01)

0.52
0.88
1
0.62
<.0001
0.54
0.31
0.49

335
2.15 (1.05, 4.39)
1.07 (0.46, 2.52)
1 (0.31, 3.23)
1.02 (1, 1.05)

0.04&
0.87
0.999
0.05

1.03 (0.98, 1.07)
1 (0.96, 1.05)
0.94 (0.89, 1)

0.23
0.96
0.05

1.91 (0.72, 5.06)
0.93 (0.31, 2.75)
3.68 (1, 13.52)
1.05 (1.02, 1.08)
0.98 (0.93, 1.04)
0.97 (0.92, 1.02)
0.97 (0.9, 1.04)

0.19
0.9
0.05&
0.003
0.51
0.26
0.41

49
86
32

330
49
84
31

Statistics are from the Solution for Fixed Effects Table
#Baseline data was modeled with a negative binomial distribution with a log link
function. Estimates and confidence intervals of fixed effects are exponentiated (base e)
and indicate the incident rates. Estimates below 1 indicate an inverse relationship
between the variable and outcome
&Overall effect of genetic group was not statistically significant at p<0.05 (based on
Type III Tests of Fixed Effects)
The model could not be run on some subscales after outliers were removed due to low
symptom endorsement. At baseline, for the self-care sub-scale, 3 participants (3
preclinical) had scores above zero after outliers were removed. At baseline, for the beliefs
sub-scale, 4 participants (1 preclinical, 2 non-carrier) had scores above zero after outliers
were removed. For the change score, for the self-care scale, 1 non-carrier endorsed a
change in symptom.
For the main effect of genetic group and Gene*EYO interaction= reference group are the
non-carriers
YEO= Years from estimated onset; CI=confidence interval
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Figure 2.3. CBI-R baseline scores by years from expected onset in preclinical mutation carriers vs. non-carriers

CBI-R scores at baseline for (a) abnormal behaviours (b) mood and (c) sleep (d) stereotypic & motor (e) motivation sub-scales. Y-axis
represents the scores as modeled through the generalized mixed models, and X-axis represents the expected years to onset. Blue =preclinical
C9orf72 mutation carriers, red =preclinical GRN mutation carriers, green=preclinical MAPT carriers, and brown =non-carriers.

54

Figure 2.4. Everyday skills change score by years from expected onset in preclinical mutation
carriers vs. non-carriers

CBI-R change score for everyday skills sub-scale. Y-axis represents the linear predicted scores
as modeled by linear mixed models and X-axis represents the expected years to onset. Blue
=preclinical C9orf72 mutation carriers, red =preclinical GRN mutation carriers,
green=preclinical MAPT carriers, and brown=non-carriers.

2.4.1 Symptomatic Period
While apathy and disinhibition were the most frequent initial symptoms across the
mutation groups, some gene specific patterns emerged. The relative proportion of MAPT carriers
(46%) endorsing disinhibition as the initial complaint relative to C9orf72 carriers (15%) and
GRN carriers (8%) is similar to group differences previously reported where 93% of MAPT
carriers exhibited signs of disinhibition over the course of their disease relative to 63% of
C9orf72 and 56% of GRN carriers [9]. GRN carriers endorsed impaired articulation and

55

decreased fluency most often, which corresponds with the language-based clinical presentation
found in some patients in this mutation group [9,13]. C9orf72 expansion carriers reported motor
symptoms most often which is consistent with reports of Amyotrophic Lateral Sclerosis found
only in C9orf72 carriers and absent in GRN and MAPT [9]. Although the symptoms discussed
above are characteristic of the specific gene affected, it is critical to recognize that these
symptoms are not endorsed by all the participants in each genetic group. Utilizing the top three
most frequently endorsed symptom to create a composite index for each genetic group
differentiated symptomatic genetic carriers from non-carriers. Future research assessing the
severity of these frequently endorsed initial symptoms may aid in the differentiation between the
genetic groups, and thus may be considered as an outcome measure or clinical endpoint in future
clinical trials for early stage FTD.

2.4.2 Preclinical Period
Overall, and counter to our predictions, the rates of initial symptoms as endorsed by
affected patients (apathy, disinhibition, memory impairments, decreased fluency and impaired
articulation), were similar between preclinical mutation carriers and non-carriers. As well, the
composite indices did not differentiate the groups, further supporting and extending recent
findings indicating that some behavioural and cognitive changes in genetic FTD are only
detectable in close proximity to conversion to the clinically affected state. Our cohort included
biologically related non-mutation carriers which enabled us to control for potential
environmental influences that may impact symptom endorsement (e.g. worry about inheriting an
FTD-causing mutation, stress from a family member with FTD). Although biomarkers in blood
and cerebrospinal fluid, grey matter atrophy, white matter hyperintensities and hypometabolism
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have been detected prior to cognitive impairments during the preclinical period [1], the present
findings indicate that the behavioural and cognitive symptoms endorsed as initial symptoms by
patients may not emerge until just a few years prior to clear disease onset. In a recent
longitudinal study of 46 preclinical mutation carriers, 8 of which “converted” to symptomatic
during follow-up, cognitive decline during the preclinical period was evident but were largely
driven by the converters. Additionally, differences in cognitive decline between converters and
preclinical mutation carriers who did not convert was detectable starting only 2 years prior to
expected onset. This may suggest that cognitive performance may remain relatively stable during
the preclinical period and cognitive decline may begin near or at disease onset [14]. This finding
is also consistent with a recent study that used a classification model on longitudinal MRI data
(anatomical, diffusion tensor imaging and resting-state) and reported that mutation carriers who
converted during follow-up had a stronger classification score increase over time relative to nonconverting mutation carriers [15]. Overall, these results indicate that for some domains
preclinical FTD mutation carriers may remain similar to controls until they are close to clinical
disease onset.
For the caregiver report, relative to non-carriers, preclinical MAPT carriers endorsed
poorer mood and sleep symptoms, and C9orf72 carriers exhibited marginally greater abnormal
behaviours. Moreover, GRN preclinical carriers endorsed fewer mood symptoms relative to noncarriers. Given the natural co-occurrence of sleep and mood alterations, it is not surprising that
MAPT carriers experienced symptoms in both domains. In line with our current findings,
depressive disorder not otherwise specified has been found to be more prevalent amongst MAPT
preclinical carriers relative to mutation non-carriers and the general population [16]. As well,
over a 4-year follow-up, it was reported that MAPT preclinical carriers (n=15) developed more
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depressive symptoms than GRN carriers (n=31) and healthy controls (n=39) [14]. In contrast to
the current study, other reports have documented inconsistent findings on the prevalence of
depressive and other neuropsychiatric symptoms during the preclinical period. For example, a
greater lifetime prevalence of major depressive disorder, generalized anxiety disorder and panic
disorder has previously been observed in non-carriers (n=46), but not in MAPT mutation carriers
(n=12) [16]. Furthermore, other studies have found that neuropsychiatric features may not
emerge until disease onset. For example, in a Dutch cohort of approximately 80 MAPT and GRN
mutation and non-carriers, mutation carriers who “converted” from preclinical to symptomatic
status (3 GRN and 5 MAPT) displayed greater depressive and general neuropsychiatric features
relative to preclinical mutation carriers and mutation non-carriers at the time of clinical disease
onset [17]. In our cohort of preclinical mutation carriers, as mood symptoms did not emerge as
participants approached their expected time of disease onset, the endorsement of symptoms by
mutation carriers’ may reflect a developmental predisposition.
When symptom endorsement was examined longitudinally, preclinical GRN carriers
endorsed worse Everyday Skills over time compared to mutation non-carriers. Relative to
healthy controls and normative data, asymptomatic GRN carriers demonstrate poorer
performance on a variety of cognitive domains including attention/processing speed [18],
visuospatial and working memory [19], verbal fluency, emotion recognition [20], attention,
mental flexibility and language [21]. With this, it is likely that the decline in Everyday skills in
preclinical GRN carriers reflects subtle changes in a variety of cognitive domains. Therefore, as
differences are evident between GRN preclinical mutation carriers and non-carriers, everyday
skills as measured through the CBI-R may potentially be used as an end point for clinical trials in
GRN preclinical individuals.
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2.4.3 Limitations
Potential clustering effects of family membership and testing site could not be accounted
for in the clinician-rating scale, due to low symptom endorsement. As well, participant’s
knowledge of their genetic status was not obtained and thus this potential effect could not be
accounted for. Future clinical trial modeling may need to consider the participants’ knowledge of
their genetic status when considering rates of symptom reporting [22]. Furthermore, although the
different scales used in the current study allow for the assessment of symptom endorsement by
multiple informants, we could not account for potential differences in reporting style based on
the sex of the informant or the relationship of the informant to the at-risk family member. An
additional potential limitation is the reliance on retrospective caregiver reports to acquire reports
of the initial symptom in symptomatic mutation carriers, though the diagnosis of FTD is reliant
on caregiver’s reports [23].

2.4.4 Conclusions
In conclusion, we report the frequencies of the most common initial symptoms for the
main genetic forms of FTD and suggest that given the heterogeneity between gene groups,
family members, and even specific mutations, composite measures of these symptoms may serve
as clinical tools for detection of early conversion to symptomatic FTD. Of interest, we did not
find differences between preclinical mutation carriers and non-carriers for the most common
initial symptoms in affected patients. Future studies examining initial symptoms with additional
longitudinal data points will aid in the understanding of the progression of these symptoms from
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the preclinical, to affected diseases stages and further pinpoint the onset of initial symptoms
heralding conversion to symptomatic FTD.
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Chapter 3: Ventricular Volume Expansion in Preclinical Genetic Frontotemporal
Dementia 2
3.1 Introduction
Frontotemporal Dementia (FTD) is a heritable neurodegenerative disorder characterized
clinically by behavioral and/or language deficits and atrophy within the frontal and temporal
lobes. Approximately 30% of patients with FTD present with an autosomal dominant family
history with mutations in MAPT, PGRN and C9Forf72 each presenting in 5-25% of familial FTD
[1]. Advances have been made in developing disease-modifying treatments that target the
underlying pathology of FTD [2]. As the initiation of FTD-treatment is anticipated to be necessary
during the preclinical or prodromal stages of the disease, biomarkers sensitive to these disease
periods are needed. Brain volumetric measurements may be a promising candidate measure of
disease onset and progression, as atrophy in regions of the frontal and temporal lobes may appear
as early as 5 to 10 years before anticipated clinical disease onset in genetic FTD [3].
Changes in ventricular volume represent a particularly attractive candidate index of
neuronal survival in FTD. Ventricular expansion is seen across the heterogenous clinical,
molecular and genetic subtypes of FTD at the symptomatic stage [4,5]. Additional advantages
include reduced image distortion from gradient non-linearities due to the proximity of the ventricle
to the magnet’s isocenter, and high contrast in intensity between ventricles and tissue which
facilitates automated segmentation techniques and implementation in large clinical trials [6,7].
Ventricular expansion during the preclinical stages of genetic FTD has not yet been
characterized. The objective of the present study was to examine ventricular volume expansion

2

A version of this chapter has been published: Tavares TP, Mitchell DG, Coleman K, Shoesmith C, Bartha R, Cash
DM, Moore KM, van Swieten J, Borroni B, Galimberti D, Tartaglia MC. Ventricular volume expansion in
presymptomatic genetic frontotemporal dementia. Neurology. 2019; 93(18):e1699-706.
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cross-sectionally and over a 1-year interval in carriers of an FTD-causing genetic mutation and
biologically related non-carriers, to determine its utility as a measure of early or preclinical
disease in genetic FTD.

3.2 Methods
3.2.1 Participants
The data used in this study was obtained from the multi-center international Genetic
Frontotemporal Dementia Initiative (GENFI). Participants were recruited from 12 research sites
across Canada, Sweden, Italy, UK and Netherlands and were either a known symptomatic carrier
of a pathogenic FTD causing mutation in MAPT, PGRN or C9orf72, or a first-degree relative of a
known symptomatic mutation carrier. As described previously [3], all participants completed
clinical interviews and standardized neuropsychological testing at baseline and at 1-year follow
up. At-risk first-degree relatives underwent genetic testing to determine mutation carrier status.
Therefore, the sample was composed of symptomatic mutation carriers, and biologically related
preclinical mutation carriers and non-carriers.

3.2.2 Imaging and Ventricular Volume Processing
Volumetric T1-weighted scans were acquired from either a 3T Philips, Siemens Trio,
Siemens Skyra or GE; 1.5 Siemens or GE were utilized if a 3T was not available. Scanning
protocols were designed to accommodate the different scanners and field strengths [4].
Longitudinal scans collected approximately one year after baseline, using the same scanner and
protocol as the baseline scan, were included in the analysis.
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The default longitudinal stream in FreeSurfer, version 5.1 (http://surfer.nmr.mgh.harvard.edu/)
was used for ventricular volume processing [8]. DICOM images were converted into NIfTI format
using the mri_convert command available in FreeSurfer. An unbiased within-subject template was
created using inverse consistent registration [9]. In addition, utilizing information from the
within-subject template, processing steps including skull stripping, spatial transformation to MNI
space, atlas registration, spherical surface maps, and parcellations were initialized to increase
reliability and statistical power [8]. Ventricular segmentations of the lateral, inferior, third and
fourth ventricles were visually checked and manually edited by TPT, while blinded to familial
mutation group membership, mutation status (carrier vs. non-carrier) and study period (baseline or
follow-up). Volumes of the left and right lateral and inferior ventricles, third and fourth ventricles,
and total intracranial volume were extracted from aseg.txt longitudinal output files.

3.2.3 Statistical Analyses
Total ventricular volume was calculated as the sum of the left and right lateral (including
inferior), third and fourth ventricles and was expressed as a percentage of the individual’s total
intracranial volume. Main analyses compared ventricular volume in preclinical carriers vs. noncarriers, collapsed across the mutation types to maximize sample size. Exploratory analysis
included genetic mutation type (C9orf72, PGRN, MAPT) to compare ventricular changes across
the three genes.
Linear mixed models were used to examine differences in baseline ventricular volumes
and change over 1-year. Preclinical carriers were compared to non-carriers to examine whether
differences were detectable between asymptomatic carriers vs. non-carriers. Predictor variables in
these analyses included random effects (family membership (variance components covariance
structure) and each participant nested within the family (unstructured covariance structure), and a
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random intercept for each) and fixed effects [visit (baseline, follow-up), genetic status (GS;
carrier, non-carriers), years from expected disease onset, and an interaction term for genetic status
and years from expected disease onset]. Years from expected age of disease onset were calculated
by subtracting the mean age of disease onset within the family from the participant’s current age
at the time of baseline scan and follow up scan [3]. As ventricular volume was predicted to change
in a non-linear fashion over time as individuals approached the time of expected disease onset, a
quadratic term for time from expected disease onset and its interaction with genetic mutation
status were included. Thus, using ventricular volume at time 1 and 2 within individuals, the
model could evaluate whether a linear or quadratic change in ventricular volume was present
across individuals as a function of years to expected disease onset. To create parsimonious
models, non-significant interaction terms were removed. The visit by genetic status interaction
was examined in a separate model without the time to expected disease onset by genetic status
interaction due to multicollinearity. Residual and influence analyses were conducted to examine
model quality and to identify potential outliers. Studentized and conditional residuals were
examined, along with several influence diagnostic measures including Cook’s D, COVRATIO,
Restricted Likelihood Distance, the PRESS statistic, and MDFFIT. Given assumptions made in
using the expected years to disease onset based on the average age of disease onset in the family,
we also conducted a confirmatory analysis using the final model, substituting years to expected
disease onset with the participants’ age.
To examine differences in ventricular volume across the preclinical, prodromal and
affected stages of the disease, similar models were included to compare all mutation carriers (both
symptomatic, preclinical mutation carriers and progressors) relative to non-carriers. This model
allows ventricular volume to be examined across the continuum of the disease and allowed an
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opportunity to examine whether and how the model might change if symptomatic patients were
included with preclinical carriers, as has been done in some prior studies (see Appendix B, Result
Section 1.0).
Significant interactions between years from expected disease onset and genetic status were
followed-up with t-tests to assess potential differences between the genetic carriers and noncarriers in the years prior to and after expected disease onset, across the baseline and follow-up
periods. Significant results were also followed up with analysis of regional ventricular volumes
(i.e. left and right). Given reported grey matter asymmetries in PGRN mutation carriers [10-12],
we also computed and examined a laterality index, defined as the absolute difference between the
left and right ventricular volumes divided by the total ventricular volume [3]. All statistical
analyses were conducted using SAS® (Version 9.4).

3.3. Results
3.3.1 Participants
A total of 106 participants met the inclusion criteria. After processing in FreeSurfer, 4
participants were removed prior to statistical analysis: 1 due to scaling errors, 1 with extensive
segmentation errors, and 2 found to be extreme outliers (1 carrier and 1 non-carrier from PGRN
families; mean volumes >3 SD), leaving 102 participants from 43 family cohorts, entered into the
statistical model (Table 3.1).
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Table 3.1: Demographic characteristics of study participants (N=102)
Preclinical
Carrier (n=46)

Non-Carriers
(n=56)

Genotype

Preclinical
carriers vs. Noncarriers

p=0.74

C9orf72

13

13

PGRN

29

36

MAPT

4

7

Sex

p=0.52

Female
Male
Years from expected
disease onset at baseline
Mean (SD)
Age (SD)

25

34

21

22

-13.34(12.65)

-9.14 (15.60)

p=0.14

44.66 (11.14)

50.56 (15.64)

p=0.03*

Years of education (SD)
14.20 (3.47)
14.34 (3.51)
p=0.84
Group differences were assessed using chi-square tests and t-tests. *significant at p<0.05

3.3.2 Preclinical Carriers vs. Non-Carriers
The final model included the genetic status by time to disease onset (linear) interaction,
which illustrates differences between the genetic groups at differing points of time to disease
onset. A diagnostic analysis identified two high-influential participants (non-carriers) who were
subsequently removed (see Table B.8), resulting in a main effect of genetic status and a genetic
status by time from disease onset interaction. Additionally, visual inspection of the scatterplot
indicated an extreme case (non-carrier). Table 3.2 shows the model estimates, p-values and
confidence intervals for the main effects [visit, genetic status, time from disease onset (linear and
quadratic term)], and the interaction between time from disease onset and genetic status.
Unadjusted post-hoc t-tests demonstrated differences in total ventricular volume between
preclinical carriers and non-carriers beginning two years prior to expected disease onset, or
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beginning at 4 years prior to expected disease onset when one extreme case (non-carrier) was
removed from the model (Figure 3.1). Table 3.3 shows the model estimates for the total
ventricular volume and total left and right volumes at specific years prior to expected disease
onset (-25 years to 10 years). To create parsimonious models, we excluded sites (n=11) as a
random effect and only accounted for family membership. In a confirmatory analysis, we
included site as a random effect in the final model to examine the potential influence of data
collection from multiple sites. Confirmatory analysis supported that site was not significant
(p=0.32). In the supportive analysis, with age used instead of expected years to disease onset, a
significant genetic group by age interaction was found. Post-hoc tests demonstrated that in
comparison to non-carriers, pre-symptomatic carriers showed greater ventricular volume
beginning at age 49.
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Table 3.2: Total ventricular volume estimates for preclinical (n=46) and non-carriers (n=53), with
no influential cases (n=2) or extreme case (n=1)
Fixed Effects
Intercept
Visit
(Baseline and 1-year followup; ref=follow-up)
Genetic Status
(ref=non-carrier)
Time from
disease onset
Time from disease
onset2
Time from
symptom
onset*Genetic Status
Random Effects
Family
Membership
Participant
Residual

Estimate

SE

p-value

CI (95%)

0.38

0.34

0.27

-0.31, 1.07

0.0004

0.01

0.97

-0.02, 0.02

0.35

0.15

0.02*

0.05, 0.66

-0.02

0.01

0.07

-0.05, 0.002

0.0007

0.0002

0.0001*

0.0004, 0.001

0.02

0.007

0.02*

0.003, 0.03

Estimate
0.02

SE
0.04

p-value
0.33

0.37

0.07

<.0001*

0.004

0.0005

<.0001*

SE=standard error; Genetic Status (preclinical carrier vs. non-carrier); CI=Confidence interval;
*significant at p<0.05; Time from disease onset2= Quadratic term for time from disease onset
variable; ventricular volume is presented as a percentage of the participant’s total intracranial
volume; The interaction between time from disease onset and genetic status illustrates
differences between the genetic groups (preclinical carriers vs. non-carriers) at differing
points of time to disease onset.
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Figure 3.1: Total ventricular volume by estimated years from expected disease onset in presymptomatic carriers (blue, n=46) and non-carriers (red, n=53).

Ventricular volume is expressed as a percentage of intracranial volume. To prevent disclosure of
genetic status, individual data points are not plotted. Differences are noted beginning at 4 years
prior to disease onset as indicated by the dashed line (p=0.04).

Table 3.3. Total ventricle volume estimates from post-hoc test between preclinical mutation
carriers (n=46) and non-carriers (n=53) by time to expected disease onset with no influential
cases (n=2) or extreme case (n=1)
-25 years

-20 years

-15 years

-10 years

-5 years

0 years

5 years

10 years

-0.010
0.14
0.94

0.08
0.13
0.53

0.17
0.13
0.18

0.26
0.14
0.05

0.35
0.15
0.02*

0.44
0.18
0.01*

0.53
0.20
0.01*

Total Left Ventricle
Estimate
-0.07
SE
0.08
p-value
0.39

-0.02
0.07
0.80

0.03
0.06
0.60

0.08
0.06
0.18

0.13
0.06
0.05*

0.18
0.07
0.02*

0.23
0.08
0.01*

0.28
0.10
0.01*

Total Right Ventricle
Estimate
-0.05
SE
0.09
p-value
0.59

-0.01
0.07
0.94

0.03
0.07
0.62

0.07
0.07
0.28

0.11
0.07
0.12

0.15
0.08
0.06

0.19
0.09
0.04*

0.23
0.11
0.03*

Total
TotalVentricle
Ven
Estimate
-0.10
SE
0.16
p-value
0.54
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*significant at p<0.05; ventricular volume is presented as a percentage of the participant’s total
intracranial volume.
3.3.3 Manually Edited Versus Fully Automated Ventricular Volumes
Manual edits to the ventricular segmentations performed in FreeSurfer were made on all
study participants for each time point (mean differences in edited vs. unedited volumes are
reported in supplementary analysis). Substitution of the fully automated ventricular volumes
produced by FreeSurfer into the final models resulted in similar findings, demonstrating that for
preclinical carriers vs. non-carriers, significant differences were observed at 4 years prior to
disease onset (Tables B.9a-b in Appendix B). See Table B.6 for annualized change of unedited
ventricular volume.

3.3.4 Total Ventricular Expansion over 1 year
To assess potential differences in ventricular expansion over the 1-year interval, an
additional model was evaluated that included the same family and participant random effects as
above and the following fixed effects: visit, years to disease onset (linear and quadratic terms),
genetic status and an interaction between visit and genetic status. Significant visit by genetic
status interaction was followed-up by simple effects estimation. There was a significant time by
genetic status interaction (p=0.03); however, follow-up tests did not reach significance (all p’s>
0.18). Annual rates of change of total ventricular volume are presented in Table.7, as a function of
genetic status and years to expected disease onset.

3.3.5 Mutation Type
Given previously reported differences in atrophy patterns across the different genotypes,
we conducted an exploratory analysis to assess potential differences in total ventricular volume
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and in the laterality index between the genotypes. Specifically, utilizing the final models from
previous analysis (with the extreme case and two influential cases), we included genotype
(C9orf72, PGRN, MAPT) and the interaction between genotype and genetic status as fixed effects
in the model. There was no significant interaction between genotype and genetic status (p=0.10).
There was no significant interaction between genetic status and genotype for the laterality index
(p=0.63).

3.4 Discussion
In this multi-center cohort of individuals from families with genetic FTD, we found that
ventricular volume enlargement is detectable in the preclinical period, on average four years prior
to the anticipated onset of symptoms. We also provide the first estimates of annualized rates of
ventricular expansion in preclinical gene carriers compared to biologically related non-carriers.
We also examined ventricular volume changes across the preclinical and prodromal to
symptomatic stages of the disease, which offers a unique opportunity to explore ventricular
volume changes throughout the disease continuum. This method has also been employed by other
studies [3] delineating cross-sectional grey matter volumes in a genetic cohort. When all mutation
carriers (symptomatic & preclinical) were included in the model, ventricular volume changes
emerged 12 years prior to disease onset. This is in contrast to the model including only preclinical
participants. Importantly, the preclinical model allows the examination of subtle changes that
emerge a few years prior to disease onset, unbiased by the increased rate of change that may occur
during the symptomatic period. Thus, the different model estimates and the earlier detection of
ventricular volume changes in the combined model of symptomatic patients with the
preclinical individuals likely reflects the increased the rate of change of ventricular volume as
the disease progresses. We suggest that the preclinical carrier vs. non-carrier model identifying
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measurable differences 4 years prior to anticipated disease onset offers the more accurate
depiction of ventricular volume changes throughout the preclinical period.
Ventricular volume expansion has been well documented in patients with symptomatic
sporadic and genetic forms of FTD [13-15]. The annual mean rates of expansion for symptomatic
mutation carriers in this GENFI cohort rate range from 6-11% and are in line with those reported
in a series of 6 symptomatic C9orf72 carriers (mean annualized rate of ventricular expansion
of~9%) [14] and in 21 MAPT symptomatic carriers (~9%) [16]. The expansion rate is slightly
lower than that reported previously in a cohort of patients with sporadic FTD (mean 11-14%)
[13] despite similarities in the mean age of symptomatic participants. Prior small series of
preclinical mutation carriers have not detected significant differences in ventricular expansion
rates in 7 C9orf72 preclinical carriers (mean age 41) over a six month interval [17], or in 9
preclinical MAPT carriers (1 year interval) [16].
The varied and dramatic atrophy patterns observed in FTD can introduce difficulties for
automated segmentation programs [18]. We focused our analysis on total ventricular volume in
particular, as in the preclinical state, the laterality and exact brain regions that may display the
earliest signs of atrophy are not certain, even within a genetic mutation. Such advantages of
whole brain measurements, such as total ventricular volume, for tracking outcomes have been
previously described [13,19,20]. Despite theoretical concerns about lesser sensitivity due to
averaging across brain regions, this study supports the potential for total ventricular volume
measurements to provide an unbiased approach to capture accelerated rates of atrophy in
preclinical and early symptomatic stages of disease. Our comparison of time-intensive, detailed
manual editing of all scans included in the study relative to the fully automated segmentation
with no editing produced remarkably similar results, further supporting the feasibility of total
ventricular volume as a practical measure of disease onset and progression in multi-center clinical
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trials in FTD.
Despite the relatively large sample for a cohort of preclinical FTD mutation carriers,
subgrouping by mutation type and years to expected disease onset resulted in significant
variability in some estimates. While significant variability in rates of atrophy has been reported
within mutation groups and even within families [21], in the current study, the variability may
potentially be due at least in part to the sample size of subgroups. Due to subgroup sample size,
the examination of differences between carriers of C9orf72, PRGN and MAPT was exploratory,
and did not reach significance. Examination of subregions of ventricular expansion identified the
third ventricle as one of the earliest markers in symptomatic patients (Appendix A, supplementary
analysis). While we did not identify a significant interaction between genetic status and time to
expected disease onset for the third ventricle in preclinical carriers, inspection of the post-hoc
tests indicate early expansion of the third ventricle (~14 years prior to expected disease onset) in
this cohort as well. Together these findings suggest that enlargement of the third ventricle in
preclinical C9orf72 carriers may be one of the first neuroimaging derived markers, due to early
thalamic atrophy [22].
An additional potential limitation of this study is the use of the estimated age at disease
onset, calculated by subtracting the mean age of disease onset within the family from the
participant’s age at the time of testing. While previous work has demonstrated a strong
association between patient’s age at disease onset and mean familial age at disease onset [3], it
has been observed that age of disease onset within families is particularly variable in GRN
mutations and somewhat variable in C9ORF72. Although we found similar results when current
age or actual age at disease onset was substituted into the models, we cannot yet confirm how
accurately the anticipated age at disease onset represents the actual age in the majority of
individuals in the pre-symptomatic cohort. Data anticipated from collaborations across large FTD
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cohorts including LEFFTDS, ARTFL, GENFI and DINAD examining individual age at disease
onset with family age of disease onset, parent age of disease onset, and other potential mediator
factors will be helpful in the future to improve such models. Furthermore, differences between the
pre-symptomatic carriers and non-carriers were based on group-wise estimates and could not yet
be applied on an individual basis. Data collection of additional longitudinal timepoints continues
for the GENFI cohort which will inform future estimates of individual rates of change in
ventricular volumes.
Overall, the present study shows ventricular volume differences during the preclinical
period in genetic FTD pathophysiology and support the potential of application of ventricular
volume as one index of disease onset in the prodromal stages of FTD. Future longitudinal follow
up of this GENFI cohort, as well as comparison with anticipated results from other familial FTD
cohorts such as LEFFTDs (https://memory.ucsf.edu/lefftds), and with complementary measures
such as rates of change in total brain volume will enable further modeling according to specific
genotype and confirm the rates of change.
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Chapter 4: Neural Correlates of Reversal Learning in Frontotemporal Dementia
4.1 Introduction
Frontotemporal Dementia (FTD) is a progressive neurodegenerative disorder that
primarily affects the frontal and temporal lobes, resulting in profound alterations in personality
and social behaviour (Neary, 1998). Disinhibition is one of the core symptoms in FTD and
emerges quite early during the disease process [1]. Patients with disinhibition often lack social
etiquette (e.g. making rude comments), engage in impulsive or careless actions (gambling,
overspending), or new criminal behaviours (e.g. shoplifting). [1,2]. Importantly, despite negative
social and legal consequences, patients with FTD continue to engage in these behaviours,
implicating a possible difficulty in flexibly altering behaviour when provided negative feedback.
In patients with FTD, disinhibition as reported by caregivers has been correlated with degree of
atrophy or hypoperfusion in frontotemporal regions, most commonly in the orbitofrontal cortex,
inferior frontal gyrus, anterior cingulate gyrus, and insula [3,4]. Despite knowledge of these
anatomic associations with symptoms of disinhibition, effective treatments for such symptoms in
patients with FTD are lacking. Here we propose to demonstrate the neural mechanisms
underlying these symptoms by examining the real-time neural correlates of reversal learning, a
classic cognitive paradigm that indexes flexible responding to negative feedback and for which
the mediating neural regions are well established.
Reversal learning is a classic measure of adaptive behaviour flexibility, specifically
assessing the ability to alter behaviour when reinforcement contingencies change [5]. Through
trial and error, participants learn stimulus-reward contingencies (acquisition phase), selecting
stimuli associated with reward and avoiding stimuli associated with punishment. During the
reversal phase, the reinforcement contingencies change, such that the stimuli that were
previously associated with punishment are now associated with a reward, and those initially
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associated with punishment are now rewarded. Functional neuroimaging studies have implicated
the ventromedial prefrontal cortex/orbital frontal cortex (vmPFC/OFC), ventrolateral PFC
(vlPFC) and dorsomedial PFC (dmPFC) during reversal learning. Specifically, when a reversal
error is made, the vmPFC/OFC demonstrates a decrease in activity [6,7], suggesting a role in
prediction error signalling which signals discrepancy between the expected and actual reward
[8]. In contrast, the vlPFC, dmPFC and dlPFC demonstrate increased activity in response to
reversal errors [6,9-12]. Consistent with the suggested role of the dlPFC in attention and
cognitive control during instances of conflict such as during reversal errors, the dlPFC augments
the representation of relevant stimulus cues and reinforcement information to guide flexible
behaviour [12,13]. As well, it has been suggested that during reversal learning the vlPFC
interacts with the caudate to increase the salience of alternative motor responding [6,12].
In patients with ventral frontal lesions, deficits in reversal learning are associated with
increased behavioural problems including disinhibition, irritability, inflexibility and
perseveration (Rolls et al, 1994). Patients with FTD exhibit reversal learning impairments [1416], and the number of reversal errors has been correlated with atrophy within the anterior
cingulate cortex (ACC; BA 24) and the medial/lateral OFC (BA 11, 47) [15]. This finding
suggests that reversal learning impairments in FTD may be related to a failed suppression of a
previously rewarded response mediated by vlPFC and ACC, and/or impaired processing of
unexpected negative feedback by ventromedial PFC. Critically, no study has delineated the
functional neural correlates of reversal learning performance in patients with FTD. Assessing the
functional integrity of the key regions involved in reversal learning may provide insights into the
fundamental pathophysiological mechanisms underlying behavioural inflexibility in FTD.
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Furthermore, the results of the current study may have implications in the selection of
therapeutic targets and future outcome markers for symptomatic treatments.

4.2 Methods
4.2.1 Participants
Twenty-seven patients with FTD and 24 controls were enrolled in the study. Five patients
were unable to complete the scan and withdrew, 2 controls withdrew due to claustrophobia, and
1 control participant’s data was unusable due to computer problems resulting in 22 patients and
21 controls with fMRI scans available for analysis. All patients met the diagnostic criteria for
probable or definite bvFTD or svPPA with significant behavioural features [1,17]; diagnoses
were made by a behavioural neurologist (ECF). Patients were recruited through the Cognitive
Neurology and Alzheimer’s Research Centre at Parkwood Hospital in London, Ontario, Canada,
and control participants were recruited through advertisements to caregivers at local FTD support
groups and from the clinic’s volunteer pool. All participants and caregivers of patients provided
written informed consent. This study was approved by the Health Science Research Ethics Board
at Western University, London, Ontario, Canada.

4.2.2 Measures
To assess cognitive functioning, patients and controls completed the Addenbrooke’s
Cognitive Examination-Revised (ACE-R) [18], Montreal Cognitive Assessment [19], Trail
Making Test, Clock drawing [20], Prose recall, and Phonemic and Semantic Fluency.
Additionally, caregivers of patients completed the Frontal Behavioural Inventory with a trained
research assistant (FBI) [21]. The FBI is a 24-item inventory used to assess behaviour and
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personality changes and each item is rated on a 4 point rating scale where higher scores indicate
more severe behavioural changes (0=none; 1=mild, occasional, 2=moderate; 3-severe, most of
the time).

4.2.3 fMRI Task
Participants completed an fMRI-adapted deterministic reversal learning task (Figure 4.1)
which consists of acquisition and reversal phases. A deterministic design was selected based on
our prior piloting in patients with FTD where we observed significant impairment in learning the
initial reinforcement associations when probabilistic feedback was given. For the current study,
on each trial, participants were presented with a pair of objects (colored Snodgrass images of
animals or furniture pieces [22] and were instructed to select one of the objects in each pair.
Participants were informed if their response selection was correct, they would win 100 points,
and conversely, if their response selection was incorrect they would lose 100 points (acquisition
phase). Subsequently participants were instructed that at some point during the task, the object in
the pair associated with a correct response may change, and they should adjust their response
accordingly. All participants completed practice trials outside of the scanner to ensure
comprehension of task instructions.
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Figure 4.1: Schematic of fMRI reversal learning task.

Schematic of the reversal learning task. During the acquisition phase, patients learn the stimulusresponse contingencies. During the reversal phase, the stimulus-response contingencies would
change

Participants completed four runs of the task; each run consisted of a reversal block (10 or
15 trials of acquisition phase, followed by 10 or 15 trials of reversal phase), and a non-reversal
block (consisting of 20 trials of acquisition phase only). Non-reversing blocks were included to
prevent participants from anticipating a contingency change across the runs. The order of the
blocks was randomly presented in each run, and each run and block consisted of new stimuli. On
each trial, the participants were presented with the response screen depicting the pair of objects
for varying durations (2500ms, 4000ms, or 5500ms), the feedback screen (1500ms) and the
fixation cross presented in the center of the screen (for 1000ms, 2500ms, or 5500ms). One of
each object in a pair was presented randomly on the left and right side of the screen at 8 possible
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locations. Participants responded using their index finger on their left and right hand to select the
button that corresponded to the location of the correct object (left or right).

4.2.4 Imaging Acquisition
All participants completed the imaging task using a 3T Siemens Magnetom Prisma
scanner with a 32-channel head coil at Robarts Research Institute, Western University.
Functional images were acquired using a T2*gradient echo-planar imaging sequence [repetition
time (TR)= 2500ms, echo time (TE)= 30ms, field of view (FoV)= 240mm, flip angle =90
degrees, 37 interleaved slices of 2 x 2x 3mm voxel resolution, 3mm slice thickness, 153 volumes
per run]. In addition, a high resolution T1-weighted anatomical scan was obtained subsequent to
the functional scan: [TR= 2300ms, TR= 2.98ms, FoV= 256mm, flip angle =9 degrees, 192
interleaved slices of 1mm isotropic voxels].

4.3 Statistical Analysis
4.3.1 Task Behavioural Performance
For each task phase (acquisition, reversal), the percentages of correct responses and nonresponses as a function of the total number of trials per phase were analyzed. Visual inspection
of histogram and Q-Q plots indicated non-normal data; thus, a Mann Whitney U Test and a
Wilcoxon Signed-Rank Test was conducted to examine differences between and within the
patient and control groups, respectively.
Behavioural performance was also examined within the patient group based on the
different atrophy patterns (frontal vs. temporal predominant). Patient’s MRI images were
classified according to their predominant atrophy pattern by a behavioural neurologist (ECF),

84

resulting in 8 patients with frontal predominant atrophy, 10 with temporal predominant atrophy,
and 1 with frontotemporal atrophy. To delineate potential differences between frontal and
temporal atrophy patterns specifically, the patient with frontotemporal atrophy was not included
in the analysis. Given the small sample size of the sub-groups, Kruskal-Wallis and DunnBonferroni post-hoc tests were used as an exploratory analysis to compare behavioural
performance across the frontal and temporal predominant atrophy groups and controls.

4.3.2 Frontal Behavioural Inventory (FBI)
We examined whether patients with different atrophy patterns (frontal vs. temporal
predominant) exhibited differences in caregiver reported behaviours associated with reversal
learning deficits [5]. Specifically, a reversal learning composite score was created from the
following FBI items: inflexibility, perseverations/obsessions, impulsivity/poor judgement,
irritability, and aggression. A Mann Whitney U Test was used to examine differences between
the patient atrophy groups.

4.3.3 Imaging
4.3.3.1 fMRI
Imaging data were preprocessed and analyzed in Analysis of Functional Neuroimages
(AFNI) [23]. Nonlinear registration was completed to the MNI template using AFNI’s
@SSwarper. Additionally, all volumes were registered to the functional volume closest to the
anatomical (last volume of the final run). Three participants’ anatomical images were acquired
prior to the functional runs, thus the 3rd EPI volume of the first run was used for registration.
Volumes were spatially smoothed using a 4mm full width at half maximum isotropic Gaussian
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kernel. Additionally, time series data were normalized by dividing the signal intensity of voxels
at each time point by the mean signal intensity of that voxel for all the runs and multiplying it by
100; thus, the regression coefficients represented the percent signal change from the mean
activity. Within task runs, volumes were censored if the derivatives of the six generated motion
parameters had a Euclidean norm greater than 2.0mm. To further account for movement, motion
derivates were included as regressors in the model. For the voxel time series, TRs with at least
10% of voxels too far from the trend (calculated using AFNI’s mean absolute deviations) was
deemed an outlier and removed. Regressors characterized the response type (correct or incorrect)
by phase type (acquisition or reversal) were created for both the choice (stimuli
presentation/decision-making phase) and feedback screens and for reversing pairs and nonreversing pairs, resulting in 24 regressors. The blood-oxygen level dependent (BOLD) response
was fitted to each regressor to conduct linear regression modelling. To account for voxel-wise
correlated drifting, a baseline and linear drift and AFNI’s default polynomial trend were
modelled to the time series of each voxel. Linear regression modelling resulted in a betacoefficient and an associated t-statistic for each voxel for each regressor. To correct for multiple
comparisons, AFNI’s updated 3dClustSim at a cluster defining threshold of p=0.05, was used on
the entire brain with a threshold of p<0.001 (22 contiguous voxels).
Three patients were removed due to excessive movement; thus 19 patients and 21
controls were included in the behavioural and functional analysis. Additionally, one patient only
completed three runs and thus a comparative run was removed from a control scan in order for
both groups to have the same number of trials. A 2 Group (patients vs. controls) x 2 Phase
(acquisition x reversal) x 2 Response accuracy (correct vs. incorrect) repeated measures ANOVA
was conducted in AFNI using 3dMVM, and the significance threshold was set to p<0.001.
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Significant interactions were followed by uncorrected paired and independent t-tests in SPSS at
p<0.05 to examine differences in percent BOLD signal change. As an exploratory analysis,
voxel-wise grey matter tissue probabilities were entered as a covariate in the fMRI analysis to
account for grey matter volume differences that may influence the fMRI signal (see Method C.1,
Table C.1, Table C.2, Figure C.1).

4.3.3.3 Region of Interest Analysis
An exploratory region of interest (ROI) analysis was conducted to examine whether
patients with different atrophy patterns (frontal vs. temporal predominant) demonstrated different
BOLD signal during the choice and feedback epochs in the regions known to be involved in
response reversal. An ROI approach was used instead of an ANOVA with group included as a
between-subject factor, due to the small sample in each atrophy group.
Anatomical ROIs were created using the CA_ML_18_MNIA atlas in AFNI. For the
choice epoch, ROIs included the left vlPFC (orbitalis), and left dorsolateral PFC
(triangularis/opercularis) that encompassed the clusters found below. A 3 group (frontal,
temporal, control) x 2 response accuracy (correct, incorrect) x 2 phase (acquisition, reversal) and
a 3 group (frontal, temporal, control) x 2 response accuracy (correct, incorrect) was used to
delineate group effects in the left vlPFC and left dlPFC, respectively. One-way ANOVAs were
completed to delineate group differences.
For the feedback epoch, the following ROIs were used to partition the large clusters
found (see results below), into specific regions known to be uniquely involved in reversal
learning [6,9,10]: left and right ventrolateral PFC, dorsolateral PFC, ventromedial PFC (superior
orbital gyrus, rectal gyrus and mid orbital gyrus), and dorsomedial PFC (anterior and middle
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cingulate cortex). A 3 group (frontal, temporal, controls) x 2 response accuracy (correct,
incorrect) repeated measures ANOVA was completed to identify group differences for the ROIs.
Uncorrected one-way ANOVAs and paired t-tests for each group were completed to delineate
differences in BOLD activity between correct and incorrect response feedback.

4.4 Results
4.4.1 Demographic
Nineteen patients and 21 controls were included in the behavioural and functional imaging
analysis. At the time of testing, patients were on average 63 years of age and controls were 64
years of age. Patients were diagnosed at a mean age of 62. Ten patients were diagnosed with
behavioural-variant FTD (bvFTD), seven patients were diagnosed with semantic dementia (SD),
one patient presented with progressive nonfluent aphasia (PNFA), and one patient presented with
bvFTD/SD (Table 1 for demographic and neuropsychological performance). There were no
significant differences for age at testing, sex, handedness, or years of education between the
patients with FTD and controls.
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Table 4.1: Demographic and Neuropsychological Characteristics
Demographic
Patients
19
63.3 (5.4)

Controls
21
64.1 (13.9)

t(26.5)= -0.23. p=0.82

Sex (Male, Female)

10, 9

10, 11

X2=0.1, p=0.8

Handedness (left, right)

0, 19

2, 18*

Fisher’s = 2.5, p=0.5

Education (years)

13.8 (1.8)

14.4 (2.8)

t(38)= -0.77, p=0.45

Age at diagnosis (SD)

61.6 (5.6)

-

-

Disease duration, Yrs (SD)

1.8 (1.9)

-

-

-

-

Age at testing, years (SD)

Atrophy Pattern

Contrasts

Frontal

8

-

-

Temporal

10

-

-

Frontotemporal

1

-

-

-

-

Diagnosis
bvFTD

10

-

-

SD

7

-

-

PNFA

1

-

-

SD & bvFTD

1

-

-

Neuropsychology
n

Patients
Mean (SD)

n

Controls
Mean (SD)

Contrasts

MoCA

18

19.0 (5.0)

18

26.9 (2.0)

t(22)= -6.3, p<0.001

ACER (total)

19

64.2 (17.8)

21

88.7 (21.1)

t(38) = -3.9. p<0.001

Prose immediate Recall

16

4.1 (3.8)

18

10.72 (3.1)

t(32)= -5.6, p<0.001

Prose delayed recall

18

3.2 (3.7)

18

10.3 (2.6)

t(32) = -6.5, p<0.001

Semantic fluency

19

10 (5.9)

18

22.0 (4.2)

t(35) = -7.1, p<0.001

Phonemic fluency

17

21.6 (14.4)

19

40.5 (12.4)

t(34) = -4.2, p<0.001

Trail A

18

50.7 (15.0)

18

27.6 (7.5)

t(25)= 5.9, p<0.001

Trail B

14

121.3 (58.5)

18

63.3 (16.4)

t(14.6)= 3.6, p=0.003

Clock draw

18

8.2 (2.5)

18

9.6 (0.8)

t(20.3) = -2.4, p=0.03

Clock (copy)

16

9.3 (1.1)

17

9.7 (0.5)

t(19.7)= -1.3, p=0.2

FBI Composite Score

19

6.4 (3.5)

-

-

-
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*Handedness was absent for one control participant
bvFTD=behavioural variant FTD; SD=semantic dementia; PNFA=progressive non-fluent
aphasia; MoCA=Montreal Cognitive Assessment; ACER= Addenbrooke’s Cognitive
Examination; FBI=Frontal Behavioural Inventory

4.4.2 Task Behavioural Performance
4.4.2.1 Patients vs. Controls
The control group made more correct responses relative to patients during the acquisition
phase (U=81.0, p=0.001) and reversal phase (U=95.5, p=0.004). Of note, two patients had 51%
or fewer correct responses during acquisition and reversal phase; when removed from the
analysis the group differences remained (Acquisition: U=81, p=0.003; Reversal: U=95.5,
p=0.012).
As expected, controls made more correct responses during the acquisition relative to the
reversal trials (Z= -3.2, p=0.002). Patients showed a trend to make more correct responses during
the acquisition relative to the reversal stage (Z= -1.9, p=0.06Figure 4.2a; Table C.3).

4.4.2.2 Frontal predominant atrophy, temporal predominant atrophy and controls
Controls made more correct responses relative to the temporal (Z=-2.48, p=0.04) and
frontal atrophy (Z=-3.42, p=0.002) group during acquisition (Mean ranks: Control = 25.5,
Temporal= 15.1, Frontal=10.0). During reversal, controls made more correct responses relative
to the frontal group (Z=-2.79, p=0.02); no differences were found between the control and
temporal group (Z= -2.09, p=0.11; Mean ranks: Control=24.5, Temporal=15.7, Frontal=11.9;
Figure 4.2b).
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Figure 4.2: Percent correct responses during acquisition and reversal trials

Boxplots of percent correct and non-responses during acquisition and reversal phases for (a)
patients and controls and (b) frontal, temporal atrophy groups and controls. (a) For the
acquisition and reversal phase controls made more correct responses relative to patients. Patients
made more non-responses relative to controls. (b) During acquisition, controls made more
correct responses relative to the temporal and frontal groups.

4.4.3 FBI
Patients with temporal and frontal atrophy did not exhibit differences in the FBI-reversal
learning composite score (U=34.0, p=0.63).
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4.4.4 fMRI
4.4.4.1 Choice Epoch
The repeated measures ANOVA of BOLD signal during the choice phase revealed a
significant 3-way interaction within the left vlPFC/anterior insula (Table 4.2), where controls
exhibited greater activity relative to patients during acquisition error responses (t= (38), -4.4,
p<0.0001) and reversal correct responses (t= (38), -3.6, p=0.001; Figure 3a). Controls showed
greater activity in vlPFC/anterior insula during acquisition for incorrect relative to correct
responses (t=(20), -4.6, p<0.001), while in patients BOLD signal did not differ for acquisition
correct vs. incorrect responses (t= (18), 1.0, p=0.31). During reversal, in this region the opposite
pattern emerged, where controls did not exhibit a difference in BOLD activity between the
response accuracy (t= (20), 1.5, p=0.16), while patients demonstrated greater activity for errors
relative to correct responses (t= (18), -2.22, p=0.04). Additionally, a group x response accuracy
interaction emerged where controls exhibited greater BOLD activity during incorrect responses
relative to patients within the left dorsal lateral PFC (t= (38), -4.6, p<0.001; Table 4.2, Figure
3b). There was also a significant interaction between phase and response accuracy within the
dorsal lateral and medial PFC, vlPFC, and striatum (see Table 4.2).

4.4.4.2 Feedback Epoch
A main effect of response accuracy was observed in two large clusters that encompassed
the right lateral and ventromedial PFC, right insula and bilateral dmPFC (cluster 1), and left
insula and left ventromedial and lateral PFC (cluster 2) where activity was greater for incorrect
relative to correct responses (Figure 4.3c-d, Table 4.2).
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Figure 4.3: Neural regions demonstrating significant effects during choice and feedback epochs

Group x phase x response accuracy during the choice epoch in the left vlPFC/anterior insula for
controls versus patients (a), group x response accuracy interaction in the left dlPFC for controls
versus patients (b), main effect of accuracy for incorrect versus correct responses for the right (c)
and (d) left lateral PFC.

Table 4.2: Regions demonstrating differential BOLD Signal Responses
Choice Phase
Fixed Effects

Region

L/R

BA

X

Y

Z

t-value

Direction

-4.1

#
voxels
57

Group

Middle temporal
gyrus
Inferior frontal
gyrus
Inferior frontal
gyrus

L

22

60.4

32.1

3.8

L

47

32.4

-28.5

0.1

-4.0

50

Ctrl> Pat

R

9

-53.4

-4.3

35.8

-4.6

27

Ctrl > Pat

Ctrl>Pat

Reinforcement

Inferior frontal
gyrus

L

6/9

41.3

-0.7

33.2

-4.3

27

Corr<incorr

Phase

Left inferior frontal
gyrus
Left medial frontal
gyrus
Lentiform nucleus
& putamen
Inferior frontal
gyrus
Inferior frontal
gyrus
Lentiform
nucleus/putmane

L

9

43.1

-4.9

34.6

4.1

276

Acq > Rev

L

6

5.6

-15.4

48.8

4.8

229

Acq > Rev

17.4

-8.9

-2.4

4.0

221

Acq > Rev

L
L

47/13

31.2

-25.4

-3.2

3.4

130

Acq > Rev

R

9

-39.6

-6.8

31.4

4.4

110

Acq > Rev

-15.0

-7.6

-1.6

3.0

95

Acq > Rev

R

93

Phase x
reinforcement

Inferior frontal
gyrus
Cingulate gyrus
Superior occipital
gyrus
Inferior parietal
lobe
Superior parietal
lobe
Inferior parietal
lobe
Precuneus

R

47

-30.7

-23.2

-2.6

4.2

76

Acq > Rev

R
R

32
19

-9.2
-31.9

-17.9
77.3

38.4
22.7

4.2
3.8

72
69

Acq > Rev
Acq > Rev

L

40

33.1

48.5

43.7

2.5

34

Acq > Rev

L

7

29.8

56.8

49.9

5.1

33

Acq > Rev

L

40

53.0

45.2

49.0

5.4

24

Acq > Rev

L

39

28.6

68.4

31.4

3.8

23

Acq > Rev

Cingulate gyrus

L

32

3.9

-20.9

45.5

-3.1

253

Acquisition
Corr<Incor

Inferior frontal
gyrus

Lentiform
nucleus/Putamen

Inferior frontal
gyrus

L

L

R

Middle frontal
gyrus

L

Inferior parietal
lobule

Cingulate gyrus

44.0

L

Lentiform
nucleus/putamen

Cingulate gyrus

9

R

L

L

17.3

47

34.3

46

32

-25.7

-2.9

-5.1

-3.6

-3.7

-4.8

208

199

96

-8.2

-3.6

-4.5

51

42.9

-28.3

21.8

-4.8

51

34.1

32

-9.4

35.9

-14.4

-7.7

40

-3.1

10.4

-16.8

51.7

-19.7

41.3

43.1

33.1

-3.8

-2.8

-3.5

46

40

34

Reversal
Corr>Incorr
Acquisition
Corr< Incorr
Reversal
Corr>Incorr
Acquisition
Corr< Incorr
Reversal
Corr>Incorr
Acquisition
Corr< Incorr
Reversal
Corr>Incorr
Acquisition
Corr< Incorr
Acquisition
Corr< Incorr
Reversal
Corr>Incorr
Acquisition
Corr< Incorr
Reversal
Corr>Incorr
Acquisition
Corr< Incorr
Reversal
Corr>Incorr
Acquisition
Corr< Incorr
Reversal
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Inferior frontal
gyrus

Middle frontal
gyrus

R

L

9

-36.3

9

36.9

-7.7

0.5

29.7

61.5

-4.2

-4.4

33

23

Corr>Incorr
Acquisition
Corr< Incorr
Reversal
Corr>Incorr
Acquisition
Corr< Incorr
Reversal
Corr>Incorr

Group x
reinforcement

Inferior frontal
gyrus

L

9

42.4

-4.7

34.0

3.7

27

Incorrect
Ctrl>pat

3-way interaction

Inferior/middle
frontal gyrus

L

47

40.1

-31.6

-1.1

4.7

22

Incorrect acq
Ctrl> Pay
Correct rev
Ctrl > Pat

Feedback Phase
Fixed Effects

Region

L/R

BA

X

Y

Z

t-value
0.3

#
voxels
9521

Reinforcement

Right
Inferior, middle,
superior frontal
gyrus/insula

R/L

47/46/9/
10
/8/6/13/
45/32

-28.9

-26.6

31.9

Incorr > corr

L

42.4

-20.9

L

47/13/10
/
9/6/8/44/
45
40

23.2

-5.1

5020

Incorr > corr

35.3

59.5

39.3

-6.9

4994

Incorr > corr

R

7

-43.0

57.8

45.3

-3.9

3083

Incorr > corr

R

18

-51.2

54.8

-1.0

1282

Incorr > corr

R
L

18
19

-0.6
28.0

82.7
66.4

-3.2
-2.9

885
631

Incorr > corr
Incorr > corr

Thalamus
Fusiform gyrus

R
L

19

0.7
45.5

5.3
69.3

-3.7
-3.2

612
296

Incorr > corr
Incorr > corr

Lingual gyrus

R

18

-12.6

82.4

-4.5

147

Incorr > corr

Cingulate gyrus

L

23

1.6

30.5

11.8
8.4
28.5
9.2
14.8
25.2
28.4

-4.6

85

Incorr > corr

Left superior,
medial frontal
gyrus/cingulate
gyrus/anterior
cingulate
Superior, middle,
inferior frontal
gyrus/insula/
precentral gyrus
Inferior parietal
lobe
Superior parietal
lobe
Inferior occipital
gyrus
Cuneus
Fusiform gyrus
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Direction

Superior frontal
gyrus
Cingulate gyrus
Middle occipital
gyrus
Superior frontal
gyrus
caudate
Nodule

Phase

Group x Phase

Phase x
Reinforcement

R

11

-21.8

-44.8

L/R
L

23
18

1.2
35.2

14.1
91.6

L

11

23.2

-42.1

-26.2
-0.3

46.2
56.4

15.0
31.1
5.9

-4.9

77

Incorr > corr

-4.0
-4.3

58
51

Incorr > corr
Incorr > corr

-4.9

43

Incorr > corr

4.8
-4.2

39
28

Corr>Incorr
Incorr > corr

-3.9
-3.9

28
26

Incorr > corr
Incorr > corr

Posterior cingulate
Superior temporal
gyrus
Middle occipital
gyrus
Parahippocampal
gyrus

R
R

39

-0.1
-44.2

42.5
57.7

15.3
15.6
35.6
7.6
23.2

R

19

-47.9

79.5

1.3

-4.3

23

Incorr > corr

8.6

38.2

4.6

-4.6

23

Incorr > corr

Inferior occipital
gyrus
Middle occipital
gyrus
Cuneus

R

18

-37.8

84.9

4.1

109

Acq> Rev

L

19

54.1

75.7

20.8
-1.6

4.4

48

Acq> Rev

R

18

-2.5

94.9

10.2

3.8

45

Acq> Rev

Superior/middle
frontal gyrus

L

10

26.5

-55.7

10.0

-4.5

34

Acquisition
Ctrl>pat

R
L

L

Inferior parietal
lobule

R

40

-41.9

47.5

56.6

-3.9

23

Inferior occipital
gyrus

R

18

-25.9

90.0

20.1

-4.3

56

Fusiform gyrus

Middle occipital
gyrus

R

R

19

-43.8

19

-48.7

80.4

77.6

21.4

-9.8

-4.4

-4.1

40

36

Reversal
Ctrl< Pat
Acquisition
Ctrl > Pat
Acquisition
Corr< Incorr
Reversal
Corr>Incorr
Acquisition
Corr< Incorr
Reversal
Corr<Incorr
Acquisition
Corr< Incorr
Reversal
Corr>Incorr

Lingual gyrus

L

18

3.6

79.6

-9.6

-3.7

28

Acquisition
Corr< Incorr
Reversal
Corr>Incorr
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Inferior parietal
lobule

R

40

-57.1

57.3

45.6

-3.7

23

Acquisition
Corr< Incorr
Reversal
Corr<Incorr

Middle occipital
gyrus

L

19

53.7

77.4

77.4

-4.2

22

Acquisition
Corr< Incorr
Reversal
Corr>Incorr

Thresholded at p<0.001 (t-value=3.570). All clusters survive correction for multiple comparison
at p<0.05. Table displays regions, hemisphere (L, left; R, right), Brodmann area (BA), Montreal
Neurological Institute (MNI) coordinates (x, y, z) at center of mass, maximum neural activity for
the cluster (t-value), cluster size in voxels, and the direction of activity [Control (ctrl), Patient
(pat), Acquisition (acq), Reversal (rev), Correct (corr), Incorrect (incorr)]. Focus point and
regions of BA according to TT_Daemon: Talairach-Tournoux atlas. The ANOVA was
completed separately for the choice and feedback phase.

4.4.4.3 Exploratory ROI Analysis
4.4.4.3.1 Choice Epoch
To examine potential differences between the atrophy groups within the resulting clusters
found during the choice epoch, anatomical ROIs were created for the left vlPFC and dlPFC. A
main effect of group emerged within the left vlPFC [F(2,35)=5.9, p=0.006] and left dlPFC
[F(2,35)=8.2, p=0.001]. Post-hoc tests revealed that the control group exhibited greater BOLD
signal relative to the frontal group (marginally for the vlPFC) and the temporal group. No
differences were found between the frontal or temporal group (Figure 4.4a-b).
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Figure 4.4: BOLD signal change across the control and atrophy groups during the choice epoch

Mean percent BOLD signal change during choice epoch within the (a) left dlPFC and (b) vlPFC.
Error bars represent SEM. Asterisks indicate p<0.05. (a) Control group exhibited greater BOLD
signal changes compared to the frontal and temporal group and (b) the temporal group only.

4.4.4.3.2 Feedback Epoch
Anatomical ROIs were used to partition the larger clusters found for the feedback epoch
and differences between the atrophy groups and controls were assessed. A group by response
accuracy interaction was observed in the right dlPFC [F(2,35)=3.5, p<0.05] and right vlPFC
[F(2,35)=3.8, p<0.05]. For both regions, a one-way ANOVA for incorrect responses revealed
trends (dlPFC: [F(2,37)=2.5, p=0.095]; vlPFC: [F(2,37)=3.7, p=0.06]); post-hoc tests revealed
that in both regions, controls exhibited greater error-related BOLD activity relative to the frontal
predominant atrophy group (dlPFC: control – frontal mean difference= 0.24, p=0.034; vlPFC:
control-frontal mean difference= 0.36, p=0.02). No differences were found between the atrophy
groups (dlPFC: frontal-temporal mean difference= -0.20, p=1.0; vlPFC: frontal-temporal mean
difference= -0.30, p=0.08) or between controls and the temporal group (dlPFC: control-temporal
mean difference= 0.03, p=0.75; vlPFC: control-temporal mean difference= 0.058, p=0.67). For
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the dlPFC, no significant main effect of group was found for correct responses. Within the vlPFC
a main effect of group was observed (F(2,37)=4.1, p=0.025), and an unexpected pattern emerged
for correct responses in which the temporal predominant atrophy group showed enhanced
activity relative to controls (Control-temporal mean difference= -0.14, p=0.007; Figure 4.5a-b).
As the significant group x response accuracy may have been driven by group differences
between correct and incorrect responses, we computed a difference scores between the BOLD
signal for correct and incorrect responses and conducted a one-way ANOVA to delineate the
effect of group. For the dlPFC and vlPFC, a main effect of group emerged (dlPFC: [F(2, 37) =
3.45, p=0.04], vlPFC: [F(2,27)= 3.78, p=0.03]). For both regions, controls showed larger
differences between correct and incorrect responses relative to the frontal group (dlPFC: controlfrontal mean difference= -0.25, p=0.01; vlPFC: control-frontal mean difference = -0.42, p=0.01).
No differences were found between controls and the temporal group (dlPFC: control-temporal
mean difference: -0.08, p=0.32; vlPFC: mean difference= -0.20, p=0.18), or between the frontal
and temporal groups (dlPFC: frontal-temporal mean difference= 0.16, p=0.15; vlPFC: mean
difference=0.2, p=0.22).
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Figure 4.5: BOLD signal change across the control and atrophy groups during the feedback
epoch

Mean percent BOLD signal change during the feedback epoch within the right (a) dlPFC and (b)
vlPFC during correct and incorrect trials. Error bars represent SEM. Asterisks indicate p<0.05.
Post-hoc comparisons revealed that controls exhibited greater error-related BOLD activity
relative to the frontal predominant atrophy group in the dlPFC (a) and vlPFC (b) for incorrect
responses. For correct responses, patients with temporal atrophy exhibited greater activity
relative to controls (b).

4.5 Discussion
Patients with FTD frequently engage in disinhibited and perseverative behaviours even
when faced with negative feedback- whether social, legal or financial. Here we used reversal
learning, a classic cognitive paradigm previously associated with such behaviours, to determine
the functional pathophysiology leading to impaired reversal learning in patients with FTD.
Reversal learning deficits have been previously shown to be correlated with behavioural
problems in other populations [5]. We found that during a classic reversal learning paradigm,
patients show reduced BOLD responses in the vlPFC and dlPFC. Furthermore, we also
demonstrated differing BOLD responses to error feedback between patients with frontal versus
temporal atrophy. These results extend the current knowledge of the underlying functional
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deficits of behavioural flexibility in FTD and have implications for the selection of outcome
markers and therapeutic targets for future clinical trials of symptomatic treatments.
During choice selection, patients demonstrated reduced responding within the
vlPFC/insula to acquisition errors and correct reversal trials. During reversal learning, the vlPFC
is implicated in selecting among competing response options. Specifically, during instances of
conflict, the anterior cingulate cortex increases the representation of stimulus-motor features
within the vlPFC, which, in conjunction with the caudate, flexibly controls motor responses [6].
Following this model, enhanced vlPFC activity is predicted to occur during instances of response
competition including response inhibition [12]. Enhanced vlPFC has been found for correct
reversals during choice selection across early relearning trials [24]. Greater response competition
and response inhibition may occur during early learning trials where stimulus-response
associations are still being formed relative to later learning trials where these associations are
more established [24]. The functional contributions of the vlPFC is consistent with the current
results demonstrating enhanced activity in healthy controls during instances of response
competition to an incorrect stimulus or a previously rewarded stimulus. Overall, the reduced
BOLD activity in the vlPFC in patients suggests that during response competition, deficient
inputs and/or processing within the vlPFC may result in impaired flexible motor control when
selecting among several potential choice options.
Impairments in response competition highlights a potential role for serotonergic
modulation as a pharmacological target for reversal learning deficits in FTD. Hughes, et al. [25]
showed that increasing serotonin in patients with bvFTD through the administration of an acute
dose of citalopram, restored activity within the right inferior frontal gyrus as measured by MEG
during response inhibition. Additionally, reducing the availability of serotonin through
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tryptophan depletion significantly reduced right orbito-inferior prefrontal activity in healthy
controls during an inhibitory motor control [26]. Based on the current study results and previous
findings, it may be predicted that serotonin may augment neural activity within the vlPFC during
response competition, which may reduce symptoms of disinhibition in patients. In fact,
Herrmann, et al. [27] demonstrated that citalopram (serotonin reuptake inhibitor), was effective
in treating behavioural symptoms including disinhibition, depression and irritability over a 6week period. Further work is needed to elucidate the possible interactions between the effects of
serotonin on vlPFC, response inhibition and disinhibition, and determine the implications for
other disorders that feature similar behavioural disinhibition.
During errors in the choice phase, patients with FTD exhibited decreased activity relative
to controls within a second region of PFC, specifically the dlPFC. Previous work has shown that
within the dlPFC BOLD signal increases during instances of decision-making conflict including
non-reversal errors, reversal errors and correct reversals [6,9,12]. One account suggests that
during instances of decision conflict, the dmPFC/ACC engages the dlPFC to increase top-down
attentional control of task-relevant features [28-31]. In these situations, increasing the salience of
relevant task features may facilitate the detection of alternative cues to guide alternative
behaviour [12,13]. Moreover, during response selection, the dlPFC (BA 9) demonstrates
enhanced activity during early relative to late reversal trials [24]. This enhanced activity is
consistent with the idea that the dlPFC is implicated in resolving decision conflict; for example,
early reversal trials may place greater demands and greater conflict relative to later reversal trials
wherein greater learning has taken place [24]. In patients with FTD, deficient inputs to the
dlPFC, possibly from the dmPFC/ACC during instances of decision conflict (i.e. error feedback
during the choice phase), may be associated with deficits in increasing attention to relevant
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stimuli to resolve these conflicts and subsequently reverse a maladaptive response. Relative to
healthy controls, patients with FTD are less averse to negative stimuli (e.g. unpleasant odour)
and expend less effort to avoid negative stimuli [32]. Given these findings, it may be predicted
that during decision-making, patients with FTD experience difficulties engaging to negatively
valanced stimuli, such as error feedback, and therefore subsequent alternative motor responses
are not generated. One potential intervention may include behavioural strategies that generate
explicit consideration of various behavioural options and the key features to help guide optimal
decision making. Another strategy may include increasing the salience of the negative
information. For example, Kumfor, et al. [33] found that increasing the intensity of negative
facial expressions improved emotion recognition performance in patients with bvFTD to a
similar degree as controls.
As potential deficient inputs to the dlPFC, possibly from the ACC during instances of
decision conflict, understanding the neurochemical mechanisms underlying conflict monitoring
within the ACC have important implications in pharmacological targets for behavioural
symptoms in FTD. Some evidence suggests that dopaminergic mechanisms are involved.
Increased dopamine transmission has been found within the ACC during performance of a setshifting task [34]. Additionally, elevated levels of dopamine via amphetamine administration,
increases the error-related negativity (ERN) signal, an event-related potential originating within
the ACC and is elicited after making an incorrect response [35]. Likewise, haloperidol
(dopamine antagonist) attenuates the ERN signal [36]. Overall, these studies suggest
dopaminergic involvement in the ACC during conflict monitoring and may suggest a potential
avenue for pharmacological treatment in FTD. Importantly though, other research has suggested
the involvement of other neurotransmitters during instances of conflict [37]. For example,
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increasing the availability of norepinephrine amplifies the ERN signal during a flanker task [38].
Further work is needed to elucidate and extend the current knowledge of the roles of
neurotransmitters involved in conflict monitoring within the ACC.

4.5.1 Atrophy Patterns
As the bulk of functional and lesion studies of reversal learning have implicated regions
of prefrontal cortex in successful reversal learning performance, it was predicted that patients
with frontal predominant atrophy would have greater neural and behavioural deficits during
reversal learning relative to patients with temporal predominant atrophy and to controls.
Behaviourally, patients with frontal predominant atrophy made more errors relative to healthy
controls; no differences were found between patients with temporal atrophy and controls.
Additionally, controls were found to exhibit greater BOLD activity relative to the frontal group
for incorrect responses during the feedback stage within the dlPFC and vlPFC, while BOLD
patterns were similar between controls and the temporal atrophy group.
Patients with bvFTD and SD show distinct behavioural and neuropsychological profiles;
however, both frontal and temporal lobe atrophy groups experience disinhibited symptoms
[39,40]. Furthermore, recent work demonstrated associations between temporal predominant
atrophy and perseverative and compulsive behaviours in patients with FTD [41]. Coupled with
previous studies, our findings indicate that disinhibited behaviours in temporal predominant FTD
may be due to distinct cognitive mechanisms than those associated with frontal predominant
FTD. For instance, it has been proposed that disinhibited behaviours in semantic dementia may
in part arise from disruptions in expressive and receptive vocabulary resulting in maintaining
fixed and rigid routines and thinking patterns in an effort to maintain control and understanding
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during daily experiences [40,42]. Patients with temporal predominant atrophy also demonstrate
disinhibition that appears distinct from language or compulsions, such as inappropriate approach
and overly personal disclosures to strangers. Such behaviours may reflect deterioration of the
anterior temporal lobe and its connections and with orbitofrontal cortex. In contrast, disinhibited
symptoms in the frontal group likely arise from disruptions primarily within the frontal cortex
[4,43]. These potentially different cognitive mechanisms underlying disinhibited symptoms in
the atrophy groups illustrate the potential need for different markers to index these mechanisms
and therapeutic approaches.

4.5.2 Behavioural Performance
Patients made more errors relative to controls during the acquisition and the reversal
stage. Previous reversal learning studies in FTD populations included a learning criterion during
the acquisition stage in which participants needed to reach prior to switching to the reversal stage
[14,16,44]. In the current study no learning criterion was employed to ensure that participants
had a similar number of acquisition and reversal trials for the fMRI analysis.

4.5.3 Limitations
Although all patients met the consensus criteria for probable or definite FTD, genetic or
autopsy confirmation of frontotemporal dementia in this cohort has not been established for all
patients; thus, patients with diseases other than FTLD may have been included in the study.
Another potential limitation is the limited sample size within each of the atrophy subgroups. It is
recognized that reversal learning is one of several tasks indexing behavioural flexibility; future
studies utilizing other fMRI-adapted tasks are suggested in order to obtain a comprehensive
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understanding of the neural deficits underlying behavioural flexibility and disinhibition in
patients with FTD.

4.5.4 Conclusion
The current investigation provides insights into the regions related to inflexible decision
making and responding in FTD. Patients with FTD and frontal predominant atrophy
demonstrated deficits in learning and reversing stimulus-reinforcement contingencies with
reduced BOLD activity in vlPFC/insula and dlPFC. Although patients with FTD with frontal
predominant atrophy and temporal predominant atrophy exhibit similar caregiver-reported
symptoms, our results indicate the neural mechanisms underlying these symptoms arise from
different mechanisms. Future studies probing additional tasks of flexible behavioural responding
and inhibition may further elucidate the neural regions and cognitive mechanisms underlying
these behaviors in patients with temporal predominant atrophy and inform tailored therapeutic
approaches.
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Chapter 5: General Discussion
5.1. Introduction
FTD is a neurodegenerative disorder for which there is no known cure. Clinical trials for
symptomatic and disease-modifying treatments are being developed, highlighting the importance
identifying disease markers to (1) indicate when treatments should be administered (2) act as
outcome markers to elucidate treatment efficacy, and (3) serve as potential targets for treatments
or interventions. Given the current gaps in knowledge, the objective of this thesis is to elucidate
elements of the pathophysiology of FTD from the preclinical to the symptomatic disease stage.
The central hypothesis is that potential markers for clinical trial designs will be identified in
preclinical and symptomatic patients with FTD. The results of this thesis support the central
hypothesis and demonstrate that FTD-related changes occur prior to disease onset, and that
functional neural deficits indexing FTD symptoms are detectable during the symptomatic disease
stage. The current thesis identifies potential markers that may be used to evaluate the clinical
effects of future therapeutic interventions and to identify possible targets for future treatments.
Study I delineated the initial symptoms within each of the three most common mutation
groups (C9orf72, GRN, MAPT) in symptomatic patients with FTD and in preclinical mutation
carriers. Consistent with reports of symptomology during the course of the disease [1,2],
symptomatic MAPT carriers frequently endorsed initial disinhibition and memory impairments,
and symptomatic GRN carriers endorsed initial language-based symptoms most often. The
second objective for study I was to examine whether preclinical mutation carriers demonstrated
greater or unique behavioural/cognitive symptoms relative to biologically related non-mutation
genetic carriers. At an average of 14 years prior to expected disease onset, preclinical MAPT
carriers endorsed poorer mood and sleep symptoms, C9orf72 carriers exhibited greater abnormal
behaviours, and GRN carriers exhibited better mood relative to non-carriers. Over time, GRN
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carriers exhibited poorer everyday skills relative to mutation non-carriers. These findings
confirm our predictions that the initial symptoms occurring at the onset of FTD vary between
and within genetic mutation groups, and that preclinical mutation carriers demonstrate aberrant
behavioural/cognitive functioning prior to disease onset that is distinct from the initial symptoms
that mark the start of clinical FTD.
In addition to behavioural and cognitive changes occurring during the preclinical period
of FTD, study II found that preclinical mutation carriers exhibited larger ventricular volumes (i.e.
greater atrophy), compared to biologically related mutation non-carriers beginning four years
prior to expected disease onset. In contrast to the previous study’s findings, no specific gene
mutation patterns were found. These results provide further evidence that pathological
neuroanatomical changes begin and are detectable in the preclinical period, prior to disease
onset.
As disinhibition and poor behaviour flexibility is one of the earliest and debilitating
symptoms in FTD, study III aimed to delineate the functional neural correlates underlying these
symptoms. The current study found that during a decision-making task, patients exhibited
reduced functional activity within the vlPFC and dlPFC as they selected between two choice
options. These neural regions have been implicated during the initiation of motor responses to
adjust current behaviour and increasing attention to task relevant stimuli [3,4]. Moreover, we
also found that patients with frontal relative to temporal predominant atrophy demonstrated
different patterns of neural activity relative to controls when receiving error-related feedback.
These results demonstrate that patients with FTD exhibit aberrant neural functioning relative to
healthy controls during a reversal learning task. Furthermore, these results also suggest that
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different cognitive mechanisms may underlie disinhibition and behaviour flexibility in patients
with frontal and temporal lobe atrophy patterns.

5.2 Preclinical Disease Period: The Need for Biomarkers

5.2.1 The Applicability of Biomarkers
Ideally, disease modifying treatments should be administered during the preclinical or
prodromal stage of the disease, prior to the occurrence of irreversible neuronal dysfunction or
loss. This highlights the needs for the identification of biomarkers during the earliest stage of the
disease to evaluate the clinical effects of treatments and to indicate when treatments should be
initiated [5]. Specifically, assessing at-risk individuals from families with genetic FTD is the
ideal cohort to evaluate disease progression from the preclinical period to the symptomatic
disease stage [6]. The results of Study I and Study II illustrate that FTD-related changes occur at
the behavioural and neuroanatomical level beginning at an average of 14 years prior to expected
disease onset in carriers of a pathogenic mutation. Similar to other neurodegenerative diseases
[7,8], the pathophysiological mechanisms of FTD begin prior to the emergence of clinical
symptoms, and thus, provides an opportunity for therapeutic treatments to intervene.

5.2.2 Preclinical Changes in Behaviour and Cognition
Recent evidence indicates that FTD-related changes in behavioural and cognition emerge
and can be detected during the preclinical disease period. Relative to mutation non-carriers,
MAPT and GRN preclinical carriers exhibit declines in various aspects of cognition including
memory, language, and social cognition, starting eight years prior to expected disease onset [9].
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As well, asymptomatic C9orf72 carriers demonstrate impaired gestural praxis abilities 25 years
prior to disease onset [10]. Although symptom characteristics have been compared across the
main mutation groups in patients [1,11], gene-specific symptoms during the preclinical and
prodromal disease period have not been investigated. This knowledge can potentially inform the
selection of outcome measures to evaluate the effectiveness of treatments targeting specific
mutations or pathologies, or basket-design trials where common symptoms arising from different
pathologies are grouped together. Furthermore, previous work was limited to assessing
symptoms based on aspects of cognition and broad neuropsychiatric functioning. Given these
limitations, study I expanded the current knowledge by evaluating the frequency and type of
symptoms that occur in genetically at-risk individuals using a comprehensive list of FTD-related
symptoms across various domains (e.g. behaviour, language, cognitive, psychiatric, motor). At
an average of 14 years prior to expected disease onset, MAPT preclinical mutation carriers
endorsing worse sleep, mood and motivation, C9orf72 carriers endorsed greater abnormal
behaviours and stereotypic/motor symptoms, and GRN carriers endorsed better mood.
Additionally, over time, GRN preclinical mutation carriers demonstrated worse everyday skills
which involve a range of cognitive features (e.g. difficulty using electrical appliances, difficulty
writing, difficulty making a hot drink, problems managing finances). The results of study I
coincide with the previous literature demonstrating that disease related alterations emerge and
can be detected early during the preclinical disease period, and that gene-specific pathological
processes begin prior to disease onset. We expanded previous work by detecting disease-related
alterations using questionnaire measures which offers a pragmatic method that can be readily
employed in clinical trials to evaluate disease onset and progression. Furthermore, we illustrate
behavioural and cognitive differences between the preclinical and non-mutation carriers several
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years earlier than previously reported. Therefore, we suggest that measures assessing these genespecific symptoms (MAPT: sleep, mood, motivation; C9orf72: abnormal behaviours,
stereotypic/motor symptoms; GRN: mood and everyday skills), may be used as outcome
measures in future clinical trials to evaluate the effectiveness of treatments.
Although we found that preclinical mutation carriers exhibited specific symptoms prior to
disease onset, the frequency of the most common initial symptoms endorsed by affected patients
(apathy, disinhibition, memory impairments, decreased fluency and impaired articulation), were
found to be similar across preclinical mutation carriers and non-carriers. These results may
suggest that specific symptoms may emerge just prior to or at disease onset. Similarly, during a
four-year follow-up, Jiskoot, et al. [12] found that preclinical MAPT and GRN carriers who
remained asymptomatic during the study period (“non-converters”), exhibited similar global
cognitive functioning and neuropsychiatric features relative to non-carriers. Importantly,
mutation carriers who “converted” during the follow-up period exhibited poorer cognitive and
neuropsychiatric functioning relative to non-convertors and non-carriers. The results of study I
raise an intriguing possibility that other symptoms are present during the preclinical period
which may differ than the symptoms that emerge at disease onset. Nevertheless, these preclinical
symptoms will be important to assess treatment efficacy during the preclinical period and to aid
in the selection of targets for potential symptomatic treatments.

5.2.3 Preclinical Changes using Neuroimaging
Recent evidence has detected pathogenic alterations in brain structure during the
asymptomatic disease stage. Investigations of genetically at-risk families have shown different
cortical involvement within each of the common FTD-related mutations. For example, MAPT
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carriers demonstrate early involvement of the anterior/medial temporal lobes; C9orf72 carriers
show a diffuse pattern of atrophy including subcortical regions of the hippocampus, thalamus
and cerebellum; in GRN carriers, studies often report inconsistent results with only some studies
finding structural changes during the preclinical disease period [13].
Ventricular volume has been proposed as a potential biomarker to index neuronal
atrophy. Relative to grey matter volume, the contrasting intensity between the ventricle and
surrounding tissue, makes the assessment of ventricular volume an efficient tool to be quantified
with visual scales and automatic segmentation software [14]. Furthermore, the ventricles are less
susceptible to scanner inhomogeneities as they located within the center of the brain and the
magnet’s isocenter [14,15]. Consequently, it has been proposed that ventricular volume
measurements may be less variable relative to whole brain volumes and have more statistical
power to detect changes over time [15]. Several studies have reported greater ventricular volume
(i.e. greater neuronal loss) in patients with FTD, across the different phenotypes and genotypes,
relative to healthy controls [16,17]. Although ventricular volume measurements have been
considered in symptomatic patients, this measure has yet to be explored in genetically at-risk
family individuals. Due to the methodological advantages, measurement of ventricular volume
may offer an efficient tool to assess neurodegenerative changes during the preclinical disease
period. Study II addressed this knowledge gap by examining ventricular volume in asymptomatic
carriers of C9orf72, GRN or MAPT mutations relative to biologically related non-carriers.
Critically, we found that beginning four years prior to expected disease onset, preclinical
mutation carriers demonstrated greater ventricular volumes relative to non-carriers. Furthermore,
supporting the proposed methodological advantages of ventricular volume segmentations, we
found that results produced by a fully automated segmentation software were comparable to the
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results completed using time-sensitive manual edits. Overall, these findings illustrate that
measurements of ventricular volume are a robust tool to assess structural alterations during the
preclinical disease period.
In contrast to previous literature [13], we did not find differences between genotypes in
the total ventricular volume or between left and right ventricular volumes. We did not observe
differences between genetic groups in the laterality index (absolute value between the left and
right ventricles), which is in contrast to the predicted asymmetry atrophy pattern found in GRN
mutation carriers [1]. One possibility may be that differences in neuronal loss across genotypes,
particularly for GRN mutation carriers, may be detected just prior to or at disease onset. For
example, Jiskoot, Panman, Meeter, Dopper, Donker Kaat, Franzen, van der Ende, van Minkelen,
Rombouts, Papma and van Swieten [12] found that starting two years prior to disease onset,
preclinical MAPT and GRN mutation carriers who “converted” into the symptomatic disease
stage, exhibited lower grey matter volumes within regions of the frontal and temporal cortex,
relative to preclinical non-convertors; structural changes were absent for preclinical carriers who
remained asymptomatic during the study period.
As alterations in cortical/subcortical volumes and cortical thickness have been detected
earlier than four years prior to disease onset, we suggest that assessments of grey matter volumes
may be used to track disease progression and/or be used as outcome measures to assess treatment
efficacy [10,18-20]. Additionally, other neuroimaging modalities including assessing white
matter integrity reveal FTD-related alterations early during the preclinical disease period [6,21].
For example, Jiskoot, et al. [22] detected white matter integrity changes 30 years prior to
expected disease onset in preclinical C9orf72 and MAPT carriers. Additionally, studies assessing
GRN and MAPT carriers detected structural and functional connectivity changes in the absence
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of grey matter alterations [23,24]. As well, Feis, et al. [25] differentiated preclinical C9orf72,
GRN and MAPT carriers from non-carriers using a multimodal MRI-based classification system
that encompassed measures of radial diffusivity and white matter density. Although the authors
assessed anatomical MRI, DTI and resting-state functional MRI in their classification system, the
best performing classification model included only aspects of white matter integrity, supporting
the notion that white matter alterations are an early marker of FTD pathology. While white
matter changes have been reported earlier compared to ventricular volume changes, we suggest
that given the relative ease, automaticity and reliability of ventricular volume measurements, in
comparison to white matter analytic methods, direct comparisons of the sensitivity and
specificity of ventricular volume to these other indices in clinical populations that may have
more hetereogenous comorbidities and white matter changes would be valuable. Importantly,
measures of ventricular volume, in addition to other neuroimaging modalities, may be applied as
an outcome measure to assess the efficacy of disease-modifying treatments.

5.3 Symptomatic Disease Period: Identifying treatment targets
5.3.1 The Need for Treatment Targets
Currently, there are no approved disease-modifying therapies that alter the course of the
disease or prevent disease progression [26]; instead, off-label use of medications that alter
neurotransmission has been used for symptom management with mixed success [27]. To further
advance the development of symptomatic treatment, measurements that aid in the selection of
promising therapeutic targets are warranted.
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5.3.2 Potential Treatment Targets for Symptomatic Disease Period
We found that across the genetic forms of FTD, the most common early symptoms were
apathy, disinhibition, memory impairments, decreased fluency, and impaired articulation. Genespecific patterns also emerged, with C9orf72 and MAPT carriers endorsing disinhibition, apathy
and memory symptoms most frequently, and GRN carriers endorsing apathy, impaired
articulation and decreased fluency early during the disease. At present, there are no effective
treatments for these initial symptoms in FTD. Relatedly, two key challenges in clinical trial
design for FTD have been identified: (1) heterogeneity of clinical symptoms leading to
difficulties in assessing treatment efficacy and (2) the rarity of FTD leading to recruitment
challenges, which necessitate the need for biomarkers that can optimize treatment effects [28].
Recently, symptomatic treatment options for FTD have begun to consider the anatomical
and functional neural deficits underlying FTD-related symptoms. A small number of studies
have used functional imaging to delineate whether potential treatments modulate neural activity
related to target symptoms. For example, based on previous work suggesting that the integrity of
the inferior frontal gyrus and serotonin regulation is critical for appropriate response inhibition,
Hughes, et al. [29] investigated whether increasing serotonin levels in patients with bvFTD
restores neural responding within the inferior frontal gyrus during a response inhibition task. As
well, it has been shown that oxytocin administered to patients with FTD modulates aberrant
neural activity in brain regions related to empathy and emotional processing [30]. This work
indicates potential implications for the results of Study III which assessed the neural correlates of
behavioural flexibility in patients with FTD and healthy controls. Patients exhibited reduced
functional activity within the vlPFC and dlPFC during the choice phase of the task, as they
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selected between two different options. These neural regions have been implicated during the
initiation of motor responses to adjust current behaviour and increasing attention of task relevant
stimuli during error responses, respectively [3,4]. Potential interventions targeting the
psychopharmacology contributions of these neural systems may be one avenue to augment
neural responding within the vlPFC and dlPFC to ameliorate these symptoms in FTD. For
example, increasing levels of serotonin has been found to enhance neural responding within the
right inferior frontal gyrus which is associated with response inhibition [29]. We also found that
patients with frontal relative to temporal predominant atrophy exhibited different neural
responding when they received error-related feedback. Relative to controls, patients with frontal
lobe atrophy demonstrated lower neural activity to error-feedback; no differences emerged
between the control and temporal atrophy group, or between the frontal and temporal atrophy
group. These results suggest that different cognitive mechanisms underlie impaired disinhibition
and behavioural flexibility in the frontal and temporal patient groups, which may necessitate
different therapeutic targets. Furthermore, changes in the neural activity in the vlPFC and dlPFC
during reversal learning may be used as an outcome marker in proof of concept challenge studies
and brief clinical trials to identify the potential of treatments targeting poor behavioural
flexibility.

5.4 Limitations and Future Directions
The current thesis provides novel insights into the preclinical and symptomatic period of
frontotemporal dementia that have implications for future clinical trial designs; however, certain
limitations need to be addressed. Consistent with previous studies assessing preclinical changes
in genetically at-risk family members of patients [31], the predicted age at disease onset for
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preclinical mutation carriers was calculated using the mean age at disease onset within the
participant’s family for Study I and Study II. Although patient’s age at disease onset is
significantly correlated with the mean familial age at disease onset [31], there is a high
variability in the contribution of family membership to predicted age of onset by mutation group
[32]. Given these results, in study I and study II sensitivity analyses were conducted substituting
the calculated age at expected disease onset for the participants current age, which yielded
similar results. The continuation of longitudinal data collection in preclinical mutation carriers
will be helpful to predict the age of clinical symptom occurrence. For example, Jiskoot, Panman,
van Asseldonk, Franzen, Meeter, Donker Kaat, van der Ende, Dopper, Timman, van Minkelen,
van Swieten, van den Berg and Papma [11] longitudinally followed preclinical mutation carriers
who became symptomatic within the study window (i.e. convertors), and thus was able to
determine the age in which these individuals became symptomatic. The continuation of
longitudinal data collection from large FTD cohorts including GENFI, LEFTDS and ARTFL
will be helpful in predicting more precise expected age at disease onset for preclinical mutation
carriers and further improving the modeling of these symptoms and imaging markers.
As study I and study II examined differences in preclinical mutation carriers and
biologically related non-mutation carriers, we were not able to examine the preclinical period in
individuals with sporadic FTD. Examining preclinical autosomal dominant FTD gene mutation
carriers provide a unique insight into the behavioural and neuroanatomical changes that lead to
the conversion from the asymptomatic to the symptomatic disease stage [28]. Importantly
though, the results from the genetically at-risk studies will provide new insights into the potential
earliest changes in sporadic FTD [28].
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Another limitation in Study II is the lack of knowledge of which genetically at-risk
individuals were aware of their genetic status (carrier vs. non-carrier), which may impact their
own and their informant’s perspective on and reporting of cognitive and behavioural symptoms.
Future studies using genetically at-risk participants should examine how one’s awareness of their
genetic status influences the presence and severity of FTD-related symptoms during the
preclinical period.
Across all three studies, the FTD related changes in the potential markers were
demonstrated at the group level; however, prior to their applicability for clinical trials, these
potential markers will need to be validated at the individual level for at-risk and symptomatic
patients. The continuation of multicenter research with large cohorts will be an asset for future
validation at the individual level [6].
Lastly, as FTD is a heterogeneous disorder, the combination of different biomarkers may
provide additive predictors of early deficits and allow accurate tracking of disease progression
and severity. Future research should focus on the multimodal combination of different
biomarkers (i.e. neuroimaging, behavioural and fluid markers) to further our knowledge on
disease onset and monitoring disease progression and treatment response [6].

5.5 Conclusion
In conclusion, FTD is a debilitating disorder that leads to great societal, patient and
caregiver burden. The heterogeneity of clinical symptoms and the rarity of FTD disorders leads
to recruitment challenges and conveys the need for appropriate markers that can efficiently
detect treatment effects [28]. Additionally, markers of preclinical changes may aid in the
selection of potential targets for treatments and help determine when treatments (disease-
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modifying or symptomatic), should be initiated. The current thesis provides novel insights into
behavioural and neuroanatomical changes during the preclinical disease stage and functional
neural deficits underlying behavioural difficulties during the symptomatic disease stage.
Using a large cohort of preclinical mutation carriers and biologically related nonmutation carriers, we found that mutation carriers endorsed greater symptomology during the
preclinical period relative to non-carriers. Measures of these specific symptoms may be used to
select treatment targets and as outcome measures to evaluate the effectiveness of treatments in
future clinical trials. Furthermore, we found that preclinical mutation carriers exhibited greater
ventricular volumes relative to non-carriers beginning four years prior to disease onset.
Quantification of total ventricular volume may be applied in clinical trials to assess whether
disease-modifying treatments slow down the progression of the disease during the preclinical
stages. Lastly, we found that symptomatic patients exhibited altered neural activity within the
vlPFC and dlPFC during choice selection in a decision-making task indexing behavioural
flexibility. These neural changes may be used in proof of concept clinical trials to investigate
symptomatic treatment effects on these altered neural regions.
Ongoing longitudinal investigations assessing symptomatic mutation carriers and
genetically at-risk mutation carriers will be instrumental in increasing our understanding of the
biology of FTD from the preclinical, prodromal and affected disease stages. These findings may
be applied to future clinical trial designs to help assess the efficacy of treatments and to
determine potential symptomatic treatment targets.
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Appendix A: Chapter 2 (Study 1) Supplementary Material
Method Section 1.0: GENFI Symptom Domains and Descriptions
Based on novel findings in the FTD literature, 31 additional symptoms, as indicated by an
asterisk, were included in March 2015 (modified symptom listed below). This symptom list was
based on and adapted from a consortium of validated scales including the Clinical Dementia
Rating Scale (CDR [1]; FTLD-CDR [2], Social Impairment Rating Scale [3], Neuropsychiatric
Inventory [4], Frontal Behavioural Inventory [5], Progressive Aphasia Severity Scale [6],
Progressive Supranuclear Palsy Rating Scale [7], and Autonomic Symptoms Questionnaire (used
in [8]. Further information can be gathered from the GENFI assessment manuals; see
http://genfi.org.uk/.

Behaviour Symptoms
(1) Disinhibition
(2) Apathy
(3) Loss of sympathy/empathy
(4) Ritualistic/compulsive behaviour
(5) Hyperorality and appetite changes
(6) Poor response to social/emotional cues*
(7) Inappropriate trusting behaviour*
Neuropsychiatric Symptoms
(1) Visual hallucinations
(2) Auditory hallucinations
(3) Tactile hallucinations
(4) Delusions
(5) Depression
(6) Anxiety
(7) Irritability/Lability*
(8) Agitation/Aggression*
(9) Euphoria/Elation*
(10) Aberrant motor behaviour*
(11) Hypersexuality*
(12) Hyperreligiosity*
(13) Impaired sleep*
(14) Altered sense of humour*
Language Symptoms
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(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)

Impaired articulation
Decreased fluency
Impaired grammar/syntax
Impaired word retrieval
Impaired speech repetition
Impaired sentence comprehension
Impaired single word comprehension
Dyslexia
Dysgraphia
Impaired functional communication

Cognitive Symptoms
(1) Memory impairment
(2) Impaired orientation*
(3) Impaired judgement/problem-solving
(4) Problems with community affairs*
(5) Problems at home or with hobbies*
(6) Impaired personal care*
(7) Person recognition difficulty*
(8) Impaired topographical memory*
(9) Visuo-spatial or perceptual impairment
(10) Impaired attention/concentration
(11) Bradyphrenia*
Motor Symptoms
(1) Dysarthria
(2) Dysphagia
(3) Tremor
(4) Slowness
(5) Weakness
(6) Gait disorder
(7) Falls
(8) Functional difficulties using hands*
Autonomic Symptoms
(1) Impaired blood pressure*
(2) Gastrointestinal symptoms*
(3) Impaired thermoregulation*
(4) Urinary symptoms*
(5) Altered responsiveness to pain*

Other Physical Symptoms
(1) Altered perception of sounds or music*
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(2) Altered perception of smell or taste*
(3) Persistent unexplained physical symptoms*
(4) Impaired breathing*
Clinical Features
(1) Seizures
(2) Stroke or TIA
(3) Traumatic brain injury
(4) Hypertension
(5) Hypercholesterolaemia
(6) Diabetes mellitus
(7) Smoking*
(8) Excess alcohol use*
(9) Recreational drug use*
(10) Autoimmune disease*

Result Section 2.0: Analysis of symptom endorsement in symptomatic patients who
completed the different versions of the GENFI symptom list
Summary of Results
As only a single initial symptom was selected for the symptomatic patients, we first
investigated whether a different pattern of results was reported for symptomatic patients who
used the original vs. modified GENFI symptom list (which included more symptom options), by
evaluating the pattern of symptom endorsement at baseline in both version groups (Table B.1,
B.2 and see detailed description of analysis below). Across the symptomatic cohort, the most
frequent symptoms within each list were items that were present in both versions of the GENFI
symptom list: disinhibition, apathy, decreased fluency, memory impairment, impaired
articulation and impaired word retrieval. Thus, subsequently, data from both cohorts for the main
analysis were combined.

Analysis
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Of the symptomatic patients, 76 completed the original and 109 completed the modified
GENFI symptom list. Disinhibition (Original: 38.8%; Modified: 4.6), apathy (Original: 28.9%;
Modified: 19.3%), decreased fluency (Original: 7.9; Modified: 8.3%), impaired articulation
(Original: 5.3%; Modified: 5.5%), memory impairment (Original: 5.3%; Modified: 16.5%) were
the most commonly endorsed symptoms in both cohorts. Of note, 5.3% of the “original cohort”
endorsed impaired word retrieval. Chi-squared tests or Fisher’s exact tests were completed on
each cohort to examine differences in symptom endorsement between the genetic groups.

Original Cohort: A greater proportion of MAPT carriers endorsed disinhibition relative to
C9orf72 and GRN carriers (X2=11.1, p=0.004). Additionally, only GRN carriers endorsed
impaired articulation (no C9orf72 and MAPT carriers endorsed impaired articulation, though this
contrast was only significant for C9orf72 carriers [p=0.01, Fisher’s]). No differences were found
for apathy (X2=2.2, p=0.3), decreased fluency (p=0.47, Fisher’s), and memory impairment
(p=0.27, Fisher’s).

Modified Cohort: A greater proportion of MAPT carriers endorsed disinhibition (p=0.03,
Fisher’s) and memory impairments (p=0.04, Fisher’s) more often than C9orf72 and GRN
carriers. Furthermore, GRN carriers endorsed decreased fluency more frequently relative to
C9orf72 and MAPT carriers (p<0.001, Fisher’s). No differences were found for apathy (p=1.0,
Fisher’s) and impaired articulation (p=0.09, Fisher’s).

Overall, the pattern of results across both cohorts were similar; both groups displayed the
same predominant symptoms, and similar differences between the mutation groups. Although no
132

significant group differences were found for impaired articulation in the “modified cohort,” both
“original” and “modified” cohorts demonstrated analogous pattern of results in which GRN
carriers showed the highest endorsement (Original: C9orf72=0, GRN=~17%, MAPT=0;
Modified: C9orf72: 2%, GRN=12%, MAPT=0). Additionally, in the “modified cohort”, memory
impairments occurred more frequently amongst the MAPT carriers and GRN carriers endorsed
decreased fluency most often. Different disease subtypes (Table A.1b) and increased samples
size in the “modified cohort” (Original: N=76, Modified: N=109) and thus greater
recruiting/testing sites and families, may have contributed to these slight differences. Importantly
however, the inclusion of additional symptoms in the modified list did not detract reporting of
symptoms found only in the original version.

Potential Limitation
Minor discrepancies in symptom endorsement reported in each version may be the result
of varying sample sizes, differing proportions of FTLD sub-types, and re-categorization of
symptoms from the original list into more specific symptoms in the modified list (e.g. including
“poor response to social/emotional cues” and “inappropriate trusting behaviour” in the modified
list may have been categorized as “disinhibition” in the original list). Importantly though, the
inclusion of additional symptoms in the modified symptom list did not detract reporting of
symptoms found only in the original version.
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Method Section 3.0: Analysis for CBI-R change score
To improve the distribution of the residuals we attempted several statistical methods (see
below). As the results of the total CBI-R change score were similar across these various
techniques, we reported the results from the linear mixed model in the manuscript.

1. To improve the distribution of the residuals in the linear mixed model we included an
additional fixed effect (gender) and weighted family membership. These additional
predictors did not improve model fit and thus were not included in the current analysis to
maintain a parsimonious model.
2. Additionally, we binned the change score into distinct categories (scores 0 or below were
categorized as one group, and the remaining scores were grouped based on 20%
intervals). Using these categories, we ran a general linear mixed model with
multinominal distribution, and a zero inflated model with a random effect. None of these
models ran successfully.
3. Using the 6 groups from above, we ran an ordinal regression (with random effects) but
this model did not meet the assumption of proportionality. As well, we ran a logistic
regression comparing each group to a reference group (no change or improvement in
symptoms); the residuals did not improve.
4. Subsequently, we categorized the change score into two groups (group 1= participants
whose symptoms deteriorated over time, group 2= participants who symptoms improved
or did no change over time) and ran a general linear mixed model with a binary
distribution and random effects. The residuals did not improve.
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Table A.1 Symptom endorsement (%) for symptomatic patients who completed the different versions of the GENFI Symptom List
Total
(N=76)
Behavioural
Disinhibition
Apathy
Loss of
sympathy/emp
athy
Ritualistic/co
mpulsive
behaviour
Hyperorality
and appetite
changes
Poor response
to
social/emotion
al cues**
Inappropriate
trusting
behaviour**
Neuropsychiat
ric
Visual
hallucinations
Auditory
hallucinations
Tactile
hallucinations
Delusions
Depression
Anxiety
Irritability/La
bility**
Agitation/Agg
ression**
Euphoria/Elat
ion**

Original GENFI symptom list
C9orF72
GRN
(N=34)
(N=24)

MAPT
(N=18)

Total
(N=109)

GENFI modified GENFI symptom list
C9orF72
GRN
(N=53)
(N=41)

MAPT
(N=15)

36.8
28.9

35.3
29.4

16.7
37.5

66.7
16.7

4.6
19.3

1.9
18.9

2.4
19.5

20.0
20.0

1.3

2.9

0.0

0.0

1.8

0.0

4.9

0.0

1.3

2.9

0.0

0.0

0.9

1.9

0.0

0.0

1.3

0.0

4.2

0.0

1.8

3.8

0.0

0.0

0.9

1.9

0.0

0.0

0.9

1.9

0.0

0.0

1.3

2.9

0.0

0.0

0.9

1.9

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.9

1.9

0.0

0.0

0.0
2.6
0.0

0.0
0.0
0.0

0.0
8.3
0.0

0.0
0.0
0.0

1.8
3.7
0.0

1.9
3.8
0.0

2.4
2.4
0.0

0.0
6.7
0.0

0.9

1.9

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0
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Total
(N=76)
Aberrant
motor
behaviour**
Hypersexualit
y**
Hyperreligiosi
ty**
Impaired
sleep**
Altered sense
of humour**
Language
Impaired
articulation
Decreased
fluency
Impaired
grammar/synt
ax
Impaired
word retrieval
Impaired
speech
repetition
Impaired
sentence
comprehensio
n
Impaired
single word
comprehensio
n
Dyslexia
Dysgraphia
Impaired
functional
communicatio
n
Cognitive

Original GENFI symptom list
C9orF72
GRN
(N=34)
(N=24)

MAPT
(N=18)

Total
(N=109)

GENFI modified GENFI symptom list
C9orF72
GRN
(N=53)
(N=41)

MAPT
(N=15)

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.9

1.9

0.0

0.0

5.3

0.0

16.7

0.0

5.5

1.9

12.2

0.0

7.9

11.8

8.3

0.0

8.3

0.0

22.0

0.0

0.0

0.0

0.0

0.0

1.8

0.0

4.9

0.0

5.3

5.9

8.3

0.0

3.7

3.8

4.9

0.0

0.0

0.0

0.0

0.0

0.9

1.9

0.0

0.0

0.0

0.0

0.0

0.0

1.8

0.0

4.9

0.0

0.0

0.0

0.0

0.0

0.9

1.9

0.0

0.0

0.0
0.0

0.0
0.0

0.0
0.0

0.0
0.0

0.0
1.8

0.0
1.9

0.0
2.4

0.0
0.0

1.3

0.0

0.0

5.6

0.9

1.9

0.0

0.0
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Total
(N=76)
Memory
Impairment
Impaired
judgement/pr
oblem solving
Visuo-spatial
or perceptual
impairment
Impaired
attention/conc
entration
Impaired
Orientation**
Problems with
community
affairs**
Problems at
home or with
hobbies**
Impaired
personal
care**
Person
recognition
difficulty**
Impaired
topographical
memory**
Bradyphrenia
**
Motor
Dysarthria
Dysphagia
Tremor
Slowness
Weakness
Gait disorder
Falls

Original GENFI symptom list
C9orF72
GRN
(N=34)
(N=24)

MAPT
(N=18)

Total
(N=109)

GENFI modified GENFI symptom list
C9orF72
GRN
(N=53)
(N=41)

MAPT
(N=15)

5.3

5.9

0.0

11.1

16.5

15.1

9.8

40.0

1.3

2.9

0.0

0.0

3.7

3.8

2.4

6.7

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

4.9

0.0

2.8

0.0
0.0
0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0
0.0
0.0
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1.9

0.9

1.9

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.9
0.9
0.9
0.0
3.7
1.8
0.0

1.9
1.9
1.9
0.0
7.5
3.8
0.0

0.0
0.0
0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0
0.0
0.0

Total
(N=76)
Functional
Difficulties
using hands**
Autonomic
Impaired
blood
pressure**
Gastrointestin
al
symptoms**
Impaired
thermoregulat
ion**
Urinary
symptoms**
Altered
responsiveness
to pain**
Other
Physical
Altered
perception to
sounds or
music**
Altered
perception of
smell or
taste**
Persistent
unexplained
physical
symptoms**
Impaired
breathing**
Other
Disorders
Seizures
Stroke or TIA
Traumatic
brain injury

Original GENFI symptom list
C9orF72
GRN
(N=34)
(N=24)

MAPT
(N=18)

Total
(N=109)

GENFI modified GENFI symptom list
C9orF72
GRN
(N=53)
(N=41)

MAPT
(N=15)

2.8

3.8

0.0

6.7

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0
0.0

0.0
0.0

0.0
0.0

0.0
0.0

0.0
0.0

0.0
0.0

0.0
0.0

0.0
0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0
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Hypertension
Hypercholeste
rolaemia
Diabetes
mellitus
Smoking**
Excess alcohol
use**
Recreational
drug use**
Autoimmune
disease**

Total
(N=76)
0.0

Original GENFI symptom list
C9orF72
GRN
(N=34)
(N=24)
0.0
0.0

MAPT
(N=18)
0.0

Total
(N=109)
0.0

GENFI modified GENFI symptom list
C9orF72
GRN
(N=53)
(N=41)
0.0
0.0

MAPT
(N=15)
0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0
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Table A.2 Demographic details for symptomatic patients completing different versions of the
GENFI Symptom List
Original Symptom List
76

Modified Symptom List
109

Genotype
C9orF72
GRN
MAPT

34
24
18

53
41
15

Sex
Female
Male

28
48

49
60

Handedness
Right
Left
Ambidextrous

71
5
0

103
4
2

Diagnosis
Alzheimer’s Disease
ALS
Behavioural variant FTD
Corticobasal syndrome
Dementia-NOS
FTD-ALS
Other
Primary progressive aphasia
Progressive supranuclear palsy

1
0
56
1
3
3
0
12
0

0
6
70
2
2
6
2
20
1

Total number of families

68

103

Total number of sites

12

19

Age (SD)

62.9 (8.2)

61.8 (8.8)

Age of onset (SD)

58.3 (8.6)

57.9 (8.9)

Education, Yrs (SD)

12.0 (4.3)

12.4 (3.7)

N

ALS= Amyotrophic lateral sclerosis
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Table A.3. Baseline (N=588) and Change Score (N=336) for CBI-R Total Score with age
substituted for Years to Expected Symptom Onset

Pre-symptomatic
Age
Baseline Score
GS*Age
Random Effects
Intercept (family)
Scale
Residual

•
•

•
•

Baseline#
Estimate (95% CI)
1.48 (0.57, 3.85)

p-value
0.42

Change Score
Estimate (95% CI)
1.76 (-0.92, 4.44)

p-value
0.2

1.02 (1, 1.03)

0.02

0.046 (0.01, 0.08)

0.01

-

-

-0.15 (-0.21, -0.1)

<.0001

0.99 (0.97, 1.02)

0.63

-0.028 (-0.08, 0.03)

0.33

Estimate
1.36

p-value
<.0001

-

-

0.32

<.0001

-

-

-

-

10.12

<.0001

Statistics are from the Solution for Fixed Effects Table
# Baseline data was modeled with a negative binomial distribution with a log link function.
Estimates and confidence intervals of fixed effects are exponentiated (base e) and indicate
the incident rates. Estimates below 1 indicate an inverse relationship between the variable
and outcome
GS= genetic status; CI=confidence interval; GS*age= genetic status by age interaction
For the main effect of genetic status and GS*age interaction= reference group are the noncarriers
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Table A.4. CBI-R total change score with outliers by genetic status and by genotype (N=342)
Genotype
Estimate (95% CI)
-1.98 (-4.24, 0.27)

p-value
0.08

GRN

0.39 (-1.20, 1.99)

0.63

MAPT

-0.12 (-2.5, 2.28)

0.92

YEO

0.06 (0.01, 0.11)

0.01

Baseline score

-0.16 (-0.23, -0.09)

<.0001

C9orf72*YEO

-0.17 (-0.28, -0.05)

0.0062

GRN*YEO

-0.03 (-0.12, 0.07)

0.57

MAPT*YEO

-0.04 (-0.18, 0.11)

0.59

Estimate
0.51

p-value
0.30

C9orf72

Random Effects
Family
•
•
•

Residual
18.7
<0.001
Statistics are from the Solution for Fixed Effects Table
YEO= years from expected disease onset; CI=confidence interval
For the main effect of genotype and the genetic mutation*YEO interactions= reference
group are the non-carriers
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Table A.5: Symptom endorsement (%) in symptomatic patients and at-risk family members (GENFI symptom list)

Total
(N=185)

Symptomatic Patients
N=185
C9orF72
GRN
(N=87)
(N=65)

MAPT
(N=33)

Group
Contrasts
X 2= 22.2,
p<0.001 MAPT
> C9orf72 &
GRN
X2= 0.8, p=0.7

Behavioural
Disinhibition

Apathy
Loss of sympathy/empathy
Ritualistic/compulsive
behaviour
Hyperorality and appetite
changes
Poor response to
social/emotional cues**
Inappropriate trusting
behaviour**
Neuropsychiatric
Visual hallucinations
Auditory hallucinations
Tactile hallucinations
Delusions
Depression
Anxiety
Irritability/Lability**
Agitation/Aggression**
Euphoria/Elation**
Aberrant motor behaviour**
Hypersexuality**
Hyperreligiosity**
Impaired sleep**
Altered sense of humour**
Language
Impaired articulation

17.8

14.9

7.7

45.5

23.2
1.6

23.0
1.1

26.2
3.1

18.2
0.0

1.1

2.3

0.0

1.6

2.3

0.9

Impaired grammar/syntax

Non-carrier
N=320
Symptom
Endorsement

Group Contrasts
X2= 1.6, p=0.2

3.5

1.9

4.10
2.52

4.38
1.88

0.0

1.89

1.25

1.5

0.0

1.26

1.25

1.9

0.0

0.0

3.13

1.23

0.9

1.9

0.0

0.0

3.65

0.61

1.1
0.0
0.5
1.1
3.2
0.0
0.9
0.0
0.0
0.0
0.0
0.0
0.0
0.9

2.3
0.0
1.1
1.1
2.3
0.0
1.9
0.0
0.0
0.0
0.0
0.0
0.0
1.9

0.0
0.0
0.0
1.5
4.6
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
3.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0

1.89
0.32
0.63
0.32
14.20
16.09
11.98
5.21
2.60
3.13
0.52
1.04
14.58
2.60

0.00
1.25
0.00
0.94
13.75
13.13
14.11
3.68
0.61
0.61
0.0
0.0
12.27
1.23

1.58

1.88

X2= 0.08, p=0.77

2.52

3.13

X2=0.21, p=0.65

0.95

1.25

5.4
1.1

Decreased fluency

Preclinical
N=317
Symptom
Endorsement

13.8

0.0

8.1

1.1

4.6

16.9

0.0

0.0

3.1

0.0

p=0.001*#
GRN > C9orf72
& MAPT
p=0.005*#
GRN > C9orf72
& MAPT
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X2=0.9, p=1.0

Impaired word retrieval
Impaired speech repetition
Impaired sentence
comprehension
Impaired single word
comprehension
Dyslexia
Dysgraphia
Impaired functional
communication
Cognitive
Memory Impairment
Impaired judgement/problem
solving
Visuo-spatial or perceptual
impairment
Impaired
attention/concentration
Impaired Orientation**
Problems with community
affairs**
Problems at home or with
hobbies**
Impaired personal care**
Person recognition
difficulty**
Impaired topographical
memory**
Bradyphrenia**
Motor
Dysarthria
Dysphagia
Tremor
Slowness
Weakness
Gait disorder
Falls
Functional Difficulties using
hands**
Autonomic
Impaired blood pressure**
Gastrointestinal symptoms**
Impaired thermoregulation**
Urinary symptoms**

4.3
0.5
1.1

4.6
1.1

6.2
0.0

0.0
0.0

7.26
0.00
0.95

10.63
0.31
0.31

0.0

3.1

0.0

1.1

0.0

0.0

0.95

0.31

0.0
1.1
1.1

0.0
1.1

0.0
1.5

0.0
0.0

1.89
1.26
0.63

1.56
2.50
0.31

1.1

0.0

3.0

11.9
2.7

11.5

6.2

24.2

10.41
1.58

12.50
1.56

3.4

1.5

3.0

0.0

0.0

0.0

0.0

0.95

0.31

0.0

0.0

0.0

0.0

5.99

8.75

2.8
0.9

1.9
1.9

4.9
0.0

0.0
0.0

2.08
1.04

0.0
0.6

0.0

0.0

0.0

0.0

1.04

1.23

0.0
0.0

0.0
0.0

0.0
0.0

0.0
0.0

0.52
1.04

0.0
3.07

0.0

0.0

0.0

0.0

2.60

2.45

0.0

0.0

0.0

0.0

2.60

3.68

0.5
0.5
0.5
0.0
2.2
1.1
0.0
2.8

1.1
1.1
1.1
0.0
4.6
2.3
0.0

0.0
0.0
0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0
0.0
0.0

3.8

0.0

6.7

0.63
1.26
2.21
0.32
0.63
0.32
0.00
1.0

0.94
0.94
5.63
1.56
0.00
0.94
0.63
0.0

0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0

5.73
2.60
4.17
4.69

4.29
5.52
5.52
4.29

0.5

p=0.46*#
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X2= 0.69, p= 0.41

Altered responsiveness to
pain**
Other Physical
Altered perception to sounds
or music**
Altered perception of smell or
taste**
Persistent unexplained
physical symptoms**
Impaired breathing**
Clinical Features
Seizures
Stroke or TIA
Traumatic brain injury
Hypertension
Hypercholesterolaemia
Diabetes mellitus
Smoking**
Excess alcohol use**
Recreational drug use**
Autoimmune disease**

0.0

0.0

0.0

0.0

1.04

1.84

0.0

0.0

0.0

0.0

0.52

1.84

0.0

0.0

0.0

0.0

2.1

2.5

0.0

0.0

0.0

0.0

2.1

0.0

0.0

0.0

0.0

0.0

0.5

1.2

0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0

1.58
0.32
9.46
12.62
9.78
2.21
27.08
4.69
9.38
5.73

0.94
0.63
11.56
11.56
11.56
2.19
34.97
4.91
11.0
6.75

**Indicates sub-symptoms collected using the modified GENFI symptom list (Symptomatic: N=109; Preclinical=192, Non-carriers N=163)
*# Fisher’s Exact Test was used as the expected count was less than 5
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Table A.6. Initial symptoms of symptomatic patients from the same family
Number of
participants
within each
family
2
2
2
3

Gene

First symptoms reported

GRN
GRN
GRN
GRN
GRN

Congruency
Score (%)

apathy (n=1), fluency (n=1)
0
apathy (n=1) & fluency (n=1)
0
apathy (n=1) & articulation (n=1)
0
apathy (n=2) & memory impairment (n=1)
33
apathy (n=1) & hyperorality and appetite change (n=1),
10
5
depression (n=1) & articulation (n=2)
3
C9orf72 disinhibition (n=1) & depression (n=1) & tremor (n=1)
0
2
C9orf72 apathy (n=1) & fluency (n=1)
0
2
C9orf72 disinhibition (n=1) & memory impairment (n=1)
0
2
C9orf72 depression (n=1) & memory impairment (n=1)
0
2
MAPT
apathy (n=1) & memory impairment (n=1)
0
2
MAPT
disinhibition (n=2)
100
2
MAPT
memory (n=2)
100
MAPT
apathy (n=2) & impaired judgement/problem-solving
33
3
(n=1)
3
MAPT
disinhibition (n=2) & depression (n=1)
33
The average congruency score across the cohort was 19%. This was calculated as the number of congruent
combinations divided by the number of possible pairwise combinations
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Table A.7. Initial symptoms of symptomatic patients with the same specific genotype
Gene

Gene Type Number of First Symptom Reported
participants

MAPT
MAPT
MAPT

Q351R
G272V
P301L

2
3
7

MAPT
MAPT
GRN
GRN
GRN

7
9
2
2
2

GRN

R406W
IVS10+16
C149fs
G35fs
Q130fs
(388_391d
elCAGT)
C31fs

GRN

S82fs

5

GRN

IVS71G>A

8

GRN

T272fs

24

4

memory impairment (n=2)
disinhibition (n=2), depression (n=1)
disinhibition (n=3), apathy (n=3), impaired judgement/problem
solving (n=1)
disinhibition (n=3), apathy (n=1), memory impairment (n=3)
disinhibition (n=5), apathy (n=1), memory impairment (n=3)
Disinhibition (n=1), impaired articulation (n=1)
Apathy (n=1), decreased fluency (n=1)
Apathy (n=1), impaired grammar/syntax (n=1)

Apathy (n=1), loss of sympathy/empathy (n=1), impaired
articulation (n=1), decreased fluency (n=1)
Apathy (n=1), hyperorality and appetite changes (n=1),
depression (n=1), impaired articulation (n=2)
Apathy (n=2), loss of sympathy/empathy (n=1), decreased
fluency (n=1), impaired word retrieval (n=1), impaired
sentence completion (n=1), memory impairment (n=2)
Disinhibition (n=1), apathy (n=10), impaired articulation
(n=5), decreased fluency (n=4), impaired grammar/syntax
(n=1), impaired word retrieval (n=1), dysgraphia (n=1),
impaired judgement/problem solving (n=1)

Congruen
cy Score
(%)
100
33
29
29
36
0
0
0

0
10
7

22

The average congruency score was 33% for MAPT and 20 for GRN. This was calculated as the
number of congruent combinations divided by the number of possible pairwise combinations
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Table A.8. Baseline symptom endorsement on the GENFI symptom list (%) by gene mutation type in at-riskŧ
family members
Preclinical
(n=117)

Sub-symptoms*
Disinhibition
Apathy
Decreased fluency
Impaired
articulation
Memory
impairment

C9orf72
Noncarrier
(n=115)

6.0
6.8

1.7
6.1

1.7
1.7

6.1
0.9

13.7

13.9

Contrast
(test
statistic,
p-value)

Preclinical
(n=144)

GRN
Noncarrier
(n=144)

Contrast
(test
statistic,
p-value)

Preclinical
(n=56)

MAPT
Noncarrier
(n=61)

0.17#
X 2=0.05,
p=0.82
0.10#
1.00#

2.1
2.8

2.1
3.5

1.00#
1.00#

1.8
1.8

1.6
3.3

1.00#
1.00#

2.8
1.4

0.7
3.5

0.37#
0.44#

3.6
1.8

3.3
0

1.00#
0.48#

X2=0.002,
p=0.96

8.3

11.8

X2=0.96,
p=0.33

8.9

11.5

X2=0.21,
p=0.65

Contrast
(test
statistic, pvalue)

• *Reflects the sub-symptoms that were most frequently endorsed as “first symptoms” by symptomatic patients
• # Fisher’s Exact Test was used as the expected count was less than 5
• ŧ At-risk: preclinical carriers and non-carriers
• No differences were found between the preclinical mutation groups (Disinhibition: Fisher’s Exact Test
p=0.21; Apathy: Fisher’s Exact Test, p=0.23; Memory X2 =2.14, p=0.4; Fluency: Fisher’s Exact Test p=0.64;
Articulation : Fisher’s Exact Test p=1.0)
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Table A.9. Symptom endorsement (%) between the first and final visit for at-risk individuals (GENFI symptom list)
Total
(N=196)

Disinhibition
No change

Increase
symptom
endorsement
Decrease in
symptom
endorsement
Apathy
No change

Increase
symptom
endorsement
Decrease in
symptom
endorsement
Decreased
fluency
No change

Increase
symptom
endorsement
Decrease in
symptom
endorsement
Memory
impairments
No change

96.9

2.0

1.0

95.4

2.0

2.6

96.4

2.6

1.0

85.7

Pre-symptomatic Mutation Carriers
Mean time
Mean
C9orf72
GRN
interval,
YEO
(n=58)
(n=95)
Yrs (SD)
(SD)#

MAPT
(n=43)

Total
(N=202)

Mean time
interval,
Yrs (SD)

2.5 (1.5)
Min: 0.8
Max: 5.6
3.3 (1.7)
Min: 2.1
Max: 4.5
3.0 (2.7)
Min: 1.1
Max: 4.9

2.6 (1.3)
Min: 0.8
Max: 5.6
2.4 (1.7)
Min: 0.9
Max: 4.5
3.4 (2.8)
Min: 1.4
Max: 5.4

-14.1
(11.2)

98.3

96.8

95.3

98.0

-7.4
(17.1)

1.7

2.1

2.3

1.0

-0.8
(14.3)

0.0

1.0

2.3

1.0

2.6 (1.3)
Min: 0.8
Max: 5.6
3.4 (1.8)
Min: 1.7
Max: 5.2
3.1 (1.8)
Min: 1.1
Max: 5.0

-14.2
(11.2)

94.8

95.8

95.3

95.5

-1.0
(11.9)

0.0

3.2

2.3

2.5

-9.2
(12.5)

5.2

1.1

2.3

2.0

2.6 (1.4)
Min: 0.8
Max: 5.6
1.8 (1.0)
Min: 0.9
Max: 3.3
2.2 (1.2)
Min: 1.4
Max: 3.1

-13.9
(11.4)

98.3

97.9

90.7

96.5

-17.7
(7.0)

1.7

2.1

4.7

2.0

0.2
(12.8)

0.0

2.6(1.3)
Min: 0.9
Max: 5.4

-14.0
(11.0)

86.2

0.0

87.4

4.7

81.4

1.5

85.1
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2.5 (1.4)
Min: 0.8
Max: 5.6
3.5 (2.3)
Min: 1.0
Max: 5.6
2.1 (1.9)
Min: 1.0
Max: 4.9

2.5 (1.5)
Min: 0.78
Max: 5.6
1.0 (0.1)
Min: 1.0
Max: 1.1
3.2 (2.0)
Min: 1.0
Max: 4.9

2.5 (1.5)
Min: 0.8
Max: 5.6

Non-carriers
Mean
C9orf72
YEO
(n=62)
(SD)#

GRN
(n=103)

MAPT
(n=37)

Group
Contrasts

Genotyp
e
Contrast
s

p=0.8

C9orf72:
p=1.0

-11.6
(13.3)

98.4

97.1

100

-6.4 (21.4)

1.6

1.0

0.0

GRN:
p=0.847

-19.0 (1.0)

0.0

1.9

0.0

MAPT:
p=1.0

-11.7
(13.2)

95.2

96.1

94.6

0.6
(13.46)

0.0

2.9

5.4

GRN:
p=1.0

-21.9 (3.4)

4.8

1.0

0.0

MAPT:
p=0.8

-11.9
(13.3)

95.2

96.1

100

-1.4 (10.3)

1.6

2.9

0.0

p= 0.9

p=0.9

C9orf72:
p=1.0

C9orf72:
p=0.746
319
GRN:
p=1.0

-7.4 (10.2)

3.2

1.0

0.0
MAPT:
p=0.247

-12.6
(12.5)

82.3

85.4

89.2

X 2=0.7,
p=0.7

C9orf72:
p=0.5

Total
(N=196)

Increase
symptom
endorsement
Decrease in
symptom
endorsement
Articulation
Impairments
No change

Increase
symptom
endorsement
Decrease in
symptom
endorsement

•
•
•

8.7

5.6

96.9

2.6

0.5

Pre-symptomatic Mutation Carriers
Mean time
Mean
C9orf72
GRN
interval,
YEO
(n=58)
(n=95)
Yrs (SD)
(SD)#

Non-carriers
Mean
C9orf72
YEO
(n=62)
(SD)#

MAPT
(n=43)

Total
(N=202)

Mean time
interval,
Yrs (SD)
2.7 (1.8)
Min: 0.9
Max: 5.6
2.1 (1.5)
Min: 1.0
Max: 5.3

-4.2 (14.8)

-7.9 (17.3)

2.5 (1.5)
Min: 0.8
Max: 5.6
2.8 (2.1)
Min: 1.0
Max: 4.9
1.3 (0.4)
Min: 1.
Max: 1.7

-11.5
(13.2)

100

93.2

100

-4.6 (14.7)

0.0

3.9

0.0

GRN:
p=0.791

-27.3 (5.4)

0.0

2.9

0.0

MAPT:
p=1.0

3.0 (1.8)
Min: 0.8
Max: 5.56
3.0 (2.0)
Min: 1.0
Max: 5.5

-11.6
(14.2)

10.3

6.3

11.6

7.4

-13.9
(13.1)

3.4

6.3

7.0

7.4

2.6 (1.4)
Min: 0.8
Max: 5.6
2.8 (1.7)
Min: 1.0
Max: 5.5
--

-14.0
(11.3)

98.3

95.8

97.7

96.5

-5.8
(13.9)

1.7

3.2

2.3

2.0

--

0.0

1.1

0.0

1.5

GRN
(n=103)

MAPT
(n=37)

8.1

6.8

8.1

9.7

7.8

2.7

Group
Contrasts

Genotyp
e
Contrast
s
GRN:
X2=0.2,
p=0.9
MAPT:
p=0.7

p= 0.7

C9orf72:
p=0.483

Number of participants for each maximum visit: Maximum of 2 visits: N=178 (n=80 pre-symptomatic; n=98 non-carrier); Maximum of 3 visits:
N=130 (n=72 pre-symptomatic; 58 non-carriers); Maximum of 4 visits: N=57 (n=30 pre-symptomatic; 27 non-carriers); Maximum of 5 visits:
N=25 (n=10 pre-symptomatic; n=15 non-carriers); Maximum of 6 visits: N= 8 (n=4 pre-symptomatic; n=4 non-carriers)
*Sub-symptoms are coded as 0=no change in symptom endorsement, 1=increase in symptom endorsement, -1 decrease in symptom endorsement
# YEO=Years from expected symptom onset. Values represent estimates from the initial visit. Mean YEO is only reported for categories where
n>1 to prevent disclosure of genetic status
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Table A.10: Sensitivity and Specificity Scores (%) for Gene Composite Indices
C9orf72/MAPT Composite Index
GRN Composite Index
Sensitivity
Specificity
Sensitivity
Specificity
(95% CI)
(95% CI)
(95% CI)
(95% CI)
*
Symptomatic vs. Non-carrier
C9orf72
96.4 (89.9-99.3)
80.4 (71.4-87.6)
89.3 (80.6-95.0)
91.2 (83.9-95.9)
GRN
96.6 (88.1-99.6)
80.4 (71.4-87.6) 98.3 (90.8-100.0) 91.2 (83.9-95.9)
MAPT
93.6 (78.6-99.2)
80.4 (71.4-87.6)
80.7 (62.5-92.6)
91.2 (83.9-95.9)
**
Preclinical vs. Non-carriers (Beginning -5 years of expected disease onset)
C9orf72
20.0 (6.8 - 40.7) 80.4 (71.4 - 87.6) 12.0 (2.6 - 31.2) 91.2 (83.9 - 95.9)
GRN
14.3 (4.8 - 30.3) 80.4 (71.4 - 87.6)
8.6 (1.8 - 23.1)
91.2 (83.9 - 95.9)
MAPT
18.2 (2.3 - 51.8) 80.4 (71.4 - 87.6)
9.1 (0.2 - 41.3)
91.2 (83.9 - 95.9)
^
Preclinical vs. Non-carriers (Beginning -2 years of expected disease onset)
C9orf72
20.0 (4.3 - 48.1) 78.4 (67.3 - 87.1) 13.3 (1.7 - 40.5) 90.5 (81.5 - 96.1)
GRN
15.4 (4.4 - 34.9) 78.4 (67.3 - 87.1) 11.5 (2.5 - 30.2) 90.5 (81.5 - 96.1)
MAPT
28.6 (3.7 - 71.0) 78.4 (67.3 - 87.1) 14.3 (0.4 - 57.9) 90.5 (81.5 - 96.1)
^^
Preclinical vs. Non-carriers (Beginning 0 years of expected disease onset)
C9orf72
23.1 (5.0 - 53.8) 76.2 (63.8 - 86.0) 15.4 (1.9 - 45.5) 90.5 (80.4 - 96.4)
GRN
22.2 (6.4 - 47.6) 76.2 (63.8 - 86.0) 16.7 (3.6 - 41.4) 90.5 (80.4 - 96.4)
MAPT
33.3 (4.3 - 77.7) 76.2 (63.8 - 86.0)
16.7 (0.4-64.1)
90.5 (80.4 - 96.4)
Gene Group

* As symptomatic

carriers were older than non-carriers the following comparison only includes
non-carriers who were at least -5 years from disease onset. Symptomatic carriers: C9orf92: n=84,
GRN: n=58, MAPT: n=31; Non-carriers n=102
** Preclinical: C9orf92: n=25, GRN: n=35, MAPT: n=11; Non-carriers n=102
^Preclinical: C9orf92: n=15, GRN: n=26, MAPT: n=7; Non-carriers n=74
^^Preclinical: C9orf92: n=13, GRN: n=18, MAPT: n=6; Non-carriers n=63
CI= 95% confidence intervals

151

Table A.11: Mean (SD) Composite Scores for At-Risk Groups
C9orf72/MAPT Composite Index

Preclinical
At-risk from -5 years to expected onset
C9orf72
GRN
MAPT

0.2 (0.5)
0.2 (0.5)
0.3 (0.6)

GRN Composite Index

Non-carrier

Preclinical

Non-carrier

0.3 (0.6)

0.2 (0.5)
0.1 (0.6)
0.2 (0.6)

0.1 (0.5)

0.3 (0.7)

0.2 (0.6)
0.2 (0.36)
0.3 (0.8)

0.1 (0.5)

0.3 (0.7)

0.2 (0.6)
0.3 (0.8)
0.3 (0.8)

0.1 (0.5)

At-risk from -2 years to expected onset
C9orf72
GRN
MAPT

0.3 (0.6)
0.2 (0.5)
0.4 (0.8)

At-risk from -0 years to expected onset
C9orf72
GRN
MAPT

0.3 (0.6)
0.3 (0.6)
0.5 (0.8)

Only one symptom was selected as the initial symptom for affected patients
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Appendix B: Chapter 3 (Study 2) Supplementary Material

Results Section 1.0: Additional analysis with all genetic mutation carriers relative to nonmutation carriers
Participants
A total of 127 participants met the inclusion criteria. After processing in FreeSurfer, 4
participants were removed prior to statistical analysis: 1 due to scaling errors, 1 with extensive
segmentation errors, and 2 found to be extreme outliers (1 carrier and 1 non-carrier from PGRN
families; mean volumes >3 SD), leaving 123 participants from 56 family cohorts, entered into
the statistical model (Table A.1).

Carriers vs. Non-carriers
In the comparison of all carriers (symptomatic and preclinical) relative to non-carriers, the final
model included a genetic status by time to disease onset (linear) interaction (Table A.2). Due to
the significant correlation between age and expected years to disease onset, (r=0.91, p<0.0001),
age could not be included in the model due to multi-collinearity. There was a significant genetic
status by time to disease onset (linear) interaction. In a sensitivity analysis with one potentially
highly-influential participant removed (carrier), the significance of the main effects and
interaction did not change and thus their data remained in the analysis. Additionally, visual
inspection of the scatterplots demonstrated an extreme case (non-carrier). Unadjusted post-hoc ttests of the genetic status by time to disease onset interaction demonstrated greater ventricular
volume in carriers relative to non-carriers starting at 10 years prior to expected disease onset, or
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at 12 years prior to expected disease onset when one extreme case (non-carrier) was removed
from the model (Figure A.1, Table A.3).

Years from Actual Disease onset: The above analysis used calculated years to expected disease
onset for all participants as in the prior GENFI study. To confirm that the results were similar
when the age of disease onset was used for symptomatic carriers, the above analysis was
repeated using actual time from disease onset, calculated by subtracting the age at disease onset
from the participant’s current age at the time of the baseline and follow-up scans. The above
analysis was repeated using the final model with the same extreme case removed, substituting
actual time from disease onset for all symptomatic carriers and for three preclinical carriers who
became symptomatic during the 1year interval between baseline and follow up. Similar to the
previous results, there was a significant genetic status by years to onset interaction, where
carriers showed greater volumes beginning 10 years prior to disease onset relative to non-carriers
(Table A.4).

Manually Edited Versus Fully Automated Ventricular Volumes
Manual edits to the ventricular segmentations performed in FreeSurfer were made on all study
participants for each time point (mean differences in edited vs. unedited volumes are reported in
supplementary analysis). Substitution of the fully automated ventricular volumes produced by
FreeSurfer into the final models resulted in similar findings, demonstrating that for all carriers
vs. non-carriers, significant differences were observed at 12 years prior to expected disease onset
(Tables A.5a-b). See Table A.6 for annualized change of unedited ventricular volume.
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Total Ventricular Expansion over 1 year
To assess potential differences in ventricular expansion over the 1-year interval, an additional
model was comprised that included the same family and participant random effects as above and
the following fixed effects: visit, years to disease onset (linear and quadratic terms), genetic
status and an interaction between visit and genetic status. A sensitivity analysis for all carriers vs.
non-carriers identified one high-influential participant (carrier) but their removal d id not change
the significance of the main effects and interaction and thus, they were retained. Carriers as a
whole demonstrated greater ventricular volume at baseline (p=0.03) and follow-up (p=0.003)
relative to non-carriers. Additionally, carriers showed significant ventricular expansion between
baseline and follow up (p<0.001), whereas non-carriers did not (p=0.23). Annual rate of change
of total ventricular volume is presented in Table A.7, as a function of genetic status and years to
expected disease onset.

Mutation Type
Specifically, utilizing the final models from previous analysis (with the extreme case removed
for carriers vs. non-carriers comparison), we included, genotype (C9orf72, PGRN, MAPT) and
the interaction between genotype and genetic status as fixed effects in the model. Significant
interactions were decomposed using simple effects estimation. For total ventricular volume, for
all carriers vs. non-carriers, the interaction between genotype and genetic status did not reach
significance (p=0.10). Additionally, there was no significant interaction between genetic status
and genotype for the laterality index (p=0.18).
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Table B.1: Demographic characteristics of study participants (N=123)
Symptomatic
(n=21)

Preclinical
Carrier
(n=46)

Non-Carriers
(n=56)

All Carriers vs.
Non-carriers

Preclinical
carriers vs.
Non-carriers

13
5
3

13
29
4

13
36
7

p=0.18

p=0.74

9
12
5.16 (5.0)

25
21
-13.34 (12.65)

34
22
-9.14 (15.60)

p=0.27

p=0.52

p=0.55

p=0.14

64.37 (6.19)

44.66 (11.14)

50.56 (15.64)

p=0.92

p=0.03*

13.09 (4.11)

14.20 (3.47)

14.34 (3.51)

p=0.46

p=0.84

Genotype

C9orf72
PGRN
MAPT
Sex
Female
Male
Years from
expected disease
onset at baseline
Mean (SD)
Age (SD)
Years of
education (SD)

Group differences were assessed using chi-square tests and t-tests. *significant at p<0.05
Symptomatic carriers (n=18) include 3 progressors

Table B.2: Estimates for total ventricular volume of carriers (n=67) and non-carriers (n=55) with
no extreme case (n=1)
Fixed Effects

Estimate

SE

p-value

CI (95%)

Intercept

-0.70

0.56

0.22

-1.83, 0.43

Visit
(ref=follow-up)

-0.04

0.02

0.07

-0.08, 0.003

GS (ref=noncarriers)

0.70

0.17

<.0001*

0.37, 1.04

Time from
disease onset

-0.06

0.02

0.006*

-0.10, -0.02
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Time from
disease onset2

0.001

0.0003

<.0001*

0.0008, 0.002

Time from
disease onset*GS

0.03

0.01

0.001*

0.01, 0.05

Random Effects

Estimate

SE

p-value

Family
Membership

0.18

0.17

0.13

Participant

0.58

0.13

<.0001*

Residual

0.02

0.003

<.0001*

SE=standard error; GS=Genetic Status (carrier vs. non-carrier); CI=Confidence interval;
*significant at p<0.05

Table B.3. Estimated difference in ventricle volume between mutation carriers (n=67) and noncarriers (n=55) by time from expected disease onset
-25 years -20 years -15 years -10 years
Total Ventricle +
Estimate
-0.12
SE
0.22
p-value
0.64

0 years

5 years

10 years

0.22
0.17
0.1929

0.38
0.15
0.0144*

0.54
0.15
0.0006*

0.70
0.17
<.0001*

0.86
0.20
<.0001*

1.02
0.23
<.0001*

Total Left Ventricle ++
Estimate
-0.06
0.02
SE
0.11
0.09
p-value
0.57
0.79

0.11
0.08
0.17

0.19
0.07
0.01*

0.27
0.07
0.0003*

0.36
0.08
<.0001*

0.44
0.09
<.0001*

0.52
0.11
<.0001*

Total Right Ventricle ++
Estimate
-0.06
0.01
SE
0.12
0.10
p-value
0.65
0.91

0.08
0.09
0.38

0.15
0.08
0.08

0.21
0.08
0.01*

0.28
0.09
0.003*

0.35
0.11
0.001*

0.42
0.12
0.001*

0.01
0.005
0.007*

0.02
0.004
<.0001*

0.02
0.004
<.0001*

0.03
0.005
<.0001*

0.04
0.006
<.0001*

0.04
0.007
<.0001*

Third Ventricle
Estimate
0.002
SE
0.006
p-value
0.79

0.06
0.19
0.7699

-5 years

0.007
0.006
0.18

SE=standard error; *significant at p<0.05
+ Total volume is comprised of the left and right lateral, inferior, and third and fourth ventricles
++ Total left and right ventricles are composed of the lateral and inferior ventricles
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Table B.4: Estimates for total ventricular volume using actual years to disease onset for carriers.
Using final model with no extreme case (N=122)
Fixed Effects

Estimate

SE

p-value

CI (95%)

Intercept

-0.03

0.56

0.95

-1.15, 1.08

Visit
(ref=follow-up)
GS (ref=noncarriers)
Real time from
disease onset
Real time from
disease onset2
Time from
disease onset*GS
Random Effects

-0.04

0.02

0.04*

-0.08, -0.003

0.60

0.18

0.0009*

0.25, 0.95

-0.04

0.02

0.08*

-0.08, 0.005

0.001

0.0003

0.0005*

0.0005, 0.002

0.03

0.01

0.010*

0.006, 0.05

Estimate

SE

p-Value

Family
Membership
Participant

0.12

0.17

0.23

0.68

0.15

<.0001*

Residual

0.02

0.003

<.0001*

SE=standard error; GS=Genetic Status (carrier vs. non-carrier); *significant at p<0.05
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Table B.5a: Estimates for carriers (n=67) and non-carriers (n=55) for unedited ventricular
volumes with no extreme case (n=1)
Fixed Effects

Estimate

SE

p-value

CI (95%)

Intercept

-0.72

0.55

0.19

-1.83, 0.38

Visit
(ref=follow-up)
GS
(ref=non-carrier)
Time from
disease onset
Time from
disease onset2
Time from
disease onset*GS
Random Effects

-0.04

0.02

0.06

-0.08, 0.002

0.72

0.17

<.0001*

0.39, 1.06

-0.06

0.02

0.004*

-0.10, -0.02

0.001

0.0003

<.0001*

0.0009, 0.002

0.03

0.009

0.0007*

0.01, 0.05

Estimate

SE

p-Value

Family
Membership
Participant

0.19

0.17

0.13

0.58

0.13

<.0001*

Residual

0.02

0.003

<.0001*

SE=standard error; GS=Genetic Status (carrier vs. non-carrier); *significant at p<0.05
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Table B.5b: Estimates between carriers (n=67) and non-carriers (n=55) for unedited total
ventricular volume by time to expected disease onset

Estimate
SE
p-value

-25 years -20 years -15 years -10 years -5 years
-0.12
0.05
0.22
0.39
0.56
0.22
0.19
0.17
0.15
0.15
0.61
0.78
0.19
0.01*
0.0004*

0 years
0.72
0.17
<.0001*

5 years
0.89
0.20
<.0001*

10 years
1.06
0.23
<.0001*

SE=standard error; *significant at p<0.05

Table B.6. Annual percent change of unedited total ventricular volume by genetic status
Years to
disease onset
(baseline)
Less than -20
-20 to -10.01
-10 to -0.1
0 to 9.99
10 and beyond

Symptomatic (n=18)

Mean (SD)
11.01 (7.86)
5.91 (4.50)

CI
6.26, 15.76
0.33, 11.50

Preclinical (n=46) and
Progressors (n=3)
Mean (SD)
1.74 (7.74)
3.28 (2.94)
6.88 (9.59)
5.96 (7.52)
-

CI
-2.10, 5.59
1.18, 5.38
0.79, 12.98
0.18, 11.74
-

Non-carriers (n=56)

Mean (SD)
-2.31 (6.83)
0.10 (3.04)
1.50 (3.92)
3.70 (4.65)
3.38 (2.08)

CI
-5.71, 1.08
-2.44, 2.64
-0.99, 3.99
0.58, 6.82
1.45, 5.30

SD= Standard deviation; CI= 95% confidence interval
Years to disease onset for symptomatic individuals and progressors are based on actual time at diagnosis.

Table B.7. Annual percent change of total ventricular volume by genetic status
Years to
symptom
Onset+

Less than -20
-20 to -10.01
-10 to -0.1
0 to 9.99
10 and beyond

Symptomatic (n=18)

Preclinical (n=46) and
Progressors (n=3)

Non-carriers (n=56)

Mean (SD)

CI

Mean (SD)

CI

Mean (SD)

CI

10.97 (7.75)
6.00 (4.47)

6.29, 15.66
0.45, 11.56

1.76 (7.62)
3.39 (2.88)
7.27 (10.33)
5.68 (7.64)
-

-2.03, 5.55
1.32, 5.45
0.71, 13.83
-0.19, 11.55
-

-2.33 (6.89)
0.01 (2.91)
1.52 (3.85)
3.69 (4.58)
3.15 (1.87)

-5.76, 1.09
2.91, 2.44
-0.92, 3.97
0.61, 6.77
1.42, 4.89

SD= Standard deviation; CI= 95% confidence intervals.
+Years to onset for symptomatic individuals and progressors are based on actual time at diagnosis.
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Figure B.1 Predicted total ventricular volume by estimated years from expected disease onset in
carriers (blue, n=67) and non-carriers (red, n=55) no extreme case.

Ventricular volume is expressed as a percentage of intracranial volume. To prevent disclosure of
genetic status, individual data points are not plotted. Differences are noted beginning at 12 years
prior to disease onset as indicated by the dashed line (p=0.05).

Table B. 8: Influence Diagnostic Statistics of High-Influential Participants (non-carriers)
Participant

PRESS
Statistic

Cook’s D

MDFFITS

Restricted
Likelihood
Distance
1
22.93
0.12
0.13
0.61
1.66
2
3.84
0.38
0.34
0.86
2.92
Note: Model does not include the genetic status*time to disease onset quadratic term
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Table B.9a: Estimates for preclinical carriers (n=46) and non-carriers (n=53) for unedited
ventricular volumes with no extreme cases (n=1) or influential cases (n=2)
Fixed Effects

Estimate

SE

p-value

CI (95%)

0.35

0.35

0.31

-0.34, 1.05

-0.0005

0.01

0.96

-0.02¸ 0.02

0.36

0.15

0.02*

0.06, 0.67

-0.03

0.01

0.06*

-0.05, 0.0009

0.0008

0.0002

0.0001*

0.0004, 0.001

0.02

0.008

0.02*

0.003, 0.03

Estimate

SE

p-Value

Family
Membership
Participant

0.02

0.04

0.33

0.38

0.07

<.0001*

Residual

0.004

0.0005

<.0001*

Intercept
Visit
(ref=follow-up)
GS
(ref=non-carrier)
Time from
disease onset
Time from
disease onset2
Time from
disease onset*GS
Random Effects

SE=standard error; GS=Genetic Status (carrier vs. non-carrier); *significant at p<0.05

Table B.9b: Estimates between preclinical mutation carriers (n=46) and non-carriers (n=53) for
unedited total ventricular volume by time to expected disease onset
-25 years -20 years -15 years -10 years
Estimate
-0.10
-0.01
0.08
0.18
SE
0.16
0.14
0.13
0.13
p-value
0.54
0.96
0.52
0.17

SE=standard error; *significant at p<0.05
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-5 years
0.27
0.14
0.05

0 years
0.36
0.15
0.02*

5 years
0.45
0.18
0.01*

10 years
0.55
0.20
0.009*

Results section 2.0: Assessing regions of the ventricles for all mutation carriers vs. noncarriers, all preclinical carriers vs. non-carriers
Carriers vs. non-carriers: Regions of the Ventricles
Upon finding that total ventricular volume showed significant differences as a function of
genetic carrier status and time to expected disease onset, we were then interested in exploring
whether regions of the ventricles showed significant changes prior to disease onset using the
same statistical model for volumes of the left ventricle, right ventricle, third and fourth
ventricles. For each region, when significant, the interaction between genetic status and years
from disease onset was followed up with t-tests. Relative to non-carriers, carriers (with extreme
case removed) showed greater ventricle volumes in the left ventricle beginning 12 years prior to
expected disease onset, in the right ventricle at 8 years, and in the third ventricle 17 years prior to
disease onset. There was no significant interaction between genetic status and years from disease
onset for the fourth ventricle or the laterality index.

Preclinical carriers vs. non-carriers: Regions of the Ventricles
Follow up analysis of left, right, third and fourth ventricular volumes with the final model
with the two high-influential (n=2) and extreme case (n=1) removed demonstrated significant
differences in the left ventricle beginning at 5 years before expected disease onset, and at 2 years
after disease onset in the right ventricle. There was no significant genetic status by time to onset
interaction for the third and fourth ventricles, and the laterality index.

Mean Ventricular Volumes: Manually Edited Versus Fully Automated Segmentations
We were interested in examining whether there were any significance differences
between the constructed total ventricular volumes based on manual edits or unedited volumes.
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Due to the potential differences in the degree of manual editing, differences were assessed
separately at each visit (baseline and follow-up) for each group (symptomatic carriers, preclinical
carriers, and non-carriers). Due to the small number of preclinical carriers who became
symptomatic at follow-up (n=3), these individuals were not included in the following analysis.
Normality was assessed using the Shapiro-Wilk and Kolmogorov-Smirnov tests using the Proc
univariate procedure. When normality was violated, a Wilcoxon Signed-Rank test was
conducted, otherwise a paired-samples t-test was used.
There were no differences between the edited and unedited volumes at baseline or
follow-up for preclinical carriers (all p’s> 0.80) and non-carriers (all p’s> 0.146). For
symptomatic carriers at baseline and follow-up, the edited (Baseline: M=3.037, SD=1.116;
Follow-up: M=3.370, SD=1.230) and unedited (Baseline: M=3.058, SD=1.113; Follow-up:
M=3.392, SD=1.227) volumes differed significantly.
Additionally, spearman’s rank-order correlations were completed on total ventricular
volume to delineate the relationship between the manual edited and unedited volumes for each
group. All correlations were significant across all groups: all p’s<0.0001, all rs>0.99.
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Appendix C: Chapter 4 (Study 3) Supplementary Material
Method C.1 Statistical Analysis for Voxel-based Morphometry Co-variate and Contrast
To account for grey matter volume differences influencing the fMRI signal, voxel-wise grey
matter tissue probabilities were entered as a covariate in the fMRI analysis. Grey-matter
probability maps were acquired using Statistical Parametric Mapping software (SPM12;
Wellcome Department of Cognitive Neurology, London, UK; http://www.fil.ion.ucl.ac.uk/spm).
T1-weighted images were converted into NifTI format using the 3dAFNItoNIFTI command in
AFNI. Next, T1-images were visually inspected and manually realigned to the anterior
commissure to ensure proper spatial normalization. Following realignment, the images were
segmented into grey and white matter and normalized to MNI space using the specifications of
the AFNI @SSwarper MNI template (voxel size: 1x1x1; bounding box: Xstart: -96.5, Xend:
96.5, ystart: -114.5, yend:114.5, zstart:-96.5, zend: 96.5; smoothing: 4mm full-width at halfmaximum Gaussian kernal). In AFNI, 3dresample was run to ensure the orientation, dimensions
and voxel size were identical between the resultant VBM images (smwc1.nii) and the
participant’s fMRI statistics file. Subsequently, the resampled grey-matter probability maps were
included into the fMRI analysis as a voxel-wise covariate using 3dMVM in AFNI as a between
subject factor.
Multiple linear regression was conducted to assess regions that showed grey matter volume
differences between patients with FTD and controls. Individual variation in brain size was
accounted for by including total intracranial volume (sum of grey matter, white matter, and
cerebrospinal fluid) as a covariate. AFNI’s 3dFWHMx and 3dClustSim was used to obtain a
cluster-size threshold at p=0.05, applied to the whole brain at an alpha threshold of p<0.001 (478
contiguous voxels).
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Table C.1 Grey Matter Volume Differences Between Controls and Patients with FTD
Cluster

Region

Cluster
tsize
statistic
(voxels)
142075 10.97

X

Y

Z

30

6

-22

1

Cluster expands across left and right frontal,
temporal lobes, basal ganglia and
cerebellum

2

Right middle temporal gyrus

809

7.26

45

9

-36

3

Left middle occipital gyrus

751

6.29

-38

-88

3

4

Left superior and middle temporal gyrus

2305

6.17

-51

7

-25

5

Left superior & medial frontal gyrus

776

5.64

-10

64

11

6

Right & left cuneus

2545

5.35

1

-87

16

7

Right inferior parietal lobe

640

5.15

34

-46

42

8

Left middle & inferior frontal gyrus

1050

5.06

-40

4

31

9

Right superior & inferior parietal lobe

520

5.00

64

-37

23

10

Left inferior parietal lobe

614

5.00

-62

-41

39

Right superior and middle temporal gyrus
1336
4.57
and precuneus
Voxel coordinates are in mm after transformation into standard MNI space.
Patients with FTD demonstrate less grey matter volume in clusters above

51

-72

26

11
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Figure C.1 Grey Matter Volume Differences Between Patients and Controls
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Table C. 2. BOLD Signal Responses While Controlling for Grey Matter Volume
Choice Phase
Fixed Effects

Region

L/R

BA

X

Y

Z

t-value

Group

Inferior frontal gyrus
Middle temporal
gyrus
Inferior parietal
lobule

L
L

47
22

32
60.4

-28.8
31.9

0.9
3.7

R

40

-54.0

47.0

Inferior frontal gyrus
Medial frontal gyrus
Lentiform
nucleus/putamen
Inferior frontal gyrus
Cingulate gyrus
Inferior frontal gyrus
Caudate/lateral
globus pallidus
Inferior parietal
lobule
Cingulate gyrus

L
L
L

9
6

43.5
5.2
16.2

R
R
L
R

9
32
47

L

Medial frontal gyrus

Phase

Phase x
reinforcement

Inferior frontal grus

Lentiform
nucleus/putamen

Inferior frontal gyrus

Cingulate gyrus

Middle frontal gyrus

Contrast

-3.0
-3.8

#
voxels
53
50

27.4

-4.0

23

Ctrl > Pat

-5.2
-13.5
-10.2

34.5
51.5
0.2

3.1
5.0
3.8

190
168
159

Acq >Rev
Acq >Rev
Acq >Rev

-39.9
-9.2
32.0
-11.8

-6.6
-18.7
-26.7
-6.8

31.0
39.1
-4.6
1.3

4.3
3.9
4.7
3.4

95
67
61
36

Acq
Acq
Acq
Acq

40

52.8

45.4

49.2

5.6

23

Acq >Rev

L

32

10.2

-16.5

34.4

4.8

22

Acq >Rev

L

8/32

4.1

-19.8

47.9

-4.5

185

Acquisition:
Incorr> Corr

L

9

L

L

R

L

44.0

+16.1

47

32

46

+35.0

-7.9

+43.0

-3.9

-10.4

-26.0

-17.6

-28.8

35.3

-0.3

-5.0

42.2

21.9

-3.8

-3.2

-4.8

-5.3

-4.7

155

125

63

46

36

Ctrl > Pat
Ctrl > Pat

>Rev
>Rev
>Rev
>Rev

Reversal:
Corr >Incorr
Acquisition:
Incorrrr > Corrr
Reversal:
Corr>Incorr
Acquisition:
Incorr> Corr
Reversal:
Corr>Incorr
Acquisition:
Incorr> Corr
Reversal:
Corr>Incorr
Acquisition:
Incorr> Corr
Reversal:
Corr>Incorr
Acquisition:
Incorr> Corr
Reversal:
Corr>Incorr
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Cingulate gyrus

L

32

+10.4

-17.9

33.4

-4.2

27

Acquisition:
Incorr > Corr
Reversal:
Corr >Incorr

Feedback Phase
Fixed Effects

Region

L/R

Reinforcement

Lateral prefrontal
cortex
Inferior parietal
lobule
Lateral prefrontal
cortex
Inferior parietal
lobule
Cuneus
Fusiform gyrus

R

Declive

L

Thalamus
Fusiform gyrus

R
L

Cingulate gyrus
Posterior cingulate
Declive

L
L
R

Superior frontal gyrus

Phase

L

BA

40

L

X

Y

Z

t-value
0.6

#
voxels
8468

-29.5

-27.3

32.1

Incorr >Corr

34.6

59.6

40.2

-6.2

4584

Incorr >Corr

42.9

-21.1

23.3

-4.4

4396

Incorr >Corr

R

40

-45.9

55.6

39.5

-4.5

3335

Incorr >Corr

R
R

17
19

-1.3
-44.3

82.8
70.3

-3.9
-4.0

896
493

Incorr >Corr
Incorr >Corr

30.7

63.3

-3.9

474

Incorr >Corr

-0.8
45.4

7.3
71.0

-3.3
-3.3

349
145

Incorr >Corr
Incorr >Corr

23
30

2.0
19.7
-12.0

24.4
63.8
82.0

-3.0
-3.9
-4.4

118
107
95

Incorr >Corr
Incorr >Corr
Incorr >Corr

R

11

-21.8

-45.8

-4.7

87

Incorr >Corr

Middle occipital
gyrus
Middle temporal
gyrus
Middle frontal gyrus

L

19

34.5

91.5

6.6
18.3
29.6
9.2
16.6
30.5
3.8
23.8
15.6
6.7

-4.1

45

Incorr >Corr

R

21/22

-47.4

28.3

-5.4

-4.5

42

Incorr >Corr

L

11

23.8

-41.0

-5.3

40

Incorr >Corr

Lingual gyrus
Middle occipital
gyrus
Medial frontal gyrus
Parahippocampal
gyrus
Caudate tail

R
L

18
19

-7.9
44.3

75.4
59.6

16.5
-7.9
-8.5

-3.0
-3.5

33
32

Incorr >Corr
Incorr >Corr

R
L

6
27

-21.3
8.9

-2.5
37.4

53.6
4.6

-4.6
-4.8

29
23

Incorr >Corr
Incorr >Corr

-25.7

46.0

16.5

4.7

23

Corr > Incorr

Fusiform gyrus

R

19

-41.8

80.2

3.8

83

Acq >Rev

Inferior occipital
gyrus
Middle occipital
gyrus
Lingual gyrus

R

18

-28.8

90

3.7

52

Acq >Rev

L

19

54.4

75.1

21.0
19.4
-1.7

4.3

42

Acq >Rev

L

18

3.7

79.6

-8.5

3.3

25

Acq >Rev

19

R
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Group x Phase

Superior frontal gyrus

L

10/11

27.8

-56.1

11.1

-5.8

50

Acquisition:
Ctrl > Pat
Reversal:
Pat >Ctrl

Phase x
Reinforcement

3-way
interaction

Middle occipital
gyrus

R

19

-47.1

78.5

10.7

-3.8

87

Acquisition:
Incorr >Corr

Inferior occipital
gyrus
Lingual gyrus

R

18

-26.4

90.1

-4.4

63

L

18

3.8

78.7

19.7
-8.7

-3.7

54

Cuneus

R

18

-4.5

97.2

8.9

-4.6

54

Cuneus

R

19

-0.8

89.5

27.6

-4.2

37

Fusiform gyrus

R

19

-42.9

78.5

22.9

-4.6

25

Acquisition:
Incorr >Corr
Acquisition:
Incorr >Corr
Acquisition:
Incorr >Corr
Acquisition:
Incorr >Corr
Acquisition:
Incorr >Corr

Superior frontal gyrus

L

10/11

26.2

-56.1

11.0

5.9

22

Acquisition
Incorr:
Ctrl > Pat
Reversal Corr:
Pat > Ctrl
Reversal Incorr:
Pat >Ctrl

Thresholded at p<0.001. All clusters survive correction for multiple comparison at p<0.05. Table displays
regions, hemisphere (L, left; R, right), Brodmann area (BA), Montreal Neurological Institute (MNI)
coordinates (x, y, z) at center of mass, maximum neural activity for the cluster (t-value), cluster size in
voxels, and the direction of activity [Control (ctrl), Patient (pat), Acquisition (acq), Reversal (rev),
Correct (corr), Incorrect (incorr)]. Focus point and regions of BA according to TT_Daemon: TalairachTournoux atlas. The ANOVA was completed separately for the choice and feedback phase.

Table C.3. Mean Percent Correct Responses and No Responses
Patients
Controls

Acquisition
Correct (SD)
83.7 (15)
93.9 (2.2)

Reversal Correct
(SD)
80.8 (16.3)
89.8(4.1)
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Acquisition No
Responses
5.1 (8.8)
0.3 (0.8)

Reversal No
Responses
3.7 (10.3)
0.2 (0.5)
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